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ABSTRACT OF DISSERTATION

NEUROPROTECTIVE STRATEGIES FOLLOWING EXPERIMENTAL
TRAUMATIC BRAIN INJURY: LIPID PEROXIDATION-DERIVED ALDEHYDE
SCAVENGING AND INHIBITION OF MITOCHONDRIAL PERMEABILITY
TRANSITION
Traumatic brain injury (TBI) represents a significant health crisis. To date there
are no FDA-approved pharmacotherapies available to prevent the neurologic deficits
caused by TBI. Following TBI, dysfunctional mitochondria generate reactive oxygen and
nitrogen species, initiating lipid peroxidation (LP) and the formation of LP-derived
neurotoxic aldehydes, which bind mitochondrial proteins, exacerbating dysfunction and
opening of the mitochondrial permeability pore (mPTP), resulting in extrusion of
mitochondrial sequestered calcium into the cytosol, and initiating a downstream cascade
of calpain activation, spectrin degradation, neurodegeneration and neurologic
impairment.
As central mediators of the TBI secondary injury cascade, mitochondria and LPderived neurotoxic aldehydes make promising therapeutic targets. In fact, Cyclosporine A
(CsA), an FDA-approved immunosuppressant capable of inhibiting mPTP has been
shown to be neuroprotective in experimental TBI. Additionally, phenelzine (PZ), an
FDA-approved non-selective irreversible monoamine oxidase inhibitor (MAOI) class
antidepressant has also been shown to be neuroprotective in experimental TBI due to the
presence of a hydrazine (-NH-NH2) moiety allowing for the scavenging of LP-derived
neurotoxic aldehydes.
The overall goal of this dissertation is to further examine the neuroprotective
effects of the mPTP inhibitor, CsA, and the LP-derived neurotoxic aldehyde scavenger,
PZ, using a severe controlled cortical impact injury (CCI) model in 3-month old male
Sprague-Dawley rats.
First, the effects of CsA on cortical synaptic and non-synaptic mitochondria, two
heterogeneous populations, are examined. Our results indicate that compared to nonsynaptic mitochondria, synaptic mitochondria sustain greater damage 24h following CCI
and are protected to a greater degree by CsA.
Second, the neuroprotective effects of a novel 72h continuous subcutaneous
infusion of CsA combined with PZ are compared to monotherapy. Following CCI, our
results indicate that individually both CsA and PZ attenuate modification of
mitochondrial proteins by LP-derived neurotoxic aldehydes, PZ is able to maintain
mitochondrial respiratory control ratio and cytoskeletal integrity, but together, PZ and
CsA, are unable to improve and in some cases negate monotherapy neuroprotective
effects.

Finally, the effects of PZ (MAOI, aldehyde scavenger), pargyline (PG, MAOI,
non-aldehyde scavenger) and hydralazine (HZ, non-MAOI, aldehyde scavenger) are
compared. Our results indicate that PZ, PG, and HZ are unable to improve CCI-induced
deficits to learning and memory as measured by Morris water maze (post-CCI D3-7). Of
concern, PZ animals lost a significant amount of weight compared to all other group,
possibly due to MAOI effects. In fact, in uninjured cortical tissue, PZ administration
leads to a significant increase in norepinephrine and serotonin. Additionally, although PZ,
PG, and HZ did not lead to a statistically significant improvement in cortical tissue
sparing 8 days following CCI, the HZ group saw a 10% improvement over vehicle.
Overall, these results indicate that pharmacotherapies which improve
mitochondrial function and decrease lipid peroxidation should continue to be pursued as
neuroprotective approaches to TBI. However, further pursuit of LP-derived aldehyde
scavengers for clinical use in TBI may require the development of hydrazine (-NH-NH2)compounds which lack additional confounding mechanisms of action.

KEYWORDS: combinational therapy, cyclosporine A, lipid peroxidation-derived
aldehyde scavenging, mitochondria, phenelzine, traumatic brain injury
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CHAPTER ONE:
Introduction
Epidemiology of Traumatic Brain Injury
Traumatic brain injury (TBI) represents a significant health crisis in the United
States and worldwide. Currently there are no FDA-approved pharmacological agents
capable of attenuating the devastating neurologic consequences that can occur following
TBI [1]. TBIs range from mild to severe, with at least two and a half million documented
cases occurring in the United States annually [2]. However, these numbers are
underestimates because the majority of TBIs are classified as mild [3], and often go
unreported, especially in sports and military communities [4, 5]. In fact, it is estimated
that sports-related TBIs alone occur at a rate of 3.8 million annually [6]. Young children
(0-4 years), older teenagers (15-19 years), the elderly (>65 years), and males across all
ages groups are at the highest risk of sustaining a TBI [7]. In the US, falls and motor
vehicle accidents are the leading causes of TBI [7].
Clinically, TBIs are classified using the Glasgow Coma Scale (GCS: mild 13-15,
moderate 9-12, severe 3-8) an injury scale which relies on assessments of eye, motor,
and verbal responses [8] (Fig. 1.1). However, it must be noted that although GCS can
give a clinical assessment of brain injury, it is unable to characterize injury pathology [9],
but clinical utilization of imaging can be useful in this regard. For example, amongst TBI
patients categorized as having a severe TBI by GCS score, CT or MRI scans can
distinguish between injury pathologies such as epidural hematoma, subdural hematoma,
subarachnoid hemorrhage, etc. [9].
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Glasgow Coma Scale
Response

Scale

Eye Opening
Response

Verbal Response

Score

Eyes open spontaneously

4

Eyes open to verbal command

3

Eyes open to pain

2

No eye opening

1

Oriented

5

Confused conversation; able to answer questions

4

Inappropriate responses; words discernable

3

Incomprehensible speech or sounds

2

No verbal response

1

Obeys movement commands

6

Purposeful movement to painful stimuli

5

Withdraws from pain

4

Spastic flexion; decorticate posture

3

Rigid extensor response; decerabrate posture

2

No Motor Response

1

Motor Response

Mild = 13 - 15, Moderate = 9 - 12, Severe = 3 - 8

Figure 1.1 Glasgow Coma Scale indicating the specific eye opening, verbal and motor
responses and the corresponding scores utilized for clinical assessment of brain injury
severity.
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Although the majority of diagnosed TBIs are classified as mild on the GCS, the
most severe injuries, those resulting in hospitalization and death, account for ninety
percent of TBI-associated costs, a staggering amount considering that in 2010 both
direct and indirect TBI medical costs were estimated to be seventy-five billion dollars [10,
11].
Additionally, there are over five million people in the United States living with a
TBI-related disability [12]. In fact, over fifty percent of persons hospitalized due to TBI,
will continue to suffer from a TBI-associated disability more than a year following injury
[13]. Such disabilities can include cognitive, physical, and emotional impairments [12].
Animal Models of TBI
Animal models have been used extensively to model TBI and are able to
recapitulate several aspects of human TBI neuropathology and behavioral impairment
[167]. Although large animal (e.g. swine) models of TBI exist, the majority of TBI studies
utilize rodents [167]. However, there are several anatomic and physiologic differences
between humans and rodents which must be taken into consideration [168]. For
example, compared to rodents, human brains contain higher ratios of white to grey
matter, higher ratios of glia to neurons, sulci, gyri, longer myelinated axons, and a
denser vascular supply [168].
In humans, TBI injury pathology is heterogeneous and as such, several animal
models of TBI have been developed, including controlled cortical impact injury (CCI),
fluid percussion injury (FPI), and the Marmarou weight drop (WD) model. In recent
years, with the growing interest in military and sports-related injuries, models of blast
injury, mild closed head injury (CHI) and rotational injury have also been developed
[167]. Due to the clinical heterogeneity of TBI, as well as the failure of TBI clinical trials,
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many recent pre-clinical TBI studies, such as “Operation Brain Trauma Therapy” are
screening drugs across multiple animal models of TBI [384]. These studies aim to
identify drugs that have robust neuroprotective effects across multiple experimental
injury paradigms, with the hope that such drugs will be clinically translationally for use in
multiple types of human TBI. On the other hand, these types of studies have the ability
to identify drugs that only have neuroprotective effects in certain experimental models, a
finding that can improve future clinical trial designs by limiting the type of human TBI
such drugs are evaluated in.
The majority of severe injury studies have utilized the CCI, FPI and WD models,
all of which have aspects of focal contusion, diffuse axonal injury, and hemorrhage.
However, WD is often identified as being diffuse, FPI as mixed (focal/diffuse), and CCI
as focal [167]. Although each model has its advantages and disadvantages, CCI, the
model utilized in this dissertation, is considered to be more reproducible and have a
lower mortality rate than both the WD and FPI models [167].
Traumatic Brain Injury Pathophysiology
Primary Injury Mechanisms
TBI consists of a primary injury followed by a secondary injury cascade. The
primary injury occurs immediately and is caused by external forces, such as a direct
impact, rapid acceleration/deceleration, or a blast wave. Primary injury can result in
contusion, hemorrhage, ischemia, shearing and straining of axons and blood vessels,
and diffuse axonal injury from the mechanical insult [14-16].
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Secondary Injury Mechanisms
Cellular strain and deformation caused by the primary injury results in membrane
depolarization, mechanoporation of membranes, ionic imbalances, and neurotransmitter
release, resulting in initiation of the secondary injury cascade, a process which occurs
hours to weeks following injury [14, 15], and is heavily influenced by alterations in
calcium homeostasis [16], mitochondrial function [17], and the process of lipid
peroxidation (LP) [17], but includes additional processes such as neuroinflammation [14,
18] (Fig. 1.2). The following sections present a simplified description of TBI secondary
injury mechanisms and focuses on specific aspects of mitochondrial function and LP.
Although not the main focus of this dissertation, because the drug of interest phenelzine
(PZ) is classified as a monoamine oxidase inhibitor, dysfunction of monoamine
neurotransmitter systems following TBI will also be briefly discussed.
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Figure 1.2 Simplified schematic of the TBI secondary injury cascade. ROS =
reactive oxygen species, RNS = reactive nitrogen species, PN = peroxynitrite, Mito =
mitochondria, 4-HNE = 4-hydroxynoneal, ER = endoplasmic reticulum. Adapted from
Kulbe et al. 2017 [19].
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TBI-Induced Calcium Influx
Activation of calcium channels by high levels of extracellular glutamate following
injury, along with activation of voltage-gated calcium channels, failure of energydependent calcium efflux pumps, and membrane leakage leads to large increases in
intracellular calcium [16]. As essential regulators of calcium [20, 21], mitochondria
attempt to maintain calcium homeostasis by taking up excess intracellular calcium, a
process dependent upon the presence of the mitochondrial calcium uniporter, a calcium
concentration gradient, and a negative mitochondrial membrane potential [22-24].
Additionally, calcium-binding proteins and the endoplasmic reticulum (ER) function to
sequester calcium following injury [16].
Mitochondria: An Introduction
Mitochondria and Physiologic Calcium
In addition to being able to sequester calcium under pathologically high
intracellular calcium concentrations, mitochondria can regulate calcium homeostasis
under physiologic conditions as well. Calcium is an activator of the citric acid cycle (TCA)
enzymes,

including

pyruvate

dehydrogenase,

NAD+

dependent

isocitrate

dehydrogenase, and α-ketoglutarate dehydrogenase, therefore increases in calcium can
induce increases in mitochondrial respiratory rates [21, 25]. Furthermore, the ability of
mitochondria to cycle calcium allows for fine tuning of calcium concentrations in
subcellular compartments such as the presynaptic terminal, allowing for tight regulation
of processes such as neurotransmitter release [21, 25, 26].
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Mitochondria and Energy Production (Fig. 1.3)
Although mitochondria serve an important role in maintenance of calcium
homeostasis under both physiologic and pathologic conditions, mitochondria are
generally known for their role in adenosine triphosphate (ATP, i.e. energy) production.
The brain primarily utilizes glucose as its energy source [27], a process which begins
with cytosolic glycolysis, in which one molecule of glucose, a product of carbohydrate
metabolism, is catabolized to form two molecules of pyruvate, two molecules of ATP,
and two molecules of nicotinamide adenine dinucleotide (NADH). Fortunately,
mitochondria can utilize pyruvate to significantly increase the amount of ATP that can be
generated

from

each

glucose

molecule,

through

the

process

of

oxidative

phosphorylation.
Pyruvate is transported across both the outer and inner mitochondrial
membranes, into the mitochondrial matrix where it is converted into acetyl-coA before
entering into the citric acid cycle (TCA). Through a series of oxidation (loss of electrons)
and reduction (gain of electrons) reactions NADH and flavin adenine diculeotide (FADH2)
are produced. NADH and FADH2 provide the electrons and protons utilized by the
electron transport chain (ETC) complexes, located in the inner mitochondrial membrane,
during the process of oxidative phosphorylation. Complex I (NADH dehydrogenase)
receives electrons from NADH, while complex II (succinate dehydrogenase) receives
electrons from FADH2. Complex I and II both pass these electrons on to complex III
(coenzyme Q-cytochrome c oxidoreductase) through the electron-carrier coenzyme Q
(ubiquinone).
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Figure 1.3 Mitochondria electron transport chain. Following glycolysis pyruvate is
transported into the mitochondrial matrix where it is converted into acetyl-coA before
entering into the citric acid cycle (TCA). Electrons and protons are passed from NADH to
complex I and from succinate / FADH2 to complex II. From there electrons are passed
through coenzyme Q (Q) to complex III and onto complex IV through cytochrome c (C).
At complex IV the electrons are passed onto the final electron acceptor O2 to generate
water. As electrons are passed through the electron transport chain H+ are pumped from
the matrix to the intermembrane space through complex I, III, and IV. Protons flow down
their gradient at complex V to generate ATP from ADP.
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From complex III electrons are transferred to cytochrome c before reaching
complex IV (cytochrome c oxidase) where they are transferred to the ETC’s final
electron acceptor, O2, resulting in the formation of H2O.
Importantly, as the initially high energy electrons are passed through the redox
centers of the ETC, this energy is used to pump protons (H+) from the mitochondrial
matrix, across the inner mitochondrial membrane at complexes I, III, and IV, into the
mitochondrial intermembrane space, producing the mitochondrial membrane potential,
which under physiologic conditions is approximately -150 mV to -180mV [25, 28].
Generation of the mitochondrial membrane potential allows for H+ to re-enter the
relatively negative mitochondrial matrix from the relatively positive mitochondrial
intermembrane space, through the transmembrane protein ATP synthase, utilizing the
energy generated as protons flow down their gradient to phosphorylate ADP and
generate ATP, thus linking the electron transport chain with ATP production (i.e.
oxidative-phosphorylation).
Analysis of Mitochondrial Respiration (i.e. Bioenergetics)
One method of evaluating mitochondrial bioenergetics is through the use of a
Clark-type oxygen electrode, a device which measures oxygen concentration.
Mitochondria are added to a 37°C continuously stirred chamber. As O2 is the final
electron acceptor of the ETC, following addition of ETC substrates, O 2 is consumed and
drops in O2 concentration can be measured to assess respiratory rates. Upon addition of
several compounds, information can be obtained regarding various individual states of
mitochondrial respiration (Fig. 1.4).
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Figure 1.4 Mitochondria states of respiration. (1) The complex I substrates pyruvate
and malate are added to initiate state II respiration. (2) Next, boluses of ADP are added
to initiate state III respiration. (3) Following addition of ADP, oligomycin is added to
inhibit complex V (i.e. ATP synthase), inducing state IV respiration. (4) Next, the
mitochondrial uncoupler FCCP is added to induce state V(I) respiration. (5) Rotenone is
added to inhibit complex I, (6) followed by the complex II substrate succinate, initiating
state V(II). Adapted from Vaishnav et al. 2010 [29].
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State II respiration occurs after addition of the complex-I substrates pyruvate and
malate, but before ADP addition, and represents a slow/basal state of respiration.
State III respiration occurs following the addition of the complex-I substrates
pyruvate and malate along with ADP, allowing for the formation of ATP (ADP + Pi) as
protons pumped out of the mitochondrial matrix during electron transport flow back down
their proton gradient via ATP synthase, thus coupling electron transport with oxidative
phosphorylation. State III is considered one of the most important states of respiration,
as decreases in State III respiration can be indicative of both impairments in complex-I
driven substrate oxidation and/or ATP turnover [30].
State IV respiration is measured following addition of the ATP synthase inhibitor
oligomycin, preventing the flow of protons down their proton gradient through ATP
synthase. Therefore, the oxygen consumption which occurs following ATP synthase
inhibition is due to proton leak across the membrane. Consequently, in healthy
mitochondria state IV respiration should be low, representative of a basal state of
respiration similar to state II [30, 31]. Intuitively, damaged mitochondria with leaky
membranes would result in an increase in state IV. However, when damaged
mitochondria show decreases in state IV, it may represent initial impairments in electron
flow either due to damage to complex-I or upstream processes, such as to the citric acid
cycle (TCA) enzymes. For example, damage to complex-I would impair electron flow to
downstream ETC complexes (Fig. 1.3), resulting in a decrease in all complex-Idependent respiration states, including that of state IV. Similarly, damage to TCA
proteins would impair electron flow into complex-I (and complex-II) (Fig. 1.3), resulting in
a decrease in all individual respiratory states, including that of state IV.
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Respiratory control ratio (RCR), the difference in oxygen utilization between
activation of ATP production (state III) and inhibition of ATP production (state IV), is a
general measure of mitochondrial health and function. Healthy mitochondria are able to
generate ATP under minimal proton leak and therefore have high RCR values, whereas
damaged mitochondria can have relatively lower RCR values, however, there is not a
single RCR value which can be considered diagnostic of dysfunction [30]. However, as
RCR is a ratio, equal drops in state III and state IV respiration would result in an
unchanging RCR value.
State V(I) is measured following addition of the protonophore, FCCP (carbonyl
cyanide p-trifluoromethoxyphenylhydrazone), which allows for free flow of protons
across the inner mitochondrial membrane down their gradient, uncoupling oxidative
phosphorylation and allowing for complex-I driven maximal respiration, with decreases in
state V(I) being indicative of deficits in complex-I initiated substrate oxidation [30].
State V(II) respiration is measured following addition of the complex-I inhibitor,
rotenone, and the complex-II substrate, succinate, and is a measure of complex-II driven
maximal respiration. Therefore, decreases in state V(II) represent defects in complex-II
driven substrate oxidation.
Heterogeneity of Mitochondria
Mitochondria are heterogeneous. Brain mitochondria have distinct properties
compared to mitochondria derived from other organ systems as well as other regions of
the CNS, such as the spinal cord [32, 33]. Additionally, there exists much heterogeneity
within brain mitochondria themselves depending on brain region, cell type, and
subcellular compartment.
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For example, the activities of respiratory chain complex enzymes vary between
brain regions (e.g. cortex, hippocampus, striatum), with high enzyme activities being
seen in the cortex. ETC enzyme activities also vary between synaptic and non-synaptic
mitochondria [34, 35]. Additionally, mitochondrial sensitivity to calcium-induced
permeability transition varies between brain regions and between synaptic and nonsynaptic mitochondria, with striatal mitochondria being more sensitive to calcium than
cortical mitochondria [36], and synaptic mitochondria being more sensitive to calcium
than non-synaptic mitochondria [37, 38].

It has been proposed that differences in

calcium sensitivities are in part due to concentrations of cyclophilin D (CyD), a protein
which interacts with the mitochondrial permeability transition pore (mPTP).

In fact,

higher concentrations of CyD are found in both striatum and synaptic mitochondria [36,
38]. Additionally, high concentrations of CyD have been found within the interneurons of
several brain regions and certain subpopulations of astrocytes [39]. Furthermore,
heterogeneity in calcium responses have also been reported within non-synaptic
populations, possibly due to differences in phosphate uptake [40].
Previous studies have revealed that synaptic mitochondria are more susceptible
to dysfunction than non-synaptic mitochondria [41-43]. In fact, non-synaptic mitochondria
can tolerate larger impairments to respiratory complex activity before ATP production is
significantly decreased [35]. Although the role non-synaptic neuronal mitochondria and
mitochondria derived from glial subtypes have in brain function should not be dismissed,
synaptic mitochondria are considered essential for proper neurotransmission and
synaptic plasticity, [44-46] processes which are impaired following TBI [47]. Synaptic
mitochondrial dysfunction has been implicated in neurodegeneration, as well as
degeneration of synapses and neurons absent overt cell death [37, 48, 49]. However,
specifically protecting synaptic mitochondria against injury may prove challenging as
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synaptic and non-synaptic mitochondria have been shown to have differential responses
to pharmacotherapy [50].
Currently, in order to examine the differences between synaptic mitochondria and
non-synaptic mitochondria the populations must be isolated and examined ex-vivo. In
the isolated mitochondrial preparations utilized in this dissertation, synaptic mitochondria
consist of pre-synaptic mitochondria located within the synaptosome, whereas nonsynaptic mitochondria consist of neuronal (axonal, somal, dendritic) and non-neuronal
(glial, vascular, etc.) mitochondria (Fig. 1.5).
The Role of Mitochondria, Oxidative Stress, Lipid Peroxidation, and Neurotoxic
Aldehydes in TBI
Reactive Oxygen Species, Reactive Nitrogen Species, and Peroxynitrite
Increases in intra-mitochondrial calcium following TBI lead to decreased
mitochondrial membrane potential, decreased mitochondrial bioenergetics/respiration,
and increased production of mitochondrial-derived reactive oxygen and nitrogen species
(ROS/RNS) [23, 51]. Although calcium-induced decreases in the membrane potential
may initially speed up the ETC in an attempt to maintain membrane potential [25],
eventually, exceedingly high levels of calcium [52], along with injury-induced damage to
electron transport complexes and upstream metabolic proteins, leads to ETC
impairment, and as respiration slows, single electrons leak from complex I (and to a
lesser degree complex III), and combine with O2, generating superoxide radicals (O2●-),
which rapidly react with the nitric oxide (●NO) generated by calcium-activated
mitochondrial nitric oxide synthase (mtNOS), forming peroxynitrite (PN) anion (ONOO-)
[53, 54].
O2● + ●NO → ONOO-
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Figure 1.5 Schematic of synaptic mitochondria. Synaptic mitochondria are isolated
from the presynaptic nerve terminal and represent a purely neuronal population. Nonsynaptic mitochondria are isolated from neuronal (e.g. axonal, somal, dendritic) and nonneuronal sources such as astrocytes (shown above) and endothelial cells (not shown).
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Protonation of ONOO- results in peroxynitrious acid (ONOOH) which
decomposes into nitrogen dioxide (●NO2) and hydroxyl (•OH) radicals. Alternatively,
ONOO- can react with CO2 to form nitrosoperoxocarbonate (ONOOCO2-) which
decomposes into the radicals ●NO2 and (CO●-3) [1, 55].
ONOO- + H+ → ONOOH → ●NO2 + •OH
ONOO- + CO2 → ONOOCO2- → ●NO2 + CO●-3
PN is demonstratively increased following brain and spinal cord injury [56-59]
and because of its unique diffusion radius, mitochondrial-derived PN and its products are
capable of damaging multiple cellular structures including proteins, lipids and nucleic
acids [1, 55]. In addition to reactive species derived from the ETC and mtNOS, the outer
mitochondrial membrane enzyme, monoamine oxidase, which is responsible for
oxidation of monoamines such as dopamine (DA), serotonin (5-HT), norepinephrine
(NE), and epinephrine (EPI) can also serve as a source of mitochondrial generated
reactive species.
Does Calcium Always Increase Generation of Mitochondria-Derived Reactive
Species?
Although increases in intra-mitochondrial calcium have been presented to lead to
increased production of ROS/RNS, there is some controversy surrounding this topic
depending on experimental conditions. For example, in naïve mitochondria calcium
decreases respiration [52] and decreases production of mitochondrial-generated
ROS/RNS, suggesting that because increases in calcium can immediately induce
decreases in respiration, increases in mitochondrial generation of ROS/RNS may be a
secondary event [52].
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In fact, calcium-induced increases in mitochondrial generated ROS/RNS may
require induction of additional pathologies. For example, mitochondrial permeability
transition (mPT) has been shown to be required for calcium-induced mitochondrial
production of ROS, possibly because mPT decreases the ability of endogenous
mitochondria antioxidants, such as glutathione (GSH) and NADH to attenuate ROS
production [60]. Additionally, inhibition of complex I (NADH dehydrogenase) [61-63] or
the presence of pro-apoptotic proteins [62] have been shown to be required for calcium
to induce increases in mitochondrial derived ROS/RNS.
However, it is difficult to extrapolate the findings of studies which utilized isolated
mitochondria ex-vivo to in-vivo pathologies, particularly because in-vivo calcium
regulation is complex and includes additional organelles, such as the endoplasmic
reticulum [52, 63]. If, in fact, respiratory dysfunction does precede calcium-induced
increases in mitochondrial ROS/RNS, it is possible that non-mitochondrial sources of
oxidative stress (see below) may contribute to the initial respiratory deficits. For
example, PN is capable of inactivating several mitochondria enzymes such as Complex I
and II, creatine kinase, ATP synthase, aconitase, voltage-dependent anion channel
(VDAC), and Mn-SOD (mitochondrial superoxide dismutase 2) [52, 54]. Although it is
likely that mitochondrial generated ROS/RNS exacerbates dysfunction of these
enzymes, it is possible that their initial dysfunction could be caused by non-mitochondrial
sources of PN.
Non-Mitochondrial Sources of Oxidative Stress
In addition to the O2•- produced by the mitochondria during oxidative
phosphorylation, O2•- is produced during several other processes, including metabolism
of purines by xanthine oxidase, autoxidation of biogenic amines, metabolism of biogenic
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amines by monoamine oxidase, and nicotinamide adenine dinucleotide phosphate
(NAD(P)H) oxidase generation of inflammatory cell oxidative bursts [1, 64]. In fact, in
addition to mitochondria, glial cells represent a significant source of ROS [64].
The metabolism of arachidonic acid, a polyunsaturated fatty acid abundant in
cellular membranes, also accounts for generation of ROS [1, 64]. Following brain injury,
phospholipases are activated resulting in the release of arachidonic acid. Arachidonic
acid is metabolized by cyclooxygenases and lipoxygenases in order to produce a variety
of signaling molecules, resulting in formation of ROS in the process [64].
•NO, which reacts with O2•- to form PN, can also be generated from several nonmitochondrial sources. For example, calcium-activated endothelial NOS (eNOS)
neuronal NOS (nNOS), and calcium-insensitive inducible NOS (iNOS) all lead to
generation of NO• [59]. In fact, increases in NOS expression following experimental TBI
coincide with PN-induced protein damage [59].
Endogenous Mitochondrial Antioxidants
As a major site of ROS/RNS generation under both pathologic and physiologic
conditions, mitochondria require endogenous antioxidant systems. Although the O2●generated through mitochondrial respiration can go onto react with NO ● to form PN, this
is not always its fate. O2●- can spontaneously dismutate to form H2O2, a reaction that is
catalyzed by superoxide dismutase (SOD) [1, 65]. Mitochondria contain a specific form
of SOD within their matrix, termed MnSOD or SOD2 [65] as well as the cytosolic Cu,ZnSOD or SOD1, within their intermembrane space [66]. Additionally, cytochrome c can act
as an antioxidant in the removal of O2●- and H2O2 [66]. Another electron carrier within the
electron transport chain, ubiquinone, similarly has antioxidant properties [66, 67].
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Although H2O2 is less reactive than its O2●- predecessor, it can itself be
damaging, particularly in the presence of iron, which catalyzes the Fenton reaction,
resulting in the highly reactive OH•.
Fe2+ + H2O2 → Fe3+ + •OH + OHFortunately, as glutathione peroxidases (GPx) are present within the
mitochondria, H2O2 can be reduced to H2O by the glutathione (GSH)/GPx system, which
is itself also capable of scavenging •OH [66]. Additionally, the reduction of H2O2 to H2O
can be catalyzed by peroxiredoxins and thioredoxins, enzymes present within brain
mitochondria, as well as catalase which is present in brain mitochondria, albeit in small
quantities [66]. Furthermore, NAD(P)H, a hydrogen donor, can participate in the
regeneration of GSH, as well as directly scavenge both ●NO2 and CO●-3 [66]. Additional
antioxidants located in brain mitochondria include ascorbic acid (i.e. vitamin C) and αtocopherol (vitamin E), which is capable of scavenging lipid peroxyl radicals present
within the mitochondrial membranes [66].
Lipid Peroxidation (Fig. 1.6)
Lipid Peroxidation: Initiation
The highly reactive PN-derived radicals,

●

NO2, •OH, CO●-3, initiate lipid

peroxidation (LP) by extracting a hydrogen atom and its electron from a polyunsaturated
fatty acid, such as arachidonic acid, which is highly enriched in neurons and cellular and
organelle membranes, forming a lipid radical (L●) [1, 55].
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Figure 1.6 Phases of lipid peroxidation. Initiation, propagation and termination of lipid
peroxidation of arachidonic acid, including catalysis of propagation by Fe++, and the
resulting formation of the lipid peroxidation-derived neurotoxic aldehyde 4hydroxynonenal (4-HNE). Adapted from Hall et al. 2010 [1].
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Lipid Peroxidation: Propagation
The lipid radical (L●) allows for self-propagation of lipid peroxidation (LP) to occur
throughout adjacent polyunsaturated acids, as it first reacts with O2 to form a lipid
peroxyl radical (LOO●) capable of extracting a hydrogen atom and it’s electron from
neighboring polyunsaturated acids, generating another lipid radical (L●) able to
participate in further propagation reactions [1, 55]. Although LP is considered to be a
self-propagating process, it is also catalyzed by the presence of iron, particularly in the
acidic tissues of TBI [1]. Following TBI, decreases in pH cause iron to be released from
the iron storage proteins, ferritin and transferritin, with additional iron being released
from the hemoglobin deposited during hemorrhages and microbleeds [1].
Lipid Peroxidation: Termination
LP terminates upon breakdown of the peroxidized polyunsaturated fatty acids to
form neurotoxic aldehydic end products, such as 4-hydroxynonenal (4-HNE) and 2propenal (acrolein) [1, 55]. It is well-established that oxidative stress, LP, and the LPderived aldehydes are increased in several CNS pathologies including TBI [57, 68-73],
spinal cord injury (SCI) [74, 75], ischemic-reperfusion injury and stroke [64, 76], multiple
sclerosis [64, 77], neurodegenerative disease [64], epilepsy [64], and psychiatric
disorders [64], as well as other conditions which involve oxidative stress such
atherosclerosis, diabetes, and obesity [78].
Lipid Peroxidation-Derived Aldehydes: 4-HNE and Acrolein
Although the breakdown of polyunsaturated fatty acids can result in multiple
classes of aldehydic end products including α,β-unsaturated aldehydes, di-aldehydes,
and keto-aldehydes, the α,β-unsaturated aldehydes, namely 4-HNE and acrolein, are
the most abundant and toxic products of LP [79]. Additionally, as 4-HNE and acrolein
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were assessed as part of this dissertation work, 4-HNE and acrolein will be the two
products discussed here by name.
The neurotoxic aldehydes, 4-HNE and acrolein, are stable, diffusible endproducts, with acrolein being the more reactive of the two [79]. In addition to being a
product of LP, acrolein is a well-known environmental pollutant and can also be formed
by other physiologic processes such as the metabolism of spermine or hydroxyl-amino
acids [79]. 4-HNE and acrolein covalently bind lysine, histidine, arginine and cysteine
protein residues through both Schiff base and Michael addition reactions (Fig 1.7), and
have multiple reactive sites which allows for formation of cross-linkage reactions [1, 7981]. Neurotoxic aldehydes can be metabolized through conjugation with the endogenous
antioxidant GSH or through oxidation/reduction of their carbonyl groups by enzymes
such as alcohol and aldehyde dehydrogenase [79, 82]. However, once neurotoxic
aldehydes bind proteins, the protein-aldehyde conjugates are often targeted for
degradation by the proteasome [83]. Additionally, once covalently bound to proteins,
such as occurs following TBI, LP-derived aldehydes induce protein dysfunction and
enzyme inactivation, neurotoxicity and cellular death [77, 84-89].
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Figure 1.7 Acrolein and 4-HNE reactions. The multiple reactive sites of 4hydroxynonenal (4-HNE) and 2-propenal (acrolein) can react with various amino acids
including lysine, histidine, and cysteine through both Schiff base and Michael addition
reactions. Adapted from Vaishnav et al. 2010 [29].
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Although LP-derived aldehydes have been shown to bind and inactivate a vast
array of cellular proteins [79, 81, 90-96], due to their polyunsaturated fatty acid
composition and as a major site of PN formation, mitochondria are particularly
susceptible to attack by LP-derived neurotoxic aldehydes [17, 68, 90, 91]. Binding of 4HNE and acrolein to mitochondria results in extensive mitochondrial dysfunction through
impairment of mitochondrial respiration and enhanced generation of ROS/RNS [29, 7173, 97-99]. Following TBI, binding of LP-derived neurotoxic aldehydes to mitochondrial
proteins further exacerbates TBI-induced impairment of mitochondrial bioenergetics and
the initial ROS/RNS-LP-aldehyde cascade (Fig 1.8), which combined with high levels of
intra-mitochondrial calcium concentrations can lead to opening of the mitochondrial
permeability transition pore (mPTP) [29, 51, 53, 60, 72, 93, 100-102].
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Figure 1.8 Downstream effects of mitochondrial dysfunction. Mitochondria
generated ROS/RNS initiate LP and the formation of the LP-derived neurotoxic
aldehydes 4-HNE and acrolein. 4-HNE and acrolein exacerbate mitochondrial
dysfunction and opening of the mPTP. Additionally, 4-HNE and acrolein-induced
mitochondrial dysfunction increases generation of ROS/RNS, creating a ROS/RNS-LPneurotoxic aldehyde-mitochondrial dysfunction-ROS/RNS feedback loop. ROS/RNS =
reactive oxygen species/reactive nitrogen species, LP = lipid peroxidation, 4-HNE = 4hydroxynonenal, mPTP = mitochondrial permeability transition pore.
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Mitochondrial Permeability Transition Pore
The mPTP is a non-selective mega channel. Upon formation it forms a pore
between the inner and outer mitochondrial membranes that is permeable to solutes
<1.5kDa [51]. Although the structure of the mPTP is not entirely elucidated it has been
proposed to contain the inner mitochondrial membrane protein adenine nucleotide
translocase (ANT) and the outer mitochondrial membrane protein VDAC [51].
Additionally, more recent studies suggest ATP Synthase is involved in pore formation
[25]. Although the matrix protein cyclophilin D (CypD) is not a structural component of
the mPTP, it can induce mPTP formation through interactions or ANT (or possibly with
ATP Synthase [25]) which results in conformational changes [103]. However, CypD is
not considered essential for mPTP formation as CypD knock-out mice can still undergo
permeability transitions when subjected to high concentrations of substrates capable of
inducing mPTP [103]. Additionally, some forms of permeability transition are considered
to be insensitive to cyclosporine A (CsA), a compound that inhibits mPTP formation by
binding CypD and inhibiting its ability to translocate to ANT to induce pore formation
[103] (Fig. 1.9). Calcium, oxidative stress, a decrease in membrane potential, and
inorganic phosphate (Pi) can induce mPTP opening, while opening of the channel can
be inhibited by magnesium (Mg2+), high membrane potential, ADP, or through
pharmacological means (e.g. CsA) [51].
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Figure 1.9 Schematic of the mitochondrial permeability transition pore (mPTP).
CsA binds to the matrix protein cyclophilin D, which prevents cyclophilin D from
translocating to the inner mitochondrial membrane and binding the mPTP protein ANT,
thus preventing induction of the confirmation change required for mPTP opening. Figure
originally adapted from www.mitosciences.com.

28

Under pathologic conditions, opening of the mPTP leads to extrusion of calcium
back into the cytosol, collapse of the membrane potential, cessation of ATP generation,
mitochondrial swelling, rupture of the outer mitochondrial membrane, and release of
cytochrome c and other apoptotic proteins [51, 104]. However, under physiologic
conditions mPTP functions to produce ROS signaling molecules, as well as to regulate
calcium concentrations in the microenvironment through transient openings and closings
[105].
Downstream Consequences of Mitochondrial Dysfunction
ATP Depletion
Following TBI, neurons are in a state of high energy demand. Upon massive
depolarization and ionic influx, cellular membrane pumps, such as Na+/K+ ATPase and
Ca2+ ATPase must utilize ATP in an attempt to restore ionic balance [16]. Neurons
primarily utilize glucose as an energy source and the initial demand for ATP following
TBI is met by acute increases in glucose uptake. However, this acute increase is
followed by a severity-dependent decrease. There are several possibilities for this
decrease in glucose uptake including decreased cerebral blood flow, impairment of
glucose transporters, and impairment of glucose metabolic processes upstream of the
citric acid cycle (TCA), decreasing the overall pool of pyruvate available to the
mitochondria for ATP generation [27]. Additionally, as calcium influx decreases the
mitochondrial membrane potential, ATP synthase begins to slow and has the potential to
run in reverse [25]. With limited substrate available to begin with, calcium-overloaded,
aldehyde-modified, low membrane potential, dysfunctional mitochondria are unable to
produce the amount of ATP required to meet the high energy demands of the injured
brain.
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Calpain Activation & Necrosis
Calpain is a calcium-activated protease capable of breaking down a variety of
cytoskeletal proteins including αII-spectrin [106], a scaffolding protein associated with
the inner surface of the plasma membrane [107]. As stated previously, following TBI the
induction of the secondary injury cascade relies heavily on increased intracellular
calcium levels. Although calpain can be activated by early increases in intracellular
calcium, calcium homeostatic mechanisms, including sequestration of calcium by the
mitochondria prevent much of the initial activation. However, once the mPTP opens
intra-mitochondrial calcium is extruded back into the cytosol where it can again activate
calpain [51]. Calpain cleavage of the 250kD αII-spectrin protein results in 145kD
(calpain-only) and 150kD (calpain/caspase 3) spectrin breakdown products (SBDP)
[106]. Formation of SBDP proceeds neurodegeneration, and SBDP have been used
extensively to assess post-TBI axonal damage and the efficacy of neuroprotective
agents [56, 70, 108-112]. In fact, prevention of mPT, inhibition of the ROS/RNS-LPaldehyde cascade, and induction of endogenous antioxidant pathways have all been
shown to attenuate αII-spectrin degradation [70, 109, 110, 113].

In TBI, calpain

activation is thought to be predominately associated with necrosis [70, 106]. In fact, in
the rat model of severe controlled cortical impact traumatic brain injury (CCI) utilized
throughout this dissertation, the 120kD SBDP (caspase/apoptosis-dependent) has been
shown to not increase with injury [73].
Caspase Activation & Apoptosis
Following opening of the mPTP or increases in mitochondria outer membrane
permeability, mitochondria can release pro-apoptotic proteins such as cytochrome c,
apoptosis inducing factor (AIF) and Smac/Diablo, leading to a cascade of caspase
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activation, including activation of the executioner caspase, caspase-3 [51, 106]. In
addition to DNA-fragmentation, caspase-3 can cleave αII- spectrin, resulting in 150kD
(calpain/caspase-3) and 120kD fragments [106]. As stated previously, cell death in TBI
is thought to be predominately necrotic. However, TBI-associated apoptosis has been
documented, particularly in pathologies involving ischemic injury [106, 114], and
caspase-3-dependent SBDP have been found to occur in the CSF of rats following
moderate CCI, albeit inconsistently and to a lesser degree than calpain-dependent
products [115].
Neurodegeneration
In addition to αII-spectrin, calcium-activated calpain can cleave a variety of other
cytoskeletal proteins including MAP2 (microtubule-associated protein 2) and tau [51,
104, 106, 116]. One of the consequences of cytoskeletal degradation following TBI is
impairment of axonal conductance and axonal transport [117]. Impairment of axonal
transport can result in the accumulation of proteins, such as amyloid precursor protein
(APP) in axonal varicosities and bulbs of damaged neurons [51, 104, 106, 116].
Additionally, cytoskeletal degradation and impairment of axonal transport interfere with
the transport of organelles, such as the transport of healthy mitochondrion from the cell
body to the synapse [118], where loss of synaptic mitochondria can result in synaptic
degeneration [37, 48, 49] and impairment of synaptic plasticity [119]. The degradation of
the cytoskeleton can further impair mitochondria by interfering with normal mitochondrial
quality control measures such as fission and fusion, processes essential to maintaining
mitochondrial health and function, particularly under times of stress such as occurs
following TBI [120].
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Sensitive methods for assessing neurodegeneration, such as de Olmos
aminocupric silver staining, which specifically stains degenerating neurons and neuronal
processes have revealed that following experimental TBI neurodegeneration often
occurs to a much greater than that of overt neuronal loss or cavitation, even in primarily
focal injury models such unilateral CCI [121].

In fact, following unilateral CCI,

neurodegeneration has been demonstrated to occur throughout the ipsilateral cortex,
hippocampus and thalamus, as well as to extend into the contralateral hemisphere [121].
Previous studies have demonstrated that both mitochondrial dysfunction and LP
contribute to the neurodegenerative process, as pharmacologic interventions aimed at
attenuating mitochondrial dysfunction and inhibiting the ROS/RNS-LP-aldehyde cascade
have been shown to decrease neurodegeneration following injury. For example,
compounds which target these processes such as CsA and NIM811 [110, 122-124], PZ
[71, 72], tempol [109], mitochondrial uncouplers [125], and N-acetylcysteine (NAC) [126]
are all able to attenuate neurodegeneration or neuronal cell death following TBI.
Time Course of Oxidative Stress, Mitochondrial Dysfunction, and
Neurodegeneration Following TBI
Formation of OH• occurs as early as five minutes following experimental TBI
[161, 162]. Within 30min, there is a significant decrease in cortical and hippocampal
mitochondrial respiration, an effect which dissipates 1h post-injury [163]. However,
because the ability of mitochondria to buffer calcium 30min post-injury remains intact, it
is speculated that this initial burst of oxidative stress [161, 162] induces mitochondrial
respiratory dysfunction without inducing permeability transition, allowing mitochondria
the ability to functionally recover from early incidences of oxidative stress [163].
However, by 3h post-injury, decreases in mitochondrial respiration reappear and
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coincide with a decrease in calcium buffering capacity [163]. Although there is some
evidence to suggest a slight recovery between 3h and 24h, this possibility can be
explained by the most damaged mitochondria being processed out prior to the 24h time
point [73, 163]. Beyond 24h, mitochondrial respiratory dysfunction continues to
deteriorate, reaching peak impairment 72h following severe CCI [73]. By five days postCCI, mitochondrial respiration has begun to recover, likely due to further removal of
impaired mitochondria as damaged tissue continues to degenerate [73]. However, it
must be noted that decreases in mitochondria respiratory function and membrane
potential have been documented as far out as two weeks following experimental TBI [22,
134].
Increases in cortical or hippocampal 3-nitrotyrosine (3-NT, marker of PN
damage), 4-HNE, and SBDP have been identified as early as 30-60 min following TBI in
mice [56, 57]. However, this time course seems to be slightly delayed in the rat [73, 121],
with small increases in cortical or hippocampal 3-NT, 4-HNE, acrolein and SBDP
beginning as early as 8h and peaking between 48h and 72h in severe CCI before
returning to baseline levels 5d to 7d following injury [73]. Regardless of species, these
processes do precede cortical and hippocampal neurodegeneration, as well as
increases in cortical lesion volume [121, 164] because although levels of mitochondrial
dysfunction, LP, and spectrin degradation have returned to baseline by 5-7days
following severe CCI [73], neurodegeneration and cortical lesion volumes continue to
progress [56, 121, 164]. In fact, although cortical contusions can be seen early following
experimental TBI, volumes continue to increase until at least 28 days post-injury [164].
Up until this point the process of mitochondrial dysfunction, LP, LP-derived
aldehyde formation, and spectrin degradation have been presented to occur in a linear
fashion for simplicities sake. However, time course studies are an important reminder
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that many of these processes can occur simultaneously. Although significant
impairments to mitochondrial respiration do appear to occur prior to these other
processes, the observation that peak dysfunction for many of these processes occurs
between 48h and 72h following severe CCI [73], reinforces the idea that these
processes often work synergistically to exacerbate each other’s dysfunction.
Time Course of Antioxidant Depletion Following TBI
Following TBI, increases in ROS/RN, LP, and neurotoxic aldehydes result in the
depletion of endogenous antioxidants. However, the temporal decrease in antioxidant
activities is variable across experimental TBI studies [165, 166]. Following unilateral CCI
decreases in a wide range of antioxidants (e.g. GSH, SOD, catalase, GPx, etc.) have
been reported to occur in both hemispheres and the hippocampus beginning as early as
3-6h following injury, with some enzymes remaining significantly decreased out to 4 days
post-TBI [165, 166].
Although the body has mechanisms for upregulating endogenous antioxidant
systems during times of oxidative stress, including through binding of the transcription
factor, nuclear factor (erythroid-derived 2) (Nrf2), to the antioxidant responsive element
(ARE), mRNA expression for several of the Nrf-2-ARE regulated antioxidants, such as
heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NqO1), and glutathione
S-transferase (GST), do not begin to increase until 24h to 72h following injury [111],
much later than 3-6h post-injury timeframe in which antioxidants begin to deplete
following TBI [165, 166].
Behavioral Impairment
In human patients, TBI often results in long-term neurobehavioral dysfunction,
including cognitive deficits (e.g. attention, memory), aggression, and psychiatric, mood,
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and anxiety disorders [127], sequelae that can be recapitulated in animal models,
although most behavioral outcome assessments in experimental TBI have focused on
motor and sensory dysfunction and impairments to learning and memory.
It is unsurprising that TBI would have neurobehavioral consequences given the
widespread neurodegeneration and neuronal dysfunction that is seen in both animal
models of injury [56, 57, 121, 128] and in human TBI patients [129-131]. Although the
behavioral impairments that occur following TBI will vary depending on the specific
neurons, pathways and networks affected by injury, mitochondria dysfunction contributes
to development of TBI-induced behavioral deficits, and pharmacologic protection of
mitochondria and inhibition of downstream consequences of mitochondrial dysfunction
such as LP and spectrin cytoskeletal degradation are able to attenuate behavioral
deficits following experimental TBI [109, 110, 123, 125, 126, 132, 133]. Although
mitochondrial dysfunction has been shown to precede behavioral impairment [134],
behavioral deficits can be seen as early as one day following injury, particularly in
regards to motor dysfunction [109, 135-137]. Similarly, although the majority of
experimental TBI studies begin assessments of cognitive function at least one week
following injury [135, 138-140], early cognitive deficits have also been reported [141144].
The experimental model of TBI utilized here, a unilateral CCI onto the motor and
sensory parietal cortex, although not assessed as part of this dissertation work,
expectedly can produce motor and sensory deficits [109, 110, 145]. However, this type
of CCI also can induce cognitive impairment. For example, severe unilateral CCI
produces widespread degeneration throughout the hippocampus [121, 128], a brain
region involved in forming new memories and in spatial memory [146, 147], and
throughout the thalamus [121, 128], a subcortical structure through which a variety of
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important neuronal tracts pass [148, 149]. Additionally, although the prefrontal cortex is
responsible for the majority of executive functions, neuronal projections involved in
executive function extend throughout the cortex beyond the pre-frontal region [150, 151].
Therefore, injuries sustained in anatomic regions distinct from the pre-frontal cortex,
such as a CCI onto the sensory-motor cortex, additionally put these projections at risk
due to Wallerian/anterograde and retrograde degeneration [121]. In fact, unilateral CCI
to the sensory-motor cortex has been shown to result in executive function (e.g.
motivation, planning, problem-solving, working memory) related behavioral deficits [152].
Although there are several behavioral tests available to assess cognitive function
following experimental TBI, the work in this dissertation utilized the Morris water maze
(MWM), a task which evaluates spatial, working and reference memory. Briefly, in MWM
animals are placed into a circular, featureless pool, filled with opaque water, and
surrounded by visual cues. During the acquisition phase, which assesses working
memory, animals are allowed 60s to find a submerged platform after which they are
allowed to remain on the platform for approximately 20s. Animals which do not find the
platform are manually guided and placed onto the platform. Animals are given several
trials per day over the course of multiple days, and as the animals learn the location of
the platform, the time and distance it take to find the platform should decrease [146,
147]. Following the acquisition phase a probe trial is utilized to test reference memory
[147]. In the probe trial, the platform is removed and animals are given 30s to search for
the previously learned platform location [147].
Overt damage to several distinct brain regions have been shown to impair MWM
performance, including damage to the hippocampus, cortex, thalamus, raphe nuclei, and
striatum [146]. However, overt damage to specific anatomical regions is not required to
induce MWM impairment per se, as dysfunction in the neural communication networks
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between regions also result in impairments to spatial learning and memory [146]. For
example, although the hippocampus is necessary for consolidation, storage, acquisition
and retrieval of spatial memory, spatial navigation is complex and requires coordination
of several brain regions, including the cortex, as cortical input is required for the planning
and execution of the task [146].
In addition to distinct anatomic regions, specific neurotransmitters, such as
norepinephrine (NE), serotonin (5-HT), and dopamine (DA) have an important role in
cognitive and motor function [150, 151, 153-155]. Although not addressed as part of this
study, the neurotransmitter acetylcholine also plays an important role in cognition [385].
In fact, acetylcholinesterase inhibitors, such as donepezil, are often used clinically to
treat memory disorders, as are NMDA antagonists, such as memantine [385]. In regards
to the monoaminergic system, stimulants, which modulate the DA system, also are
clinically used to improve cognition and attention [385]. However, the role each
monoamine has in spatial learning in memory remains controversial. For example, drugs
which can modulate these systems (e.g. monoamine oxidase inhibitors (MAOI), selective
serotonin reuptake inhibitors (SSRI), amphetamines, DA agonists, 5-HT agonists) have
variously been reported to improve, decrease, or have no effect on spatial learning and
memory performance [146, 156-159].
There are several caveats to utilizing MWM in the assessment of spatial learning
and memory. For example, although the intent of MWM is to evaluate spatial learning
and working memory by requiring animals to utilize distal cues to locate the platform,
animals can utilize other strategies such as a learned set of movement sequences or
use of proximal cues [146]. However, varying the start position of trials each day and
using featureless pools with opaque surfaces, as was done in the current dissertation
work, should help to control for these factors. Furthermore, MWM performance is often
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considered independent of locomotor deficits [147] and probe trial performances have
been reported to be insensitive to swim speed deficits [147]. However, that assumption
is not entirely true as sensorimotor deficits can indeed interfere with MWM performance
[147]. For example, animals with sensorimotor deficits often continually follow the pool
perimeter without initiating a search pattern, jump off or swim over the platform [147],
thus reducing the ability of the animal to associate the platform with a means of escape,
which make it more difficult to accurately assess memory impairments [147].
Additionally, visual acuity is required for use of the distal MWM cues, which can be
concerning considering that visual pathways run through the thalamus [148] and have
been demonstrably damaged following experimental TBI, although this is more
commonly seen in closed head injury models [160]. Visual acuity can be assessed
through use of visual platform cues, such as a platform flag. However, such visual acuity
assessments were not conducted as part of this dissertation work [386].
An Introduction to Biogenic Amines
Biogenic Amines
Biogenic amines consist of polyamines (e.g. putrescine), trace amines, such as
phenethylamine (PEA), which exists endogenously as a metabolite of the amino acid
phenylalanine and as a metabolite of the drug PZ, and the monoamine neurotransmitters
[151, 169]. The monoamine neurotransmitters include the catecholamines DA, NE, and
epinephrine (EPI), as well as the non-catecholamines histamine and 5-HT [151, 169].
DA, NE, and EPI are synthesized sequentially from the amino acid tyrosine, while
histamine is derived from the amino acid histidine and 5-HT is derived from the essential
amino acid tryptophan [151](Fig. 1.10).
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Figure 1.10 Synthesis of the monoamines. Dopamine, norepinephrine, and
epinephrine are sequentially synthesized from the amino acid tyrosine. Histamine is
synthesized from the amino acid histidine, and serotonin (i.e. 5-HT) is synthesized from
the amino acid tryptophan.
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Biogenic Amine Anatomic Pathways and Physiologic Functions
Dopamine
Within the nervous system DA is involved in a wide range of processes including
movement, motivation, reward, addiction, memory, stress and mood [154]. Although the
majority of DA is found within the striatum, DA is found throughout the brain [154]. For
example, within the mesocorticolimbic system, DA neurons from the ventral tegmental
area project directly to the hippocampus and prefrontal cortex [153, 170]. Further,
although the nigrostriatal pathway, predominately involved in movement regulation,
consists of dopaminergic neurons projecting directly from the substantia nigra to the
striatum, it is part of complex circuitry that includes input and output to the motor cortex,
along tracts that pass through the thalamus [153]. As a catecholamine, in addition to
binding DA receptors, DA can bind adrenergic receptors [154]. Clinically, DA can be
used as a vasopressor to elevate cerebral perfusion pressure and mean arterial blood
pressure following severe TBI [154].
Norepinephrine
Within the brain NE neurons are concentrated in the locus coeruleus with
widespread connections to areas including the cortex, limbic system, and thalamus, and
it is involved in modulation of arousal, attention, mood, cognition and memory [150, 151].
As a catecholamine, NE, also known as the “flight or fight” neurotransmitter can bind
adrenergic receptors and induce sympathetic responses such as vasoconstriction [154,
171]. As such, similar to DA, NE can be used as vasopressor in clinical TBI [154].
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Serotonin
Within the CNS, 5-HT neurons arise from the raphe nuclei and project
extensively throughout most of the brain including the cortex, limbic system, and
thalamus [151], modulating arousal, mood, cognition and memory [155]. Interestingly,
the majority of 5-HT is found outside the CNS, within the gastrointestinal tract [155].
Additionally, 5-HT plays a role in platelet activation, vasodilation, and vasoconstriction
[172].
TBI and Acute Monoamine Dysregulation
Neurobehavioral sequelae following TBI are common and include dysregulation
of cognition (e.g. attention, memory), mood (e.g. depression, anxiety), and emotion (e.g.
aggression) [127]. Given the role the monoamines DA, NE, and 5-HT have in modulating
these domains, sustained neurobehavioral impairments following TBI points to chronic
dysregulation of monoamine neurotransmitter systems. However, as the goal of this
dissertation is to evaluate acute neuroprotective pharmacologic strategies, the following
brief discussion only includes acute changes in the monoamine systems following TBI.
In general, less is understood about acute effects to monoamine systems
following TBI, with the majority of work being focused on DA systems [154, 170].
Although DA is known to be acutely altered following experimental TBI [154, 170], some
studies indicate increased DA levels, whereas others report decreased DA levels
depending on brain region and time point [173, 174]. Additionally, other aspects of the
dopaminergic system such as DA synthesis, metabolism, and DA transporter protein
expression, have also been reported to be altered following TBI [175-177].
Similarly, NE levels and turnover rates have been demonstrated to be acutely
altered following experimental TBI, with variations again been seen across distinct brain
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regions [174, 178, 179]. Further, high NE levels have been shown to be associated with
worse outcomes and/or mortality rates in TBI patients [180, 181]. However, because
catecholamine levels increase with activation of the sympathetic nervous system, as
would occur following trauma, it is difficult to determine whether high catecholamine
levels following TBI are an actual cause or rather an effect of injury severity [181].
Less data are available regarding acute levels of 5-HT following TBI. However,
increases in extracellular 5-HT levels have been demonstrated to occur [182]. Similarly,
at subacute time points 5-HT expression has been shown to be increased [183]. On the
other hand, at subacute time points 5-HT transport protein expression has been reported
to decrease [184] and degeneration of 5-HT neurons has been seen following multiple
types of experimental TBI [185], unsurprising given the widespread projections of 5-HT
pathways throughout the brain.
Monoamine Metabolism
Monoamines are removed from the synaptic cleft by reuptake into pre-synaptic
nerve terminals and glial cells [151]. DA has two major metabolites, 3,4
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), both of which are
measured in this dissertation. The metabolism of DA involves three enzymes,
monoamine oxidase (MAO), catechol-O-methyl transferase (COMT), and aldehyde
dehydrogenase (ALDH), and the additional intermediate metabolite 3-methoxytyramine
(3-MT) [186] (Fig. 1.11).
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Figure 1.11 Simplified monoamine metabolism pathways. Dopamine is metabolized
by monoamine oxidase (MAO-A/B), catechol-O-methyl transferase (COMT), and
aldehyde dehydrogenase (ALDH) to form the metabolites 3,4 dihydroxyphenylacetic acid
(DOPAC) and homovanillic acid (HVA), and the intermediate metabolite 3methoxytyramine (3-MT). Norepinephrine (NE) is metabolized by MAO-A and COMT.
Serotonin (5-HT) is metabolized by MOA-A and ALDH to form 5-hydroxyindolacetic acid
(5-HIAA).
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MAO is located in the outer mitochondria membrane. MAO requires the presence
of the cofactor FAD+/FADH2 and oxygen to function [186]. ALDH is also a mitochondrial
protein, located within the matrix and requires the cofactors NAD+/NADH. COMT is a
cytosolic enzyme [186]. DA is metabolized by MAO-A/B and ALDH to form DOPAC
which can be further metabolized to HVA by COMT. Additionally, DA can first be
metabolized by COMT to form 3-MT before being further metabolized to HVA by MAOA/B and ALDH [186]. The metabolism of NE also involves MAO-A and COMT, as well as
a variety of other enzymes, and results in the formation of metabolites such
vanillylmandelic acid (VMA) and 3-methyoxy-4-hydroxyphenylglycol (MHPG) [186].
However, NE metabolites were not measured as part of this study due to their low
cortical tissue levels. 5-HT is metabolized to 5-hydroxyindoleacetic acid (5-HIAA) by
MOA-A and ALDH [186], and is measured as part of this dissertation.
As part of this dissertation work the cortical tissue levels of NE, DA, 5-HT and the
metabolites DOPAC, HVA, 5-HIAA were measured using HPLC [187]. The turnover of
DA to DOPAC/HVA and the turnover of 5-HT to 5-HIAA were used a surrogate measure
of MAO inhibition [188].
Monoamine Oxidase: An Outer Mitochondrial Membrane Protein
The MAO enzyme exists as two subtypes, MAO-A and MAO-B, both of which are
located in the outer mitochondrial membrane. MAO contains a flavin group allowing it to
participate in oxidative deamination reactions [186]. MAO is responsible for the
metabolism of the monoamine neurotransmitters NE, 5-HT, and DA, measured within
this dissertation, but additionally participates in the metabolism of EPI, several amino
acids, and PEA, a trace amine under physiologic conditions, but which is also an active
metabolite of PZ [186, 189]. MAO-A and MAO-B have differing substrate affinities. For
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example, MAO-A is selective for NE, 5-HT, and EPI, whereas MAO-B is selective for
PEA [186]. DA, on the other hand, is metabolized by both MAO-A and MAO-B [186].
However, the metabolism of DA by MAO differs between rodents and humans, with DA
being predominately metabolized by MAO-A in rats and MAO-B in humans [186]. In the
brain, monoamines are removed from the synaptic cleft by reuptake into pre-synaptic
nerve terminals and glial cells [151]. In fact, the majority of MAO in the brain is located
within the glia [190], with the MAO-B isoform predominating in glia as well as in
serotonergic neurons and platelets [190].
Monoamine Oxidase Inhibitors
Clinically, MAOIs have been used as anti-depressants, as MAO inhibition leads
to increases in neurotransmitters that are dysregulated in mood and other psychiatric
disorders. However, MAOIs, particularly irreversible inhibitors, have numerous side
effects, including several food interactions that can lead to a dangerous tyramine toxicity
syndrome and hypertensive crisis. With the development of newer class antidepressants, MAOIs are no longer considered a first-line therapy for depression [191].
Multiple classes of MAOIs exist, including irreversible MAO-A selective inhibitors,
irreversible MOA-B selective inhibitors (e.g. selegiline, rasagiline), irreversible nonselective inhibitors (e.g. PZ, isocarboxazide, tranylcypromine, pargyline), and several
reversible inhibitors, including methamphetamine (MAO-A selective) [191]. PZ,
isocarboxazide, and tranylcypromine have all been used clinically in the treatment of
anxiety and depression, while selegiline and rasagiline are currently used clinically to
treat the symptoms associated with Parkinson’s disease [191].
Given their use for the symptomatic treatment of neurodegenerative disease,
there has been increasing interest in studying the neuroprotective properties of MAOs
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[192]. However, in theory MAOIs could have both neuroprotective and neurotoxic
effects. For example, oxidative deamination of monoamine neurotransmitters by MAO,
generates ROS [193], suggesting that MAO inhibition could reduce ROS and provide a
therapeutic benefit. However, inhibition of MAO also leads to increases in biogenic
amines, such as DA, which is capable of directly inhibiting mitochondrial respiration
[194], and undergoing non-enzymatic autoxidative formation of toxic H2O2 and quinones
[194], suggesting that MAO inhibition could also lead to increases in neurotoxicity and
oxidative stress.
Although the plasma half-lives of the MAOIs vary, irreversible MAOIs have longer
lasting effects than their plasma half-lives suggest due to the rate of MAO turnover. In
fact, the half-life of MAO in the rat brain is 10-13 days [195], increasing to 30 days in
humans [196]. However, it must be noted that because effects on neurotransmitter levels
and behavior can require 65-80% MAO inhibition, the effective recovery time for MAO in
the rat brain may be as low as 4 days [186]. However, multiple doses of an MAOI may
prolong MAO inhibitory effects, as might TBI given the fact that regeneration of MAO
within presynaptic nerve terminals requires trafficking of MAO and mitochondrion to the
synapse [191].
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MAOI Properties of Phenelzine
Although PZ is classified as a non-selective MAOI, it is slightly more preferential
to MAO-A [197]. The structure of PZ contains a hydrazine moiety (-NH-NH2), which
confers it the ability to scavenge LP-derived neurotoxic aldehydes [72, 198] (Fig. 1.12).
However, this moiety is also purported to contribute to its ability to act as an irreversible
MAO inhibitor [199]. As a MAOI, PZ has both anti-depressant and anxiolytic properties
[169]. However, similar to other MAOIs, PZ is not clinically utilized as a first line therapy
to treat psychiatric disorders, although it is a choice for the treatment of atypical or
intractable depression [191].
In humans, following oral administration the plasma half-life of PZ is
approximately 11.5 hours [74], although following intraperitoneal administration in rats,
the half-life could be as short as 30min [74]. However, in regards to PZ’s MAOI
properties, the plasma half-life is of minimal importance, as the effects of irreversible
MAO inhibitors are prolonged and based on MAO turnover rates. In rats, the ED50 for
oral administration of PZ has been reported to be 6 mg/kg for MAO-A and 12 mg/kg for
MAO-B, resulting in a 2:1 selectivity ratio of MAO-A to MAO-B [197].

47

Figure 1.12 Chemical structures of phenelzine and pargyline. Phenelzine contains
an aldehyde-scavenging hydrazine moiety (-NH-NH2, circled in red), while pargyline
does not. However, PG contains an N-propargyl moiety (circled in blue)
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MAOI Properties of Pargyline
Pargyline (PG) is similarly structured to PZ, but does not contain the hydrazine
moiety (-NH-NH2) which gives PZ its aldehyde-scavenging capabilities (Fig. 1.12).
Instead, PG contains an N-propargyl moiety, which confers its MAOI effects [200].
Interestingly, the N-propargyl moiety, itself, has also been suggested to be
neuroprotective [201]. PG has been both referred to as a non-selective irreversible MAOI
[191], as well as a MAO-B specific irreversible inhibitor [197], likely based on IC50 values
of 0.011522 μmol/L for MAO-A and 0.00820 μmol/L for MAO-B [202]. However, in rats,
the ED50 for oral administration of PG has been reported to be 9.3 mg/kg for MAO-A and
1.4 mg/kg for MAO-B, resulting in a 6.6:1 selectivity ratio of MAO-B to MAO-A [197].
Although PG is classified as a MAOI, clinically it was used more frequently as an
anti-hypertensive than as an anti-depressant [203]. This is somewhat paradoxical as the
interaction between MAOIs and tyramine-containing foods can induce a hypertensive
crisis [191]. However, its anti-hypertensive properties are thought to be due to increased
NE levels acting on inhibitory α2-adrenergic receptors, such as those found in the
brainstem and periphery [204]. Therefore, it is possible that several other irreversible
MAOIs may also have anti-hypertensive effects.
Comparison of Phenelzine and Pargyline MAO Inhibitory Effects on Drug-Induced
Behavioral Changes
The MAOI drug class was developed decades ago. Therefore, recent
comparisons between PZ and PG are sparse. However, both drugs have been utilized
within single studies to assess the effects of MAOIs on drug (e.g. nicotine, cocaine,
ethanol) administration. Whereas it has been shown that PZ, but not PG is able to
enhance the discriminatory effects of nicotine [205] and nicotine-induced locomotor
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activity [206], both PZ and PG are able to decrease cocaine [207] and ethanol selfadministration, with PZ requiring lower doses and producing prolonged effects compared
to PG [208].
TBI and Neuroprotective Drug Development
Failure of Clinical TBI Drug Trials
Guidelines for acute management of severe TBI do exist. However, these
guidelines contain supportive measures such as monitoring and management of
intracranial pressure, cerebral perfusion pressure, and systolic blood pressure [209].
Although there are interventions available, for example, utilization of decompressive
craniotomy, CSF drainage, and hyperosmolar therapy for the control of intracranial
pressure
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consequences that can occur following TBI [1]. However, this is not for lack of effort.
Recently, large scale clinical trials for progesterone failed to improve outcome
following TBI [210]. Similarly, glutamate antagonists, steroids, antioxidants, antiepileptics, and erythropoietin clinical TBI trials have all failed [211, 212]. Numerous
reasons have been cited for the failure of neuroprotective compounds in clinical TBI
studies, such as heterogeneity of injury, lack of consideration for pre-injury and postinjury factors, reliance on clinical assessments of injury insensitive to injury pathology
such as GCS score, lack of sensitivity in outcome measures or use of inappropriate
outcome measures, lack of appropriate subgroup analyses, inadequate pre-clinical
experimental design, and lack of understanding of secondary injury mechanisms [9, 211,
213, 214]. However, within the context of pre-clinical experimental design and the
complexity of the secondary injury cascade, it is conceivable that investigation into
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innovative

pre-clinical

neuroprotective

pharmacological

strategies,

such

as

combinational therapies or single drugs with multiple neuroprotective mechanisms of
action, may improve the success of future clinical trials.
Review of Selected Neuroprotective Strategies
A multitude of neuroprotective strategies have been investigated in experimental
TBI models, including but not limited to NMDA antagonists, calpain inhibitors, hormonal
therapy, attenuation of neuroinflammation, stem cell administration, induction of
neurogenesis, hypothermia, environmental enrichment, and post-injury rehabilitation,
[215, 216]. Although all have led to a greater understanding of TBI pathophysiology, the
following discussion will focus on a selection of therapies directed toward attenuation of
mitochondrial dysfunction and oxidative stress. Use of monoamine modulators will also
be briefly discussed.
Targeting of Mitochondrial Dysfunction
Due to the significant role mitochondria serve in secondary injury processes, they
have been and continue to be therapeutic targets for neuroprotection following TBI.
Several strategies have been utilized in attempts to improve mitochondrial function and
prevent downstream consequences of dysfunction following TBI, including but not limited
to inhibition of the mPTP, mild uncoupling, and use of alternative energy sources such
as ketones.
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Inhibition of mPTP: Cyclosporine A and NIM811
CsA (Fig. 1.13) is an FDA-approved immunosuppressant, used clinically to
prevent organ rejection after transplant through a mechanism that involves inhibition of
calcineurin and T-cell activation [217]. However, CsA also has the ability to bind the
mitochondrial matrix protein cyclophilin D (CyD) [218, 219], which inhibits its interaction
with ANT, an inner mitochondrial membrane protein, thus preventing formation of the
mPTP [220]. Although under normal physiologic conditions CsA is minimally blood brain
barrier (BBB) penetrable [221], CsA is able to enter the CNS following TBI due to
increases in BBB permeability following injury [222].
In experimental TBI, CsA and NIM811, an mPTP inhibitor but nonimmunosuppressive analog of CsA, have been shown to protect against mitochondrial
dysfunction, decrease production of reactive species and their termination products,
decrease cytoskeletal degradation, attenuate axonal pathology and neurodegeneration,
improve cortical tissue sparing, and improve motor and cognitive function [110, 122-124,
135, 136, 223-227].
Although there are studies to suggest that the immunosuppressive properties of
calcineurin inhibitors (e.g. CsA, tacrilomus) have neuroprotective effects [228-233], the
ability of NIM811 to recapitulate the neuroprotective effects of CsA, confirms mPTP
inhibition as a means of neuroprotection.
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Figure 1.13 Chemical structure of cyclosporine A
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To date, large scale clinical trials utilizing CsA have not been conducted,
however, small phase II trials have shown CsA to be safe for use clinically in severe TBI
patients [234, 235], with the possibility of improved outcomes being seen with a
continuous infusion dosing paradigm. However, CsA does have some concerning
properties that could make clinical dosing in the TBI patient population challenging, such
as a biphasic dose-response curve, [227] and the fact that it is both a substrate and an
inhibitor of ATP-dependent p-glycoprotein drug efflux pumps [236]. Additionally,
depending on the concentration and length of dosing, CsA and its vehicle, cremophor,
have associated toxicities, including neurotoxicities [237-245].

Furthermore, CsA is

metabolized by Cyp3A4 and therefore has several adverse drug interactions [246].
Mild Uncoupling
Although mitochondria serve an important role in maintaining calcium
homeostasis following TBI, high concentrations of intra-mitochondrial calcium can lead
to increased production of ROS, collapse of mitochondrial membrane potential, and
induction of mPT [125]. Therefore, it is important for mitochondria to maintain an optimal
balance between the two scenarios, particularly under the stressful conditions that occur
following TBI. Hence, somewhat counterintuitively, decreasing the mitochondrial
membrane potential (i.e. a more positive membrane potential) should result in decreased
uptake of positively charged calcium ions, resulting in decreases in ROS production and
improved mitochondrial function [125]. One way to decrease mitochondria membrane
potential is to mildly uncouple the ETC from ATP synthesis, allowing protons to bypass
ATP synthase, and freely flow down their gradient through the inner mitochondrial
membrane into the mitochondrial matrix [125]. Although mitochondria endogenously
express uncoupling proteins [247], uncoupling can also be induced through
pharmacologic means through use of chemical uncouplers such as 2,4-dinitrophenol
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(2,4-DNP) and FCCP [125]. In fact, following TBI mild uncoupling can improve
mitochondrial respiration, decrease ROS production, improve cortical tissue sparing and
improve motor and cognitive function [125, 248].
Ketones
Although the brain relies on glucose as its primary energy source [27], alternative
energy substrates, such as ketone bodies do exist. Upon depletion of glucose the body
can shift to catabolism of fatty acids, generating ketones in the process, such as βhydroxybutyrate. During the conversion of β-hydroxybutyrate to acetyl-coA, the complex
II substrate succinate is formed, bypassing the citric acid cycle (TCA). From there,
acetyl-coA can enter the citric acid cycle (TCA), producing complex I and II substrates,
while bypassing the need for glycolysis [139]. Ketones can be provided either directly
through administration of β-hydroxybutyrate, or through ketogenic diets and fasting. In
TBI, ketones have been shown to improve cortical tissue sparing, decrease cognitive
impairment, decrease oxidative stress, and improve mitochondrial function [139]. In
addition to being utilized as an alternative substrate, it is possible ketones also provide
their neuroprotective effects through direct antioxidant mechanisms and through
activation of uncoupling proteins [249, 250]. However, the utility of ketones as
neuroprotectants may be limited to juveniles, as juvenile brains are better able to utilize
non-glucose energy substrates and use of ketones in TBI seems to be more effective in
this population [27, 249].
Targeting of ROS/RNS, LP, and LP-Derived Neurotoxic Aldehydes
Select Antioxidant Therapies
A multitude of antioxidants have been utilized over the decades in an attempt to
attenuate oxidative stress following TBI [1, 55]. In this context, “antioxidant” will refer to
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compounds with the ability to scavenge ROS, RNS, lipid peroxyl radicals, alkoxyl
radicals, or inhibit LP propagation. Presented here are selections of antioxidant agents
that have been evaluated in TBI.
Superoxide Dismutase
As SOD is an endogenous O2•- scavenger, it follows that administration of SOD
following injury should result in neuroprotective effects by reducing oxidative stress.
Although experimental TBI models were able to show that administration of SOD
decreases O2•- induced microvascular dysfunction and that overexpression of SOD1 or
SOD2 prevents mitochondrial dysfunction and attenuates TBI pathophysiology [1, 55,
251], clinical trials with PEG-SOD (a more stable form of SOD) failed, possibly due to the
short half-life of O2•- and brain penetrability issues [1, 55].
Lazaroids
Lazaroids are compounds structurally related to steroids without having any
glucocorticoid activity. Examples of lazaroids include tirilazad and the compound U83836E. These compounds function to scavenge lipid peroxyl radicals while also
preventing LP propagation through phospholipid membrane stabilization. U-83836E has
the added benefit of being structurally comprised of a portion of α-tocopherol (i.e. vitamin
E) allowing for regeneration of its antioxidant properties through redox reactions with
ascorbic acid and GSH. Although both compounds showed neuroprotective effects in
experimental TBI, tirilazad failed clinical trials in the United States. Although, post-hoc
analysis revealed that tirilizad was able to decrease mortality in a subset of male
patients with subarachnoid hemorrhage, the design of these trials has been heavily
criticized, underscoring the importance of appropriate clinical trial design [1, 55].
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Spin-Trapping Agents
Spin-trapping agents refer to a group of antioxidants which contain a nitroxide
group, and include agents such tempol. Tempol is capable of scavenging PN-derived
radicals such as NO●2 and CO●-3, as well as other reactive species such as O2•- and
H2O2. Tempol has shown to be neuroprotective in experimental TBI, decreasing
oxidative damage, cytoskeletal and neuronal degeneration, and improving mitochondrial
function. However, its limited therapeutic window of 1hr makes clinical translation
unlikely [1, 55].
Induction of Endogenous Antioxidant Pathways
Nrf2
Neurons contain endogenous antioxidant systems which are activated in times of
increased oxidative stress, such as occurs in TBI. Many of these systems are regulated
by binding of the transcription factor Nrf2, which is able to translocate to the nucleus
under stressful conditions, to ARE, which results in the induction and expression of
antioxidants such as HO-1, NqO1, and GST. Compounds such as sulforaphane (found
in broccoli and other cruciferous vegetables) and carnosic acid (found in rosemary and
sage) are considered Nrf2 activators and have been shown to be neuroprotective in
experimental TBI, reducing LP-derived aldehyde formation, improving mitochondrial
bioenergetics, decreasing cytoskeletal and neuronal degeneration, decreasing edema,
and attenuating motor and cognitive deficits [55, 97, 113, 138, 252].
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Glutathione Precursors
In addition to induction of endogenous antioxidant transcription pathways,
another approach at enhancing endogenous antioxidant activity is through utilization of
glutathione precursors, such as gamma-glutamylcysteine ethyl ester (GCEE) or NAC
[126, 253-255]. Following TBI, GCEE is able to attenuate increases in PN and carbonyl
protein damage and decrease BBB permeability [255]. More impressively, NAC and the
more membrane permeable, N-acetylcysteine amide (NACA) have been shown to
reduce

PN

and

4-HNE

protein

damage,

increase

mitochondrial

glutathione

concentration, improve mitochondrial respiration, and attenuate cortical lesion volume
and cognitive impairment [126, 254].
Carbonyl Scavenging
Although LP, itself, is known to directly affect membrane fluidity and destabilize
membrane integrity [256], the LP-derived aldehydes, including 4-HNE and acrolein are
known to have directly toxic effects [29, 72, 76, 77, 85-89, 93, 101, 102, 257, 258], with a
notably devastating effect on mitochondrial function.
Therefore, scavenging of LP-derived aldehydes, such as 4-HNE and acrolein, the
stable final breakdown products of LP represents a practical neuroprotective approach to
TBI [1, 79]. In fact, scavenging of LP-derived aldehydes is more clinically feasible than
the use of conventional antioxidants, as LP-derived aldehydes are longer lived than their
highly reactive free radical predecessors [79, 81, 259].
LP-derived aldehydes, such as 4-HNE and acrolein, are considered strong
electrophiles [260]. Therefore, strong nucleophiles can be used as scavengers [260].
Several classes of compounds have been shown capable of scavenging LP-derived
aldehydes such as thiol compounds (e.g. NAC, D-penicillamine), histidine containing
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compounds (e.g. carnosine), and guanidine derivatives (e.g. metformin) [79]. However,
hydrazine (-NH-NH2) compounds, which react with LP-derived aldehydes to form
hydrazone derivatives, represent one of the most potent aldehyde scavenging groups
available (Fig. 1.14) [258, 261].
Further, hydrazine (-NH-NH2) compounds are able to scavenge both free
aldehydes and aldehyde-protein conjugates to prevent further cross-linking [79, 262].
There are several FDA-approved drugs in current clinical use which contain a hydrazine
moiety (-NH-NH2) capable of scavenging aldehydes, including the anti-tuberculosis
agent isoniazid, the anti-hypertensive hydralazine (HZ), and the MAOI PZ [198] (Fig.
1.15). Of these FDA-approved hydrazine containing (-NH-NH2) compounds, HZ and PZ
have been the most extensively studied in experimental models of brain and spinal cord
injury.
Following brain or spinal cord injury, HZ, clinically used as an anti-hypertensive,
or PZ, an irreversible non-selective MAOI-class anti-depressant, are able to attenuate
formation of aldehyde-protein conjugates, enhance tissue sparing and neuronal survival,
attenuate mitochondrial respiratory dysfunction, and improve behavioral outcomes [71,
72, 74-76]. Although PZ contains both aldehyde-scavenging and MAOI capabilities, invitro experiments comparing PZ to the similarly structured MAOI pargyline (PG), which
lacks a hydrazine moiety (-NH-NH2), confirm that the presence of the hydrazine moiety (NH-NH2) and not steric hindrance confers PZ’s aldehyde scavenging abilities [72].
However, due to the absence of MAO substrate, the cited in-vitro study by Cebak et al.
did not allow for rigorous assessment of MAOI affects [72]. However, in further support
of the hydrazine moiety (-NH-NH2) being protective, in-vivo studies show that PZ but not
PG decrease carbonyl and atherosclerotic plaque formation in experimental models of
atherosclerosis [198].
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Figure 1.14 Phenelzine scavenging of lipid peroxidation-derived aldehydes.
Phenelzine covalently binds 4-HNE (4-hydroxynonenal) and acrolein, leading to the
formation of phenelzine-aldehyde conjugates.
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Figure 1.15 Chemical structures of phenelzine and hydralazine. Phenelzine is a
monoamine oxidase inhibitor class anti-depressant and hydralazine is an antihypertensive. However, both compounds contain hydrazine moieties (-NH-NH2), circled
in red, which are capable of scavenging lipid peroxidation-derived aldehydes.
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However, there are some concerns regarding the use of carbonyl scavengers as
neuroprotective compounds. For example, hydrazine (-NH-NH2) drugs can react with
physiologically important molecules and enzymes that contain carbonyl groups, such as
pyridoxal phosphate, a cofactor required for several enzymes involved in the
biosynthesis of neurotransmitters such as DA, 5-HT, and gamma-aminobutyric acid
(GABA) [78]. Additionally, it is currently unknown how drug-aldehyde-protein conjugates
are metabolized or what, if any, the long-term consequences of drug-aldehyde-protein
conjugate formation are [78]. In fact, there is evidence to suggest that drug-aldehydeprotein complexes can induce an immune response [258]. For example, the use of
hydralazine has been linked to development of systemic lupus erythematosus [258].
Additional Properties of Phenelzine
As stated previously PZ is an irreversible non-selective MAOI which contains an
aldehyde-scavenging hydrazine moiety (-NH-NH2), and although the plasma half-life of
PZ, which is 11.5h in humans and possibly as short as 30min in rats [74], is not as
clinically relevant to its MAOI properties, it likely does have an effect on its role as an
aldehyde scavenger.
In general PZ has complex pharmacokinetics which must be considered in
regards to developing it for clinical use in TBI patients. For example, in addition to being
a MAO inhibitor, PZ is also a MAO substrate, being metabolized to PEA and
phenylethyldenehydrazine (PEH). Both PEH and PEA are considered to be active
metabolites [263]. For example, PEA, is similar to amphetamine and can produce
stimulatory effects [207], whereas PEH inhibits several transaminases, including GABA
transaminase (GABA-T), alanine transaminase (ALA-T), and ornithine transaminase
(ORN-T) [169]. These transaminases serve important physiologic functions. For
example, GABA-T is responsible for the conversion of the inhibitory neurotransmitter
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GABA, to succinic semi-aldehyde, which can be further oxidized to succinate [169], a
substrate of the Krebs cycle and complex II of the ETC. Therefore, inhibition of GABA-T
could lead to increases in GABA, which can paradoxically cause excitotoxicity following
neuronal injury through reversal of chloride channels [264], as well as decreases in ETC
substrates during a time in which there is ongoing mitochondrial dysfunction and ATP
depletion [22, 25, 51, 73]. Similarly, inhibiting ALA-T, the enzyme which catalyzes the
reaction of alanine + α-ketoglutarate to form glutamate + pyruvate, could also lead to
decreased formation of Krebs cycle substrates. Further, ORN-T catalyzes the formation
of glutamate, from the urea cycle product, ORN. However, inhibition of ORN-T could
alternately lead to decarboxylation of ORN by ornithine decarboxylase (OCD), the result
of which is formation of neurotoxic polyamines [169].
Of additional concern in

regards to clinical translation of PZ is that anti-

depressants can lower seizure threshold [265], a complication for which TBI patients are
already at increased risk [209], although of all the anti-depressant drug classes, MAOIs
are at the least risk to do so [265]. Therefore, use of PZ could increase the risk of posttraumatic seizure in TBI patients. Additionally, it must be noted that although PZ is not
technically classified as a CYP3A4 inhibitor, there is data to suggest that PZ is capable
of inhibiting CYP3A4 [266, 267], which could lead to several adverse drug interactions.
Properties of Hydralazine
Although HZ’s hydrazine (-NH-NH2) moiety can act as an aldehyde scavenger,
HZ is an anti-hypertensive, used clinically to treat emergent and essential hypertension,
eclampsia, and congestive heart failure in African-Americans [268]. In humans, HZ has a
short plasma half-life of 30-60 minutes, similar to the 60min half-life seen in rats [74, 78].
The anti-hypertensive properties of HZ are due to its ability to act as an arteriolar
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vasodilator. Although the exact mechanism of action remains unknown, it has been
hypothesized to be due to activation of guanylate cyclase, inhibition of sarcoplasmic
reticulum calcium release, or increased conductance of calcium-dependent K+ channels
[258]. Interestingly, in relation to the properties of PZ, there is evidence to suggest that
HZ may also be able to act as a reversible non-selective MAOI, with a slight preference
to MAO-A [258, 269].
Although HZ’s anti-hypertensive effects could be a barrier to using it clinically in
TBI patients, in experimental SCI intraperitoneal doses of HZ ranging from 5mg/kg25mg/kg, do not induce changes in systolic blood pressure [270]. However, HZ does
undergo polymorphic acetylation within the liver, which means even an optimized dose
of HZ could lead to elevated concentrations in patients with slow acetylator phenotypes
[268].
Use of Monoamine Agonists, Antagonists, and Monoamine Oxidase Inhibitors in
TBI
Although there is a need for more established guidelines for the pharmacological
treatment of TBI-induced chronic neurobehavioral sequelae, several options do exist
which

work

by

modulating

monoamine

neurotransmitter

systems,

such

as

antidepressants for the treatment of depression and aggression, dopamine enhancers
and stimulants for the treatment of attention deficits and enhancement of learning and
memory, and beta blockers for the treatment of aggression [127].
In the context of acute TBI, drugs that modulate monoaminergic systems such as
DA and 5-HT agonists have shown promise as neuroprotective agents [154, 170, 271].
However, these drugs often have additional purportedly protective mechanisms of
action. For example, amantadine, in addition to being a DA agonist is an NMDA
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glutamate receptor antagonist. Additionally these drugs are often receptor subtype
specific, such as the D2 agonist bromocriptine and the 5-HT1A agonist buspirone [154,
170, 271], and therefore would have more specific effects than an overall increase in
monoamine levels, as would be induced through use of an MAOI.
Specifically in regards to MAOIs, they have been demonstrated to be
neuroprotective in both models of stroke and closed head injury [272, 273]. Although
some studies suggest that inhibition of MAO itself is protective [193], others have shown
MAOIs can be neuroprotective at concentrations which are too low to inhibit MAO [274,
275]. Therefore, it is possible that the neuroprotective effects of several similarly
structured MAOIs such as PG, deprenyl (selegiline), clorgyline, and rasagiline [192, 201,
276-278] are due to another property such as the presence of an N-propargyl moiety
[201], which, itself, has been proposed capable of exerting neuroprotective effects
through a variety of mechanisms ranging from modulation of apoptotic proteins to direct
targeting of the mPTP [192, 274-276, 278, 279].
Combinational Therapies
To date, all single agent pharmacotherapy clinical trials for TBI have failed.
Although there have been numerous reasons cited for these failures, due to the
heterogeneity of injury and the complexity of the secondary injury cascade, there is
interest in developing multi-mechanistic combinational therapies for the treatment of TBI
[213]. Indeed, the need for combinational approaches can be seen in experimental TBI
models where agents, such as CsA and PZ, are unable to completely restore pre-injury
function [71, 72, 76, 110, 136].
In 2008, NIH funded six multi-drug combinational experimental TBI studies. Of
the six studies, only the combination progesterone and nicotinamide (NAD+ precursor,
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antioxidant, anti-inflammatory) was able to significantly improve cognitive and motor
deficits over monotherapy [280]. On the other end of the spectrum, despite studies
showing that creatine (maintenance of ATP levels)[281] or choline (various mechanisms
of action, precursor to neurotransmitter synthesis)[140] were protective in experimental
TBI, combining the two worsened outcomes [280].
However, a recent comprehensive review by Kline and colleagues detailing
experimental TBI combinational therapy studies is more optimistic [215]. Of the 35
studies reviewed, all of which included behavioral outcomes, 46% resulted in additive or
synergistic effects, 35% had neutral outcomes, and only 19% resulted in negative
interactions [215]. Unlike the six studies that were funded under the NIH “multi-drug
combinational therapy” funding announcement, several of these studies included nondrug therapies such as hypothermia, environmental enrichment, exercise, and stem cell
administration. Although the Kline review focused on distinct categories (inflammation,
oxidative stress, neurotransmitter dysregulation, neurotrophins, stem cells, and
rehabilitative therapies), environmental enrichment combinations were utilized the most,
and the majority of successes were either achieved through a combination of stem cell
implantation

and

environmental

enrichment

[282],

or

through

attenuation

of

neuroinflammation [215]. Of important note here is that one study, which utilized CsA
and minocycline (antibiotic, anti-inflammatory), saw a 100% lethality rate in the
combination group [215, 283].
In general both reviews highlight some of the challenges in developing
combinational therapies for TBI including optimization of combined dosing paradigms,
consideration of sub-optimal doses, consideration of altered pharmacokinetics,
pharmacodynamics, toxicities, and side effects, choice of time point, choice and
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sensitivity of outcome measures, inclusion of behavioral assessments, use of
appropriate statistics, and variations in efficacy across outcome measures [215, 280].
Overall Dissertation Objective and Specific Aims
Traumatic brain injury (TBI) represents a significant health crisis in the United
States. To date there are no FDA-approved pharmacotherapies available to prevent the
devastating neurologic deficits caused by TBI. Due to the complex pathophysiology
which occurs following TBI, more robust pharmacological approaches must be
developed. As central mediators of the TBI secondary injury cascade, mitochondria and
LP-derived neurotoxic aldehydes make promising therapeutic targets. In fact,
Cyclosporine A (CsA), an FDA-approved immunosuppressant capable of inhibiting the
mitochondria permeability transition pore (mPTP) has been shown to be neuroprotective
in experimental TBI. Additionally, phenelzine (PZ), an FDA-approved non-selective
irreversible monoamine oxidase inhibitor (MAOI) class antidepressant has also been
shown to be neuroprotective in experimental TBI due to the presence of a hydrazine (NH-NH2) moiety allowing for the scavenging of LP-derived neurotoxic aldehydes.
The overall goal of this dissertation is to further examine the neuroprotective
capabilities of the mPTP inhibitor, CsA, and the LP-derived neurotoxic aldehyde
scavenger, PZ, using a severe controlled cortical impact injury (CCI) model in 3-month
old male Sprague-Dawley rats. First, the neuroprotective effects of CsA are examined in
isolated synaptic and non-synaptic mitochondria, two heterogeneous populations. Next,
the ability of a novel 72h subcutaneous continuous infusion of PZ combined with CsA to
improve mitochondrial respiration, attenuate mitochondria-aldehyde conjugate formation,
and prevent cytoskeletal spectrin degradation is compared to monotherapy. Finally, the
effects of PZ (MAOI, aldehyde scavenger) on learning and memory and cortical tissue
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sparing following injury are compared to the effects of pargyline (MAOI, non-aldehyde
scavenger) and hydralazine (non-MAOI, aldehyde scavenger).
Specific Aim 1: To test the hypothesis that CsA will have a differential
neuroprotective effect on isolated synaptic and non-synaptic mitochondrial bioenergetics
following experimental traumatic brain injury. Following a severe controlled cortical
impact injury (2.2mm) in 3mo male Sprague-Dawley rats, an intraperitoneal dose of CsA
(20mg/kg) will be administered 15min following injury. At 24h following injury cortical
synaptic and non-synaptic mitochondria will be isolated and respiratory rates will be
measured using a Clark-type oxygen electrode.
Specific Aim 2: To test the hypothesis that a 72h subcutaneous continuous
infusion of PZ combined with CsA will improve mitochondrial respiration, attenuate
formation of LP-derived aldehyde mitochondrial protein conjugates, and maintain
cytoskeletal integrity following experimental TBI to a greater degree than monotherapy.
Following a severe controlled cortical impact injury (2.2mm) in 3mo male SpragueDawley rats, subcutaneous osmotic pumps containing PZ (10mg/kg/day/3d) and/or CsA
(10mg/kg/day/3d) will be implanted. Loading doses of PZ (10mg/kg) and/or CsA
(20mg/kg) will also be administered 15min following injury. At 72h post-injury 1) cortical
mitochondria (total) respiratory rates will be assessed using a Clark-type oxygen
electrode and 2) cortical mitochondria (total) bound 4-HNE and acrolein will be assessed
using Western blot. Additionally, Western blot will be used to assess cortical tissue for
145kD (calpain-only) and 150kD (calpain/caspase 3) αII-spectrin breakdown as a marker
for cytoskeletal integrity.
Specific Aim 3: To test the hypothesis that PZ, a LP-derived neurotoxic
aldehyde scavenger and MAOI, and hydralazine (HZ), an LP-derived neurotoxic
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aldehyde scavenger incapable of inhibiting MAO will improve cognitive function and
cortical tissue sparing following experimental TBI, whereas pargyline (PG), a MAOI
incapable of scavenging LP-derived neurotoxic aldehydes, will not. Following severe
controlled cortical impact injury (2.0mm), 3mo male Sprague-Dawley rats will receive an
intraperitoneal dose of PZ (15mg/kg), HZ (5mg/kg), or PG (15mg/kg) at 15min, 24h, and
48h following injury. Morris water maze testing will be conducted on day 3 – day 7, and
animals will be perfused on day 8 for analysis of cortical tissue sparing. Additionally, the
effects of the PZ, HZ, and PG dosing paradigms on MAO inhibition and monoamine
neurotransmitter (NE, 5-HT, DA) tissue levels will be evaluated via HPLC in uninjured
cortical tissue.
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CHAPTER TWO:
Synaptic Mitochondria Sustain More Damage than Non-Synaptic Mitochondria
after Traumatic Brain Injury and are Protected by Cyclosporine A

Preface: Chapter Two has been adapted from: Kulbe JR, Hill RL, Singh IN, Wang JA,
Hall ED. Synaptic mitochondria sustain more damage than non-synaptic mitochondria
after traumatic brain injury and are protected by cyclosporine A. Journal of Neurotrauma.
34(7): 1291-1301 (2017). DOI: 10.1089/neu.2016.4628. (Mary Ann Leibert, Inc., New
York, NY). Figures have been renumbered and formatted in accordance with University
of Kentucky Graduate School requirements.
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Introduction
Traumatic brain injury (TBI) represents a significant health crisis. In the United
States, there are over 5 million persons currently living with a disability resulting from a
TBI [12] with an associated economic burden of 76.5 billion dollars. [10, 11] TBI consists
of a primary mechanical injury followed by a secondary injury cascade. [14] Aspects of
this cascade include increases in excitotoxic amino acids such as glutamate, increases
in intracellular calcium, mitochondrial dysfunction, production of reactive oxygen and
nitrogen species (ROS/RNS), initiation and propagation of lipid peroxidation (LP),
formation of LP-derived neurotoxic aldehydes, activation of calcium-dependent
proteases such as calpain, cytoskeletal degradation, cell death, and neurologic
dysfunction. [1, 16, 17, 22, 24, 41, 51, 55, 56, 58, 71, 108, 109, 114, 161-163, 223, 224,
284-288] The secondary injury cascade should be amenable to therapeutic intervention.
Currently,

there

are

no

Food

and

Drug

Administration

(FDA)-approved

pharmacotherapies for the treatment of patients with TBI, however. [1]
Mitochondria play a central role in the secondary injury cascade. Mitochondria
are essential regulators of calcium homeostasis [20, 21] and buffer increased
intracellular calcium after TBI. [22] High levels of mitochondrial calcium, however, lead to
mitochondrial dysfunction, including increased generation of ROS/RNS, decreased
oxidative phosphorylation and adenosine triphosphate (ATP) production, and induction
of the mitochondria permeability transition pore (mPTP). [22, 51, 53, 56, 60, 163, 225,
251, 289, 290]
The mPTP is a non-selective mega channel located in the inner mitochondrial
membrane that is permeable to solutes <1.5 kDa. [51] Opening of the mPTP leads to
extrusion of calcium back into the cytosol, mitochondrial swelling, and rupture of the
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outer mitochondrial membrane. [51, 104] Mitochondrial dysfunction contributes to
several aspects of the aforementioned injury cascade, including ROS/RNS induction of
LP and formation of the LP-derived neurotoxic aldehydes 4-hydroxynonenal and
acrolein, which are capable of covalently binding mitochondrial proteins, further
exacerbating mitochondrial dysfunction. [29, 69, 71, 77, 101, 113, 163]

Additional

downstream consequences of mPTP formation include activation of the calciumdependent protease calpain, cytoskeletal degradation, cell death, and neurologic
dysfunction. [1, 17, 29, 51, 55, 56, 58, 69, 70, 84, 93, 98, 99, 110, 163, 226] Therefore,
as central mediators of the secondary injury cascade, mitochondria are promising
therapeutic targets for prevention of cellular death and dysfunction after TBI.
Several therapies targeting mitochondria have been shown to be neuroprotective
in experimental models of TBI, including mild uncoupling, [125, 248] ketogenic diets,
[249, 291] increased antioxidant availability, [113, 126] and scavenging of neurotoxic
aldehydes. [71] One of the most promising and extensively studied mitochondrial
targeted TBI therapies, however, is inhibition of mPTP by the FDA-approved
immunosuppressant, cyclosporine A (CsA). In experimental TBI, CsA or its nonimmunosuppressant analog, NIM811, prevent mitochondrial swelling and axonal
pathology, [223, 224] maintain mitochondrial membrane potential and decrease
production of reactive oxygen species, [225] improve total (synaptic and non-synaptic)
mitochondrial

respiration,

[226]

prevent

oxidative

(synaptic

and

non-synaptic)

mitochondrial damage, [123, 226] improve cortical tissue sparing, [122, 124, 227]
decrease calpain-mediated cytoskeletal degradation and neurodegeneration, [110] and
improve motor and cognitive function. [110, 123, 135, 136]
Interestingly, despite the fact that CsA directly targets mitochondria, only a
limited number of studies have evaluated the effects of CsA on mitochondria after
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experimental TBI, [225, 226, 292] with no studies evaluating the effects of CsA on
isolated synaptic and non-synaptic mitochondria. Mitochondria are heterogeneous,
consisting of both synaptic and non-synaptic populations. Isolated synaptic mitochondria
consist of pre-synaptic mitochondria located within the synaptosome, while isolated nonsynaptic mitochondria consist of neuronal (axonal, somal, dendritic) and non-neuronal
(glial, vascular, etc.) mitochondria.
To our knowledge, there is currently no method available to further separate the
non-synaptic mitochondrial population into non-synaptic neuronal and non-synaptic nonneuronal, (e.g., glial) populations. Therefore, whereas synaptic mitochondria consist of
pure pre-synaptic neuronal mitochondria, non-synaptic mitochondria are isolated from
numerous cell types. Synaptic mitochondria are considered essential for proper
neurotransmission and synaptic plasticity, [44-46] processes which are impaired after
TBI. [47]

Their dysfunction has been implicated in neurodegeneration, as well as

degeneration of synapses and neurons absent overt cell death, [37, 48, 49] and studies
reveal synaptic mitochondria to be more susceptible to dysfunction. Importantly, these
two mitochondrial populations show different characteristics both in-vitro [37, 38] and invivo, [41, 50] including differential responses to pharmacotherapy. [50]
The heterogeneity of the two populations, however, can be masked in total
mitochondrial (synaptic and non-synaptic) preparations, especially because of the high
glia to neuron ratio of the cerebral cortex. [293]

Therefore, it is essential that

mitochondria targeted pharmacotherapies, such as CsA, be evaluated in both
populations.
This is the first study to examine the effects of CsA on isolated synaptic and nonsynaptic mitochondria after experimental TBI.

We hypothesized that synaptic

mitochondria would sustain more damage than non-synaptic mitochondria 24h after
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severe controlled cortical impact injury (CCI), and that intraperitoneal administration of
CsA (20 mg/kg) 15 min after injury would differentially attenuate injury-induced synaptic
and non-synaptic respiratory impairment.
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Methods
Animals
Young adult male Sprague-Dawley rats (n=20, Harlan, Indianapolis, IN) weighing
300 to 350 g were used for all studies. Animals were allowed food and water ad libitum
and were housed in the Division of Laboratory Animal Resources of the University of
Kentucky Medical Center. All animal and husbandry were conducted in accordance with
the University of Kentucky Institutional Animal Care and Use Committee. Animals were
randomly assigned to experimental groups: sham (n=6), CCI + vehicle (n=6), CCI + CsA
(n=8).
CCI TBI
Animals were initially anesthetized with 4% isoflurane and placed in a stereotaxic
frame (David Kopf, Tujunga, CA), where they were maintained at 3% isoflurane for the
duration of the procedure. A midline incision was made to expose the skull, and a 6 mm
craniotomy was made lateral to the sagittal suture midway between lambda and bregma.
The exposed brain with intact dura was injured using a computer controlled pneumatic
impactor (TBI 03010; Precision Systems and Instrumentation, Fairfax Station, VA) fitted
with a 5 mm beveled tip set to impact at ~3.5 m/sec, 2.2 mm depth and 500 msec dwell
time, as described previously. [71] After injury, Surgicel was placed onto the dura, and
an 8 mm plastic disk was affixed with tissue adhesive to close the craniotomy site. Body
temperature was monitored and maintained at 37°C with a thermo-regulating heating
pad. Sham animals underwent all procedures but did not receive an impact injury.
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Cyclosporine A Administration
The

CsA

concentration

chosen

was

based

on

previously

optimized

concentrations for CCI. [225, 294] The CCI + CsA group was administered CsA obtained
from the University of Kentucky Medical Center Hospital Pharmacy (Perrigo,
Minneapolis, MN; 50 mg/mL) 15 min after injury as a single intraperitoneal dose of 20
mg/kg in saline/650 mg cremophor/33.2% (v/v) ethanol diluted in saline to a final
concentration of 10 mg/mL. The injection volume was 0.2 mL/100g of body weight. CCI
+ vehicle-treated animals received an equivalent dose of saline/cremophor/ethanol 15
min after injury.
Tissue Extraction
Animals were euthanized at 24h using CO2 anesthetization followed by
decapitation, and an 8 mm cortical punch centered over the injury site was collected for
analysis of mitochondrial respiration.
Mitochondrial Isolation
Mitochondria were isolated as described previously [71, 163] with modifications
to isolate synaptic and non-synaptic populations. [41, 50] Cortical tissue was
homogenized in ice-cold isolation buffer (215 mmol/L mannitol, 75 mmol/L sucrose,
0.1% bovine serum albumin, 20 mmol/L HEPES, 1 mmol/L EGTA, pH 7.2) using PotterElvejhem homogenizers. Samples were then centrifuged twice at 1400 x g for 3 min at
4°C. Supernatants were collected and spun at 13,000 x g for 10 min at 4°C.
The crude mitochondrial pellet was resuspended and layered onto a
discontinuous 7.5% and 10% Ficoll gradient and centrifuged at 100,000 x g for 30 min at
4°C. The non-synaptic mitochondria pellet was resuspended in isolation buffer without
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EGTA and centrifuged at 10,000 x g for 10 min at 4°C to remove Ficoll and then
resuspended to a final concentration of approximately 10 mg/mL in isolation buffer
without EGTA.
The synaptosomal layer was removed from the 7.5%-10% Ficoll interface,
resuspended in isolation buffer and spun at 13,000 x g for 10 min at 4°C to remove
Ficoll. The synaptosome pellet was resuspended in isolation buffer, placed into a
nitrogen bomb at 1200 psi for 10 min at 4°C to release synaptic mitochondria, [295, 296]
layered onto a second discontinuous 7.5% and 10% Ficoll gradient, and centrifuged at
100,000 x g for 30 min at 4°C. The synaptic mitochondria pellet was resuspended in
isolation buffer without EGTA and centrifuged at 10,000 x g for 10 min at 4°C to remove
Ficoll and resuspended in isolation buffer without EGTA. Protein concentrations were
determined with a BCA protein assay kit and measured at absorbance 562 nm with a
BioTek Synergy HT plate reader (Winooski, VT, USA). Mitochondria were immediately
used for respiratory analysis.
Measurement of Mitochondrial Respiratory Function
Mitochondria respiratory rates were measured using a Clark-type electrode in a
continuously stirred, sealed, thermostatically controlled chamber (Oxytherm System,
Hansatech Instruments, Norfolk, UK) that was maintained at 37°C. Mitochondria (>30
µg) were placed into a chamber containing 250 µl of KCl respiration buffer (125 mmol/L,
2 mmol/L MgCl2, 2.5 mmol/L KH2PO4, 0.1% bovine serum albumin, 20 mmol/L HEPES,
pH 7.2). Mitochondria equilibrated for 1 min prior to complex-I initiation.
Complex-I respiration was initiated with 5 mmol/L pyruvate and 2.5 mmol/L
malate and state II respiration was monitored. Two boluses of 150 μmol/L adenosine
diphosphate (ADP) were added to initiate state III respiration. State IV respiration was
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monitored following 2 μmol/L addition of the ATP synthase inhibitor oligomycin. Maximal
state V(I) respiration was initiated by addition of 2 μmol/L of the protonophore FCCP.
Complex I was inhibited by addition of 100 nmol/L rotenone. Complex II driven
respiration was initiated by addition of 10 mmol/L succinate and state V(II) was
monitored. Respiratory control ratio (RCR) was calculated by dividing the state III
respiration rate (second bolus ADP rate) by the state IV respiration rate. [163, 248]
Statistical analysis
Statistical analysis was conducted using Prism version 6.0 (Graph Pad, San
Diego, CA). Results are reported as mean ± standard deviation. Initial statistical analysis
was performed using a two-way analysis of variance (ANOVA), followed by a Tukey post
hoc analysis when appropriate.
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Results
The following details the comparative effects of CCI TBI, with and without early
CsA treatment, on the respiratory functional status of non-synaptic versus synaptic
mitochondria as measured by changes in oxygen utilization during the various
respiratory states. Overall, the results show that, in general, synaptic mitochondria are
more susceptible to post-traumatic complex I and II-driven dysfunction within the
electron transport chain than non-synaptic mitochondria.

Nevertheless, early CsA

treatment is able to protect respiration that is linked to neuronal ATP production within
the more damaged synaptic mitochondria.
State II: Addition of Pyruvate + Malate to Activate Mitochondrial Complex I
A two-way ANOVA (injury x population) revealed a significant main effect for
injury [F (1, 20) = 23.75, p < 0.0001] and population [F (1, 20) = 17.22, p = 0.0005], but
not interaction [F (1, 20) = 0.2018, p = 0.6581]. Post-hoc testing (Tukey’s) revealed that
state II respiration for non-synaptic CCI + vehicle was significantly impaired compared
with non-synaptic sham (p < 0.01), synaptic CCI + vehicle was significantly impaired
compared with synaptic sham (p < 0.05), and that the state II respiration rate for synaptic
sham was significantly decreased compared with non-synaptic sham (p < 0.05) (Fig.
2.1A).
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Figure 2.1 State II: Effect of CsA on synaptic and non-synaptic mitochondria. (A)
Effect of injury on non-synaptic and synaptic mitochondria for state II respiration
(pyruvate/malate) 24 h after severe controlled cortical impact (CCI). (B) Effect of early
post-injury (15 min) intraperitoneal administration of cyclosporine A (CsA) (20 mg/kg) on
non-synaptic and synaptic mitochondria for state II respiration (pyruvate/malate) 24h
after severe CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6), Sham
Syn, sham synaptic (n = 6), CCI + Veh NS, CCI + vehicle non-synaptic (n = 6), CCI +
Veh Syn, CCI + vehicle synaptic (n = 6), CCI + CsA NS, CCI + CsA non-synaptic (n = 8),
CCI + CsA Syn, CCI + CsA synaptic (n = 8); values, mean ± standard deviation; two-way
analysis of variance followed by Tukey post hoc; *p < 0.05, **p < 0.01, #p < 0.05
compared with non-synaptic sham.
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To assess drug effect, state II respiratory rates for CCI + vehicle and CCI + CsA
were calculated as a percentage of the sham respiratory rate. A two-way ANOVA
(treatment x population) revealed a significant main effect for treatment [F (1, 24) =
11.07, p = 0.0028], but not for population [F (1, 24 = 0.06332, p = 0.8035] or interaction
[F (1, 24) = 3.182, p = 0.0871). While CsA improved state II respiration in both injured
non-synaptic and injured synaptic mitochondria, post-hoc testing (Tukey) revealed this
effect was only significant in the synaptic population (p <0.01) (Fig. 2.1B).
State III: Addition of ADP to Activate Complex V ATP Production
A two-way ANOVA (injury x population) revealed a significant main effect for
injury [F (1, 20) = 31.10, p < 0.0001) and population [F (1, 20) = 12.39, p = .0022], but
not interaction [F (1, 20 = .0075, p = 0.9318]. Post-hoc testing (Tukey’s) revealed that
state III respiration for non-synaptic CCI + vehicle was significantly impaired compared
with non-synaptic sham (p < 0.01), and synaptic CCI + vehicle was significantly impaired
compared with synaptic sham (p < 0.01) (Fig. 2.2A).
To assess drug effect, state III respiratory rates for CCI + vehicle and CCI + CsA
were calculated as a percentage of the sham respiratory rate. A two-way ANOVA
revealed a significant main effect for treatment [F (1, 24) = 10.45, p = 0.0036], and
population [F (1, 24) = 4.847, p = 0.0375], but not interaction [F (1, 24) = 0.5409, p =
0.4692). While CsA improved state III respiration in both injured non-synaptic and injured
synaptic mitochondria, post-hoc testing (Tukey) revealed this effect was only significant
in the synaptic population (p < 0.05) (Fig. 2.2B).
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Figure 2.2 State III: Effect of CsA on synaptic and non-synaptic mitochondria (A)
Effect of injury on non-synaptic and synaptic mitochondria for state III respiration
(pyruvate/malate/adenosine diphosphate [ADP]) 24h after severe controlled cortical
impact (CCI). (B) Effect of early post-injury (15 min) intraperitoneal administration of
cyclosporine A (CsA) (20 mg/kg) on non-synaptic and synaptic mitochondria for state III
respiration (pyruvate/ malate/ADP) 24h after severe CCI, calculated as % sham. Sham
NS, sham non-synaptic (n = 6), Sham Syn, sham synaptic (n = 6); CCI + Veh NS, CCI +
vehicle non-synaptic (n = 6); CCI + Veh Syn, CCI + vehicle synaptic (n = 6); CCI + CsA
NS, CCI + CsA non-synaptic (n = 8); CCI + CsA Syn, CCI + CsA synaptic (n = 8); values
= mean ± standard deviation; two-way analysis of variance followed by Tukey post hoc;
*p < 0.05, **p < 0.01.
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State IV: Addition of Oligomycin to Inhibit Complex V ATP Production
A two-way ANOVA (injury x population) revealed a significant main effect for
injury [F (1, 20) = 27.77, p < 0.0001) and population [F (1, 20) = 8.680, p = .0080], but
not interaction [F (1, 20 = .0276, p = 0.8698]. Post-hoc testing (Tukey) revealed that
state IV respiration for non-synaptic CCI + vehicle was significantly impaired compared
with non-synaptic sham (p < 0.01), and synaptic CCI + vehicle was significantly impaired
compared with synaptic sham (p < 0.01) (Fig. 2.3A).
To assess drug effect, state IV respiratory rates for CCI + vehicle and CCI + CsA
were calculated as a percentage of the sham respiratory rate. A two-way ANOVA
revealed a significant main effect for treatment [F (1, 24) = 11.91, p = 0.0021], but not
population [F (1, 24) = 1.964, p = 0.1738] or interaction [F (1, 24) = 0.0046, p = 0.9465).
While CsA improved state IV respiration in both injured non-synaptic and injured
synaptic mitochondria, post-hoc testing (Tukey) revealed these effects were not
significant (Fig. 2.3B).
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Figure 2.3 State IV: Effect of CsA on synaptic and non-synaptic mitochondria (A)
Effect of injury on non-synaptic and synaptic mitochondria for state IV respiration
(oligomycin) 24h after severe controlled cortical impact (CCI). (B) Effect of early postinjury (15 min) intraperitoneal administration of cyclosporine A (CsA) (20 mg/kg), on nonsynaptic and synaptic mitochondria for state IV respiration (oligomycin) 24h after severe
CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6); Sham Syn, sham
synaptic (n = 6); CCI + Veh NS, CCI + vehicle non-synaptic (n = 6); CCI + Veh Syn, CCI
+ vehicle synaptic (n = 6); CCI + CsA NS, CCI + CsA non-synaptic (n = 8); CCI + CsA
Syn, CCI + CsA synaptic (n = 8); values mean ± standard deviation; two-way analysis of
variance followed by Tukey post hoc; **p < 0.01.
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RCR (State III / State IV): Difference in Oxygen Utilization Between Activation and
Inhibition of ATP Production
A two-way ANOVA (injury x population) revealed a significant main effect for
injury [F (1, 20 = 26.02, p < 0.0001), population [F (1, 20) = 12.23, p = 0.0023], and
interaction [F (1, 20) = 5.418, p = 0.0305]. Post-hoc testing (Tukey) revealed that RCR
for synaptic CCI + vehicle was significantly impaired compared with synaptic sham (p <
0.001) and that synaptic CCI + vehicle was significantly impaired compared with nonsynaptic CCI + vehicle (p < 0.01) (Fig. 2.4A).
To assess drug effect, RCR for CCI + vehicle and CCI + CsA were calculated as
a percentage of sham RCR. A two-way ANOVA revealed a significant main effect for
treatment [F (1, 24) = 7.092, p = 0.0136) and population [F (1, 24) = 9.680, p = 0.0048],
but not interaction [F (1, 24) = 3.437, p = 0.0761]. Post-hoc testing (Tukey) revealed that
CsA treatment significantly improved RCR in the injured synaptic population (p < 0.05)
and that the RCR for synaptic CCI + vehicle is significantly impaired compared to the
RCR for non-synaptic CCI + vehicle (p < 0.05) (Fig. 2.4B).
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Figure 2.4 RCR: Effect of CsA on synaptic and non-synaptic mitochondria (A)
Effect of injury on non-synaptic and synaptic mitochondria for respiratory control ratio
(RCR) (state III/state IV) 24h after severe controlled cortical impact (CCI). (B) Effect of
early post-injury (15 min) intraperitoneal administration of cyclosporine A (CsA) (20
mg/kg), on non-synaptic and synaptic mitochondria for RCR (state III/state IV) 24h after
severe CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6); Sham Syn,
sham synaptic (n = 6); CCI + Veh NS, CCI + vehicle non-synaptic (n = 6); CCI + Veh
Syn, CCI + vehicle synaptic (n = 6); CCI + CsA NS, CCI + CsA non-synaptic (n = 8); CCI
+ CsA Syn, CCI + CsA synaptic (n = 8); values = mean ± standard deviation; two-way
analysis of variance followed by Tukey post hoc; *p < 0.05, **p < 0.001, #p < 0.05 vs
non-synaptic vehicle, ##p < 0.01 vs. non-synaptic vehicle.
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State V(I): Maximal Complex I-Driven Respiration After Addition of the
Protonophore FCCP
A two-way ANOVA (injury x population) revealed a significant main effect for
injury [F (1, 20) = 37.82, p < 0.0001) and population [F (1, 20) = 9.556, p = .0058], but
not interaction [F (1, 20 = .2492, p = 0.6231]. Post-hoc testing (Tukey) revealed that
state V(I) respiration for non-synaptic CCI + vehicle was significantly impaired compared
with non-synaptic sham (p < 0.001), and synaptic CCI + vehicle was significantly
impaired compared with synaptic sham (p < 0.01) (Fig. 2.5A).
To assess drug effect, state V(I) respiratory rates for CCI + vehicle and CCI +
CsA were calculated as a percentage of the sham respiratory rate. A two-way ANOVA
revealed a significant main effect for treatment [F (1, 24) = 14.25, p = 0.0009], but not
population [F (1, 24) = 3.580, p = 0.0706] or interaction [F (1, 24) = 0.0084, p = 0.9276).
While CsA improved state V(I) respiration in both injured non-synaptic and injured
synaptic mitochondria, post-hoc testing (Tukey) revealed neither effect was statistically
significant (Fig. 2.5B).
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Figure 2.5 State V(I): Effect of CsA on synaptic and non-synaptic mitochondria (A)
Effect of injury on non-synaptic and synaptic mitochondria for state V(I) respiration
(FCCP) 24h after severe controlled cortical impact (CCI). (B) Effect of early post-injury
(15 min) intraperitoneal administration of cyclosporine A (CsA) (20 mg/kg) on nonsynaptic and synaptic mitochondria for state V(I) respiration (FCCP) 24h after severe
CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6); Sham Syn, sham
synaptic (n = 6); CCI + Veh NS, CCI + vehicle non-synaptic (n = 6); CCI + Veh Syn, CCI
+ vehicle synaptic (n = 6); CCI + CsA NS, CCI + CsA non-synaptic (n = 8);CCI + CsA
Syn, CCI + CsA synaptic (n = 8); values = mean ± standard deviation; two-way analysis
of variance followed by Tukey post hoc; **p < 0.01, ***p < 0.001.

88

State V(II): Succinate-Activated Complex II-Driven Respiration after Inhibition of
Complex I with Rotenone
A two-way ANOVA (injury x population) revealed a significant main effect for
injury [F (1, 20 = 23.97, p <0.0001] and population [F (1, 20) = 15.37 p = 0.0008], but not
for interaction [F (1, 20 = 0.3787, p = 0.5452]. Post-hoc testing (Tukey) revealed that
state V(II) respiration for non-synaptic CCI + vehicle was significantly impaired compared
with synaptic sham (p < 0.05), and that the state V(II) respiration rate for synaptic sham
was significantly decreased compared with non-synaptic sham (p < 0.05) (Fig. 2.6A).
To assess drug effect, state V(II) respiratory rates for CCI + vehicle and CCI +
CsA were calculated as a percentage of the sham respiratory rate. A two-way ANOVA
revealed a significant main effect for treatment [F (1, 24) = 10.45, p = 0.0035], but not for
population [F (1, 24) = 0.3533, p = 0.5578] or interaction [F (1, 24) = 1.272, p = 0.2706].
While CsA improved state V(II) respiration in both injured non-synaptic and injured
synaptic mitochondria, post-hoc testing (Tukey) revealed this effect was only significant
in the synaptic population (p < 0.05) (Fig. 2.6B).
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Figure 2.6 State V(II): Effect of CsA on synaptic and non-synaptic mitochondria (A)
Effect of injury on non-synaptic and synaptic mitochondria for state V(II) respiration
(rotenone/succinate) 24h after severe controlled cortical impact (CCI). (B) Effect of early
post-injury (15 min) intraperitoneal administration of CsA (20 mg/kg) on non-synaptic
and synaptic mitochondria for state V(II) respiration (rotenone/succinate) 24h after
severe CCI, calculated as % sham. Sham NS, sham non-synaptic (n = 6); Sham Syn,
sham synaptic (n = 6); CCI + Veh NS, CCI + vehicle non-synaptic (n = 6); CCI + Veh
Syn, CCI + vehicle synaptic (n = 6); CCI + CsA NS, CCI + CsA non-synaptic (n = 8); CCI
+ CsA Syn, CCI + CsA synaptic (n = 8); values = mean ± standard deviation; two-way
analysis of variance followed by Tukey post hoc; *p < 0.05, **p < 0.01, #p < 0.05 vs. nonsynaptic sham.
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Discussion
These results indicate that synaptic mitochondria sustain more damage than
non-synaptic mitochondria 24h after severe CCI and that intraperitoneal administration
of CsA (20 mg/kg) 15 min after injury improves synaptic and non-synaptic respiration
(Fig. 2.7), with a significant improvement being seen in the more severely impaired
synaptic population.
CsA is an FDA-approved immunosuppressant, used clinically to prevent organ
rejection after transplant through a mechanism that involves inhibition of calcineurin and
T-cell activation. [217] CsA, however, also has the ability to bind the mitochondrial matrix
protein cyclophilin D, [218, 219] which inhibits its interaction with the adenine nucleotide
transporter, an inner mitochondrial membrane protein, thus preventing formation of
mPTP. [220] It is through inhibition of mPTP that CsA exerts its neuroprotective effects
after TBI.
NIM811, a non-immunosuppressive analog of CsA unable to bind calcineurin, but
capable of binding cyclophilin D and inhibiting mPTP, [297]

maintains the

neuroprotective effects of CsA, improving mitochondrial respiration, decreasing oxidative
damage, decreasing calpain-mediated cytoskeletal degradation and neurodegeneration,
and improving motor and cognitive function after experimental TBI. [110, 123, 226]
Under normal physiologic conditions CsA is minimally blood brain barrier
penetrable. [221] After TBI, however, CsA is able to enter the CNS because of bloodbrain-barrier breakdown, [222] and although concerns have been raised regarding CsA
and neurotoxicity, [237-244] two phase II clinical trials show CsA to be safe for use in
patients with severe TBI. [234, 235]
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Figure 2.7 Representative oxymetric traces. Rates of oxygen consumption of sham,
vehicle, and cyclosporine A (CsA) (20 mg/kg, intraperitoneally, 15 min post-injury) for (A)
non-synaptic and (B) synaptic mitochondria isolated from ipsilateral cortex 24h after
severe controlled cortical impact (CCI). Purified mitochondrial protein (>30 µg) was
suspended in respiration buffer (125 mmol/L KCl, 2 mmol/L MgCl2, 2.5 mmol/L KH2PO4,
0.1% BSA, 20 mmol/L HEPES, pH 7.2) in a final volume of 250 µl, and oxygen
consumption rates were measured using a Clark-type oxygen electrode in the presence
of 5 mmol/L pyruvate and 2.5 mmol/L malate (state II), two boluses of 150 µmol/L ATP
(state III), 2 µmol/L oligomycin (state IV), 2 µmol/L FCCP (state VI), and 100 nmol/L
rotenone and 10 mmol/L succinate (state VII). Sham, sham; CsA, CCI + CsA; vehicle,
CCI + vehicle; ADP, adenosine diphosphate.
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Despite the fact that the neuroprotective effects of CsA rely on direct protection
of mitochondria, [51, 110, 124, 226] many experimental TBI studies using CsA have
focused on outcome measures downstream of mitochondrial dysfunction, such as
cortical lesion volume, [122, 124, 227, 294] axonal pathology, [110, 117, 223, 224, 298]
behavior, [110, 135] and synaptic plasticity. [119] Although important work does confirm
the ability of CsA to protect mitochondria after injury, those studies focused on acute
injury, [225] microscopic structure analysis, [223] or more indirect measures of
mitochondrial function such as brain oxygen consumption [135] and whole brain ATP
levels. [299] Only two studies have assessed mitochondrial bioenergetics via oxygen
consumption rates, one of which did not extend beyond 12h and was conducted in mice,
[226] and one of which utilized juvenile animals. [292]

Importantly, none of these

mitochondria-focused studies evaluated isolated synaptic and non-synaptic populations.
While it should be noted that Sullivan and coworkers [225] showed that CsA
maintains mitochondrial membrane potential in isolated non-synaptic mitochondria and
intact synaptosomes acutely (30-60 min) after CCI, this is the first study to examine the
effects of CsA on isolated and purified synaptic and non-synaptic mitochondria after
experimental TBI.

As such, CsA was administered 15 min post-injury. Early

administration allows for the greatest chance of neuroprotection, and allows for
contextualization of future therapeutic window studies. The 20mg/kg intraperitoneal
dosage used is considered optimal and has been used extensively in previously
experimental TBI studies. [110, 117, 119, 124, 225-227, 292, 294]
The CsA used in this study is solubilized in a vehicle containing cremophor.
Toxicity concerns have been raised in regard to cremophor, and reported side effects
include hypersensitivity reactions,

hyperlipidemia,

erythrocyte aggregation,

and

peripheral neuropathy, but are usually associated with intravenous infusions or high
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cremophor concentrations. [245] Several studies have shown that cremophor has the
ability to impair mitochondrial function. These studies, however, were performed in
mitochondria isolated from heart muscle, skeletal muscle, and kidney tissue, and
cremophor was either administered chronically or in-vitro. [300-302]
Interestingly, chronic administration of cremophor or CsA + cremophor impairs
heart and skeletal muscle mitochondria similarly, suggesting that any cremophor toxicity
is still observable when administered along with CsA. The safety of low doses of CsA +
cremophor, such as the dose used in this study (20mg/kg, intraperitoneally), is well
supported in the literature, however. For example, administration of CsA + cremophor to
sham animals has no effect on long term potentiation, [119] motor or cognitive function,
[136] or brain metabolism, [299] although chronic administration can result in weight
loss. [136]
Although it is feasible that administration of vehicle or CsA to sham animals could
alter basal mitochondrial respiration, evaluating the protective effect of CsA after injury in
comparison to sham animals not receiving vehicle or drug is the most clinically
appropriate assessment. Therefore, neither vehicle nor CsA were administered to sham
animals for this study.
The respiratory function of isolated synaptic and non-synaptic mitochondria was
assessed 24h after injury. Total (synaptic and non-synaptic) mitochondrial respiratory
dysfunction peaks between 12h and 24h after severe rat CCI, [22] with several studies
confirming mitochondrial respiratory dysfunction 24h after injury. [22, 248, 303]
In sham animals, synaptic mitochondria showed decreased respiratory rates
compared to non-synaptic mitochondria, decreases that were only significant in state II
and state V(II). Previous studies have also shown that healthy synaptic mitochondria
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have decreased respiration rates compared with healthy non-synaptic mitochondria, [41,
42] as well as decreased pyruvate dehydrogenase activity, [304] the enzyme responsible
for generating the nicotinamide adenine dinucleotide that feeds into complex I of the
electron transport chain. Because non-synaptic mitochondria contain mitochondria from
both neurons and glia, it is possible the higher respiration rates found in non-synaptic
mitochondria are because of astrocytic mitochondria; mitochondria isolated from cultured
astrocytes have higher respiration rates than mitochondria isolated from cultured
neurons as well as higher levels of electron transport chain subunits. [296]
RCR (state III/state IV) is considered one of the best general measures of
mitochondrial function and health and represents the ability of mitochondria to couple
oxidation of substrates with generation of ATP via ADP phosphorylation under minimal
proton leak. Therefore, healthy mitochondria will have a high RCR, while damaged
mitochondria will have a low RCR [30]. In this study, the RCR for synaptic mitochondria
was significantly reduced 24h after injury compared with sham, while the RCR for nonsynaptic mitochondria was not. The RCR for injured synaptic mitochondria was also
significantly reduced compared to the RCR for injured non-synaptic mitochondria.
Interestingly, statistical analysis revealed a significant interaction between injury and
population for this measure, indicating that synaptic mitochondria are indeed more
susceptible to injury.
Importantly, the decrease in synaptic RCR was significantly attenuated by CsA
administration. While RCR represents an overall measure of mitochondrial function, its
value is affected by multiple aspects of oxidative phosphorylation. [30] Therefore, in
addition to RCR we assessed individual states of respiration to identify specific aspects
of bioenergetic impairment.

95

State II respiration is measured after addition of the complex-I substrates
pyruvate and malate, but before ADP addition, and represents a slow state of
respiration. Severe CCI significantly reduced state II respiration for both synaptic and
non-synaptic mitochondria 24h after injury. Decreases in state II respiration are
consistent with the fact that pyruvate dehydrogenase, the enzyme linking glycolysis with
the citric acid cycle, is known to have decreased activity after TBI. [305, 306] While CsA
was able to improve injury induced decreases in state II respiration in both populations,
the improvements only reached statistical significance in the synaptic population.
State III respiration is measured following addition of ADP, allowing coupling of
oxidative phosphorylation, and is considered one of the most important states of
respiration to measure after injury, because decreases in State III respiration are
indicative of defects in complex I-driven substrate oxidation and/or ATP turnover. [30]
Severe CCI significantly reduced state III respiration for both synaptic and non-synaptic
mitochondria 24h after injury. While CsA was able to improve injury-induced decreases
in state III respiration in both populations, the improvements only reached statistical
significance in the synaptic population. Importantly, the ability of CsA to significantly
improve state III synaptic respiration is a major contributory factor to the ability of CsA to
also significantly improve synaptic RCR (state III/IV) after injury.
State IV is measured after addition of the ATP synthase inhibitor oligomycin,
which returns the mitochondria to a basal state of respiration. Severe CCI significantly
reduced state IV respiration for both synaptic and non-synaptic mitochondria 24h after
injury. While CsA was able to improve injury induced decreases in state IV respiration in
both populations, the improvements were not statistically significant.
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State V(I) respiration is measured following addition of the protonophore FCCP,
which uncouples substrate oxidation from ATP production, and is used to assess
maximal respiration, with decreases in state V(I) respiration being indicative of defects in
complex-I driven substrate oxidation. [30] Severe CCI significantly reduced state V(I)
respiration for both synaptic and non-synaptic mitochondria 24h after injury. While CsA
was able to improve injury-induced decreases in state V(I) respiration in both
populations, the improvements were not statistically significant.
State V(II) respiration is assessed following addition of the complex-I inhibitor
rotenone, and the complex-II substrate succinate. Therefore, decreases in state V(II)
respiration are indicative of defects in complex-II driven respiration. Severe CCI
significantly reduced state V(II) respiration for both synaptic and non-synaptic
mitochondria 24h after injury. While, CsA improved injury-induced decreases in
complex-II driven respiration in both populations, the improvements only reached
statistical significance in the synaptic population.
In summary, synaptic mitochondria sustain more damage 24h after severe CCI
than non-synaptic mitochondria, as best evidenced by the changes in RCR. This is in
agreement with previous work indicating that synaptic mitochondria are more susceptible
to dysfunction. For example, synaptic mitochondria are more susceptible to damage 3h
after moderate CCI compared with non-synaptic mitochondria, an effect that is
compounded by aging. [41] In addition, in-vitro, healthy synaptic mitochondria have a
decreased ability to buffer calcium before undergoing permeability transition compared
with non-synaptic mitochondria. [37]
Several hypotheses have been offered to explain the increased vulnerability of
synaptic mitochondria compared with non-synaptic mitochondria, including high
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concentrations of cyclophilin D, leading to increased susceptibility toward calciuminduced permeability transition, [38]

as well as increased exposure of synaptic

mitochondria to oxidative damage. [37, 38] Because non-synaptic mitochondria contain
both neuronal and non-neuronal cell types, however, and mitochondria isolated from
neurons and glia have differing properties, [38, 296] part of the increased susceptibility
of synaptic mitochondria to injury may be because synaptic mitochondria represent a
more purely neuronal population, [37-39] rather than their specific subcellular localization
to the pre-synaptic terminal. It is likely, however, that both cell type and subcellular
localization contribute to synaptic mitochondria vulnerability.
These results also indicate that intraperitoneal administration of CsA (20 mg/kg)
15 min after injury attenuates respiratory dysfunction in both populations 24h after
severe CCI, with a statistically significant improvement being seen in the synaptic
population. Although there was a significant decrease in each respiration state following
injury for the non-synaptic mitochondria, the non-synaptic RCR was unaffected by injury,
indicating no overall bioenergetics dysfunction. [30]

It is therefore likely that the

improvements CsA had on the non-synaptic respiration states were only non-significant
due to a lack of robust injury effect in this population, and that CsA would offer significant
improvements at time points later than 24h when non-synaptic mitochondria are more
significantly impaired.
The fact that CsA is able to significantly protect synaptic mitochondria following
injury is impressive, because synaptic mitochondria do not always respond as favorably
to pharmaceutical intervention as the non-synaptic population. For example, following
spinal cord injury, the catalytic peroxynitrite inhibitor, tempol, is only effective in nonsynaptic mitochondria, while the mitochondrial uncoupler 2-4 DNP works in both
populations, but has a shorter therapeutic window in the synaptic mitochondria. [50]
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Future studies will investigate if there is, indeed, a difference in the therapeutic
window for CsA between synaptic and non-synaptic mitochondria. If so, studies may
explain the fact that while CsA is able to improve cortical tissue sparing when
administration is delayed up to 8h, it is significantly more protective when administered
within 3h of injury. [122]

Further, the ability of CsA to protect synaptic neuronal

mitochondrial respiration is made more impressive by the knowledge that there are
higher concentrations of the CsA target protein cyclophilin D in synaptic mitochondria,
[37] gamma-aminobutyric acid-ergic interneurons, [39] and cultured neurons when
compared to cultured astrocytes. [38]
In fact, in-vitro healthy synaptic mitochondria require higher concentrations of
CsA to prevent calcium-induced permeability transition. [38] Future studies will therefore
evaluate the ability of CsA to attenuate calcium-induced permeability transition in both
populations after injury, as well as the ability of CsA to retain its synaptic neuroprotective
effect at time points beyond 24h.
Conclusion
This study confirms that synaptic mitochondria are more vulnerable than nonsynaptic mitochondria after experimental TBI, and therefore emphasizes the need for
further characterization of synaptic and non-synaptic mitochondria after experimental
TBI, including the contribution each population makes to TBI pathology, as well as the
response each population has to mitochondrial-directed pharmacotherapies.
While the pathology of TBI is complex and factors other than mitochondrial
dysfunction contribute to downstream processes such as cytoskeletal degradation,
neurodegeneration, and neurologic impairment, it is likely that successful protection of
the more vulnerable synaptic population greatly contributes to inhibition of these
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downstream processes. Because this study confirms the ability of CsA to significantly
improve synaptic respiration following injury, CsA remains a promising neuroprotective
candidate for the treatment of TBI.
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CHAPTER THREE:
Continuous Infusion of Phenelzine, Cyclosporine A, or Their Combination:
Evaluation of Mitochondrial Bioenergetics, Oxidative Damage, and Cytoskeletal
Degradation Following Severe Controlled Cortical Impact Traumatic Brain Injury in
Rats

Preface: Chapter Three has been adapted from: Kulbe JR, Singh IN, Wang JA, Cebak
JE, Hall ED. Continuous infusion of phenelzine, cyclosporine A, or their combination:
evaluation of

mitochondrial bioenergetics, oxidative damage, and cytoskeletal

degradation following severe controlled cortical impact traumatic brain injury in rats.
Journal of Neurotrauma 35(11):1280-1293 (2018). DOI: 10.1089/neu.2017.5353. (Mary
Ann Leibert, Inc., New York, NY). Figures have been renumbered and formatted in
accordance with University of Kentucky Graduate School requirements. The figures 3.73.9 have been added and portions of the Discussion and Conclusion have been
expanded upon. The data which appears in Figure 3.6 was generated by Dr. John E.
Cebak, Ph.D. and was first presented in his University of Kentucky Doctoral Dissertation,
“Mitochondrial and neuroprotective effects of phenelzine related to scavenging of
neurotoxic lipid peroxidation products” (2015).
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Introduction
In the United States, there are more than 2.5 million documented cases of
traumatic brain injury (TBI) annually [2], which resulted in direct and indirect medical
costs of over $75 billion dollars in 2010, with the most severe injuries (those resulting in
hospitalization and death) accounting for 90% of these costs [10, 11]. Currently, there
are over 5 million people in the U.S. living with a TBI-related disability [12]. Further, over
50% of persons hospitalized due to TBI will continue to suffer from a TBI-associated
disability more than a year following injury [13]. Such disabilities can include cognitive,
physical, and emotional impairments [12]. To date, there are no FDA-approved
pharmacotherapies for neuroprotection following clinical TBI [1].
Although numerous reasons have been cited for the failure of neuroprotective
compounds in clinical TBI studies, [9, 213], due to the complex secondary injury cascade
which occurs following injury and encompasses a multitude of neurodegenerative
processes, single agent therapies may be unlikely to succeed at completely preventing
the devastating neurological consequences that occur following injury [213]. In fact, in
2008, the National Institutes of Health (NIH), in conjunction with the Department of
Veterans Affairs, convened a workshop focusing on development of combinatorial
approaches for the treatment of traumatic brain injury over the first 72h following injury;
[213] underscoring the importance of developing multi-mechanistic combinational
neuroprotective approaches for acute TBI.
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Following injury (Fig. 3.1), increases in intracellular calcium are taken up by
mitochondria in an attempt to maintain calcium homeostasis [22, 23]. However, high
levels of intra-mitochondrial calcium lead to opening of the mitochondrial permeability
transition pore (mPTP), resulting in collapse of the mitochondrial membrane potential,
cessation of adenosine triphosphate (ATP) production, and release of calcium back into
the cytosol [51]. Further, increases in intra-mitochondrial calcium can lead to increased
generation of mitochondrial-produced reactive oxygen and nitrogen species (ROS/RNS)
[17, 163]. For example, as the levels of mitochondrial calcium increase and the
mitochondrial membrane potential depolarizes, electron transport slows, allowing
electrons to leak from complex-I to combine with O2 to form superoxide radical (O2•-)
[307], which can go on to react with nitric oxide radicals (NO•) generated by the calciumactivated mitochondrial nitric oxide synthase (mtNOS), forming peroxynitrite anion
(ONOO-) [17, 53]. Peroxynitrite is unique in the fact that it has quite a large diffusion
radius, thus allowing it to cross membranes, expanding its area of devastation [308].
Peroxynitrite is either protonated to form peroxynitrous acid (ONOOH) or reacts with CO 2
to form nitrosoperoxycarbonate (ONOOCO2-), followed by decomposition into the highly
reactive radicals, hydroxyl (•OH), nitrogen dioxide (•NO2) or carbonate (CO3•-) [17, 55,
308].
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Figure 3.1 Simplified schematic of TBI pathophysiology and phenelzine and
cyclosporine A mechanisms of action. The role of mitochondrial dysfunction and lipid
peroxidation following traumatic brain injury (TBI) and the mechanisms of action of
phenelzine (PZ) and cyclosporine A (CsA). Following injury, mitochondria uptake
calcium (Ca2+) which leads to opening of the mitochondrial permeability transition pore
(mPTP), generation of superoxide (O2•-) and activation of mitochondrial nitric oxide
synthase (mtNOS), which leads to formation of nitric oxide (•NO). O2•- and •NO combine
to form peroxynitrite anion (ONOO-), which can be protonated or react with CO2 to form
peroxynitrous acid (ONOOH) or nitrosoperoxycarbonate (ONOOCO2-), followed by
degradation into hydroxyl (•OH), nitrogen dioxide (•NO2) or carbonate (CO3•-), highly
reactive radicals which initiate lipid peroxidation (LP). LP terminates with the formation of
the LP-derived aldehydes 4-hydroxynonenal (4-HNE) and acrolein. 4-HNE and acrolein
bind mitochondrial proteins causing mitochondrial dysfunction and can exacerbate
opening of the mPTP. Mitochondrial dysfunction itself exacerbates the reactive oxygen
species/nitrogen species-lipid peroxidation-aldehyde cascade. Ca2+ is released back into
the cytosol upon mPTP opening, activating calpain, which degrades cytoskeletal αspectrin, resulting in neurodegeneration and neurologic impairment. CsA inhibits mPTP.
PZ scavenges the LP-derived aldehydes 4-HNE and acrolein.
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These highly reactive radicals initiate lipid peroxidation (LP) of polyunsaturated
fatty acids, which are highly enriched in brain cells and cellular and organelle
membranes [1, 55]. As lipid peroxyl radicals are formed, they are able to react with
neighboring polyunsaturated acids, resulting in a self-propagating process [1, 55]. Lipid
peroxidation terminates upon formation of LP-derived aldehydes, such as 4hydroxynonenal (4-HNE) and acrolein [1, 55]. These LP-derived aldehydes have multiple
reactive sites, making it possible for them to covalent bind lysine, histidine, arginine and
cysteine protein residues through both Schiff base and Michael addition reactions [1, 7981]. Once covalently bound to proteins, including mitochondrial proteins, LP-derived
aldehydes induce protein dysfunction and enzyme inactivation, neurotoxicity and cellular
death [77, 84-89]. In the case of mitochondria, binding of LP-derived aldehydes
exacerbates impairment of bioenergetics and generation of the ROS/RNS-lipid
peroxidation-aldehyde cascade, as well as opening of mPTP [29, 72, 93, 100-102]. Once
permeability transition occurs and calcium has been released back into the cytosol, it
can activate calcium-dependent proteases, such as calpain, which can cleave
cytoskeletal proteins, such as α-spectrin, resulting in further downstream consequences,
including neurodegeneration and neurologic impairment [1, 51, 55, 56, 70, 109, 110].
As central mediators of the TBI secondary injury cascade, both mitochondria and
LP-derived aldehydes make promising neuroprotective targets. In fact, several preclinical studies have demonstrated the neuroprotective ability of agents which aim to
prevent mitochondrial dysfunction or attenuate lipid peroxidation [58, 69-72, 75, 109,
110, 123, 125, 226, 249, 257, 309, 310]. One of the most extensively investigated
mitochondrial protective agents, the FDA-approved immunosuppressant cyclosporine A
(CsA), is capable of inhibiting the mPTP [110, 218, 219, 226] (Fig. 3.1), and has been
shown to be safe for use clinically in severe TBI patients [234, 235]. Another drug,
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phenelzine (PZ) (Fig. 3.1), which is an FDA-approved irreversible non-selective
monoamine oxidase inhibitor, contains a hydrazine moiety (-NH-NH2), which is capable
of scavenging LP-derived aldehydes [71, 72, 74, 76, 198, 258, 262, 311, 312].
Importantly, scavenging of LP-derived aldehydes is likely to offer a more clinically
translational approach in regards to therapeutic window, compared to conventional
antioxidants, as LP-derived aldehydes are longer lived than their highly reactive free
radical predecessors [79, 81, 259].
Both CsA and PZ have individually been shown capable of attenuating
pathophysiologic processes in pre-clinical models of neurotrauma [71, 72, 74, 76, 110,
122-124, 136, 223-227, 292, 294, 298, 309, 313]. Therefore, it follows that the mPTP
inhibitor CsA and the LP-derived aldehyde scavenger PZ may together enhance
neuroprotection over either agent alone through the combining of distinct but
complementary mechanisms. In fact, CsA was one of the agents identified as a
candidate for combinational therapy during the NIH combinational therapy TBI workshop
[213]. Additionally, as the first 72h represents a critical time period following injury [213],
including the peak of mitochondrial dysfunction, lipid peroxidation, and neuronal
cytoskeletal (α-spectrin) degradation [73], it follows that continuous drug infusion over
the first 72h following injury may also lead to optimal neuroprotective effects [79].
This is the first study to investigate the neuroprotective effects of the combination
CsA and PZ 72h following severe controlled cortical impact injury (CCI), a model
combining focal, contusive, hemorrhagic and diffuse injury pathologies [128, 314].
Additionally, this is the first study to investigate the effects of 72h continuous infusion of
CsA, PZ, and the combination on mitochondrial dysfunction, aldehydic modification of
mitochondrial proteins, and α-spectrin degradation 72h following severe CCI, using a
CsA dosing paradigm that previously has been shown to improve cortical tissue sparing
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following CCI [122], and a PZ dosing paradigm based upon a 12hr intermittent dosing
protocol which has previously been shown to be neuroprotective following CCI [72].
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Methods
Animals
Three-month-old male Sprague-Dawley rats (Harlan, Indianapolis, IN) were
housed in the Division of Laboratory Animal Resources of the University of Kentucky
Medical Center. All animal and husbandry were conducted in accordance with the
University of Kentucky Institutional Animal Care and Use Committee. Animals were
housed in a 12hr light and dark cycle and allowed food and water ad libitum.
Experimental Design
Two cohorts of animals were randomly assigned to the following subcutaneous
continuous infusion dosing paradigm experimental groups: sham, vehicle, PZ, CsA, and
phenelzine + cyclosporine A (PZ + CsA), with one cohort of animals being used for all
mitochondria experiments and another cohort of animals being used for cortical αspectrin analysis. An additional cohort of animals was randomly assigned to the
following 12hr intermittent PZ dosing paradigm experimental groups: sham, vehicle, or
PZ. Following injury and closing of the craniotomy site, all animals in the subcutaneous
continuous infusion dosing paradigm, other than sham, were immediately implanted with
two subcutaneous osmotic pumps loaded with either drug or vehicle, and additionally
received two bolus doses of either drug or vehicle 15 min following impact. Animals
within the subcutaneous continuous infusion dosing paradigm received the following
doses: i) sham (no impact injury, no drug administration); ii) vehicle (15 min post-injury
bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus dose:
subcutaneous

saline;

subcutaneous

osmotic

pump:

cremophor/ethanol/saline;

subcutaneous osmotic pump: saline); iii) PZ (15 min post-injury bolus dose:
intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous
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10mg/kg PZ in saline; subcutaneous osmotic pump: cremophor/ethanol/saline;
subcutaneous osmotic pump: 10mg/kg/day/3d saline); iv) CsA (15 min post-injury bolus
dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury bolus
dose: subcutaneous saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA in
cremophor/ethanol/saline; subcutaneous osmotic pump: saline) v) PZ + CsA (15 min
post-injury bolus dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min
post-injury bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic
pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline, subcutaneous osmotic pump:
10mg/kg/day/3d PZ in saline) (Table 3.1). Following euthanasia one group of the
subcutaneous continuous infusion dosing paradigm animals were used for mitochondria
experiments while the other group was utilized for analysis of α-spectrin degradation.
The third cohort of animals was assigned to the 12hr intermittent PZ dosing
paradigm. Animals in the 12hr intermittent PZ dosing paradigm received the following
dosing schedule: sham (no impact injury, no drug administration); vehicle (15 min postinjury bolus dose of subcutaneous saline, followed by subcutaneous bolus saline every
12h up to and including 60h); PZ (15 min post-injury bolus dose of 10mg/kg PZ in saline,
followed by subcutaneous bolus 5mg/kg PZ in saline every 12h up to and including 60h)
(Table 3.2).
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Table 3.1 Subcutaneous Continuous Infusion Dosing Paradigm
Loading Dose

Osmotic Pump

(15min post-injury)

(Immediate)

None

None

Saline s.c.

Saline

Cremophor i.p.

Cremophor

10mg/kg s.c. PZ

10mg/kg/day/3d PZ

Cremophor i.p.

Cremophor

Saline s.c.

Saline

20mg/kg i.p. CsA

10mg/kg/day/3d CsA

Phenelzine + Cyclosporine

10mg/kg s.c. PZ

10mg/kg/day/3d PZ

A

20mg/kg i.p. CsA

10mg/kg/day/3d CsA

Group

Sham

Vehicle

Phenelzine

Cyclosporine A

Demonstration of the subcutaneous continuous infusion dosing paradigm followed.
Osmotic pumps were placed subcutaneously immediately following impact injury and
closure of the craniotomy site. Pumps were removed 72h later at the time of euthanasia.
Loading doses were administered 15 min following impact. Cremophor (saline/650mg
cremophor/32.9% ethanol/ml) was prepared to deliver an equal amount cremophor as
received by CsA animals. Saline was prepared to deliver an equal amount of saline as
PZ animals. PZ, phenelzine (in saline); CsA, cyclosporine A (in saline/650mg
cremophor/32.9% ethanol/ml); s.c, subcutaneous, i.p., intraperitoneal.
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Table 3.2 Phenelzine 12hr Intermittent Dosing Paradigm
Loading Dose

Maintenance dosing:

(15min post-injury)

12h, 24h, 36h, 48h, 60h

Sham

None

None

Vehicle

Saline s.c.

Saline s.c.

Phenelzine

10mg/kg s.c. PZ

5mg/kg s.c. PZ

Group

Demonstration of the PZ 12hr intermittent dosing paradigm followed. Loading doses
were administered 15 min following impact. Maintenance doses were administered every
12h up to and including 60h. Animals were euthanized 72h post-injury. Saline was
prepared to deliver an equal amount of saline as PZ animals. PZ, phenelzine (in saline);
s.c., subcutaneous.
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Controlled Cortical Impact Traumatic Brain Injury
Animals were anesthetized using 4% isoflurane, shaved, and placed into a
stereotaxic frame (David Kopf, Tujunga, CA), where isoflurane was maintained at 3% for
the duration of the procedure. A midline incision was made to expose the skull, and a 6
mm craniotomy was created lateral to the sagittal suture and midway between lambda
and bregma using a Michele Trephine (Miltex, Bethpage, NY). The exposed brain with
intact dura received a severe CCI using a computer-controlled pneumatic impact device
(TBI 03010; Precision Systems and Instrumentation, Fairfax Station, VA) fitted with a 5
mm beveled tip and set to impact at a depth of 2.2 mm with a 500 ms dwell time and an
impact velocity of ~3.5 m/s, as described previously [71]. After injury, Surgicel (Johnson
& Johnson, Arlingtin, TX) was placed onto the dura and an 8 mm plastic disk was affixed
to the skull using tissue adhesive (Gesswein, Bridgeport, CT) to close the craniotomy
site, and the incision was closed using wound clips. Sham animals underwent the same
procedure but did not receive an impact injury.
Loading Dose Drug Administration
Fifteen minutes following injury, animals assigned to the subcutaneous
continuous infusion dosing paradigm, received a loading dose of the appropriate drug.
CsA (Perrigo; Minneapolis, MN; 50mg/ml in saline/650mg cremophor/32.9% ethanol/ml)
was administered intraperitoneal at 20mg/kg [122, 227]. Cremophor (CsA vehicle) was
administered

intraperitoneal

to

deliver

an

equivalent

volume

of

saline/cremophor/ethanol. Phenelzine (MP Biochemicals, Solon, OH) was administered
subcutaneously at 10mg/kg in saline [72]. Saline (PZ vehicle) was administered
subcutaneously to deliver an equivalent volume of saline. Sham animals did not receive
injections.
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Osmotic Pump Preparation
The day prior to implantation, osmotic pumps (2ML1, Alzet osmotic pumps,
Cupertino, CA) were loaded with appropriate drug concentrations and allowed to prime
overnight at 37°C and then maintained at 37°C until the time of implantation. CsA
pumps were loaded to deliver 10mg/kg/day/3d of CsA (Perrigo; Minneapolis, MN;
50mg/ml in saline/650mg cremophor/32.9% ethanol/ml) based on a previously optimized
CsA dosing protocol [122, 227]. Cremophor pumps (CsA vehicle) were loaded to deliver
an equivalent volume of saline/cremophor/ethanol. PZ pumps were loaded to deliver
10mg/kg/day/3d of PZ (MP Biochemicals, Solon, OH) in saline based on an approximate
12h plasma half-life in humans and a previously optimized 12hr intermittent dosing
protocol [72]. Saline pumps (PZ vehicle) were loaded to deliver an equivalent amount
saline.
Implantation of Osmotic Pumps
Immediately following impact injury and closure of the craniotomy site, a sagittal
incision was made approximately half-way down the animal’s back. Hemostats were
used to create a subcutaneous pocket anterior and posterior to the incision site. Preloaded osmotic pumps (2ML1, Alzet osmotic pumps, Cupertino, CA) were inserted into
the subcutaneous pockets with the flow moderator positioned away from the incision
site. The incision was then closed with wound clips, and animals were allowed to recover
while body temperature was maintained at 37°C using a warm water circulating heating
pad. Vehicle animals received a saline pump (PZ’s vehicle) and a cremophor pump
(CsA’s vehicle). PZ animals received a PZ pump and a cremophor pump. CsA animals
received a CsA pump and a saline pump. PZ + CsA animals received a PZ pump and a
CsA pump. Sham animals did not undergo pump implantation.
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Phenelzine 12hr Intermittent Dosing Protocol
Fifteen minutes following injury, PZ animals received 10mg/kg PZ (MP
Biochemicals, Solon, OH) in saline subcutaneously, followed by 5mg/kg PZ
subcutaneously every 12h up to including 60h [72]. Vehicle animals received an
equivalent amount of saline at the appropriate time point. Sham animals did not receive
injections (Table 3.2).
Tissue Extraction and Pump Removal
Animals were euthanized 72h following injury, which represents the peak of
mitochondrial dysfunction, LP and α-spectrin degradation [73], using CO2, followed by
decapitation. An 8 mm cortical punch centered over the injury was collected in order to
collect the epicenter of injury and the penumbral region. Cortical punches were either
processed for isolation of mitochondria or cortical protein. Pumps were removed and
residual volumes were measure to ensure proper drug delivery. Animals in which pumps
did not run properly, as determined by the removed pumps still having most of their drug
still in the pumps, were removed from the study.
Isolation of Ficoll-Purified Cortical Mitochondria
Mitochondria were isolated as described previously [71, 163]. Cortical punch
tissue was immediately homogenized in ice-cold isolation buffer (215 mmol/L mannitol,
75 mmol/L sucrose, 0.1% bovine serum albumin, 20mmol/L HEPES, 1mmol/L EGTA, pH
7.2) using Potter-Elvejhem homogenizers. Samples were then centrifuged twice at 1300
g for 3 min at 4°C. Supernatants were additionally centrifuged at 13,000 g for 10 min at
4°C. The crude mitochondrial pellet was resuspended in isolation buffer, placed into a
nitrogen bomb at 1200 psi for 10 min at 4°C to release synaptic mitochondria, and then
layered onto a discontinuous 7.5% and 10% Ficoll gradient and centrifuged for 100,000
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g for 30 min at 4°C. The mitochondrial pellet was resuspended in isolation buffer without
EGTA, centrifuged at 10,000 g for 10 min at 4°C to remove Ficoll, and then resuspended
in isolation buffer without EGTA to a final concentration of ~10mg/kg. Protein
concentrations were determined with a BCA protein assay kit (ThermoFisher, Cleveland,
OH) and measured at absorbance 562nm with a BioTek Synergy HT plate reader
(Winooski, VT).
Mitochondrial Bioenergetics Analysis
Mitochondrial respiratory function was measured using a Clark-type electrode in
a continuously stirred, sealed, and thermostatically controlled chamber maintained at
37°C (Oxytherm System; Hansatech Instruments, Norfolk, UK). Mitochondria (60 μg – 80
μg) were placed into the chamber containing 250 μl of KCl respiration buffer (125
mmol/L KCl, 2 mmol/L MgCl2, 2.5 mmol/L KH2PO4, 0.1% bovine serum albumin, 20
mmol/L HEPES, pH 7.2). Following a 1 minute equilibration, complex-I respiration was
initiated by addition of 5 mmol/L pyruvate and 2.5 mmol/L malate. Two boluses of 150
μmol/L ADP were added and state III respiration was monitored. The ATP synthase
inhibitor, oligomycin (2 μmol/L) was added and state IV respiration was monitored. The
protonophore FCCP (2 μmol/L) was added and maximal state V(I) respiration was
monitored. Complex-I was inhibited by addition of 100 nmol/L rotenone. Complex-II
maximal respiration was initiated by the addition of succinate (10 mmol/L) and state V(II)
was monitored. Respiratory rates for individual states were calculated as nmol O 2 per
mg of protein per min. Respiratory control ratio (RCR) was calculated by dividing state III
respiration rate (second bolus of ADP) by state IV respiration rate [163, 248]. Following
bioenergetics analysis, remaining mitochondrial protein was immediately frozen at -80°C
for use in Western blot.
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Western Blot Analysis: Cortical α-Spectrin Degradation & Lipid PeroxidationInduced Cortical Mitochondrial Oxidative Damage
Cortical punch tissue collected from the cohorts of animals designated for
analysis of α-spectrin degradation was immediately placed into ice-cold Triton-lysis
buffer (1% Triton, 20 mmol/L Tris-HCl, 150 mmol/L NaCl, 5 mmol/L EGTA, 10 mmol/L
EDTA, 20 mmol/L HEPES, pH 7.4) containing protease inhibitors (Complete Mini™
Protease Inhibitor Cocktail tablet, Roche). Similarly, mitochondria protein being stored
at -80°C following bioenergetics analysis was thawed and resuspended in lysis buffer.
All samples were sonicated, vortexed, and then centrifuged at 14,000 rpm for 30 min at
4°C. Protein concentrations were determined with a BCA protein assay kit
(ThermoFisher, Cleveland, OH) and measured at absorbance 562nm with a BioTek
Synergy HT plate reader (Winooski, VT). Due to the limited yield of mitochondrial protein
following Ficoll-purified isolation, bioenergetics analysis and processing for Western blot,
only samples containing greater than 100 μg of protein, allowing for analysis of both 4HNE and acrolein, were utilized for Western Blot. For analysis of α-spectrin, 10 μg of
protein was run on a 3-8% Tris-Acetate Criterion™ XT polyacrylamide gel (Bio-Rad,
Hercules, CA) with XT Tricine Running Buffer (Bio-Rad, Hercules, CA). For analysis of
4-HNE or acrolein, 50 μg of protein was run on a 4-12% Tris-Acetate Criterion™ XT
polyacrylamide gel (Bio-Rad, Hercules, CA) with MOPS buffer (Bio-Rad, Hercules, CA).
Following separation of proteins by polyacrylamide gel, protein was transferred to a
nitrocellulose membrane using a semi-dry electro-transferring unit for 15 min (α-spectrin)
or 1hr (4-HNE, acrolein) at 15V. Following transfer, membranes were blocked at room
temperature for 1hr in Tris-buffered saline (TBS) containing 5% milk. Membranes were
incubated with the following primary antibodies in TBS with Tween (TBST) containing
5% milk overnight at 4°C: mouse monoclonal anti-αII-spectrin (Enzo, Farmingdale, NY,
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1:5,000), rabbit polyclonal anti-β-tubulin (Abcam, Cambridge, CA, 1:5,000-1:10,000),
rabbit polyclonal anti-4HNE (Alpha Diagnostics, San Antonio, TX, 1:1,000), rabbit
polyclonal anti-acrolein (Abcam, Cambridge, CA, 1:2,000), and rabbit polyclonal antiVDAC (EMD Millipore,

Billerica, MA, 1:30,000). Membranes were washed in TBST

following incubation with primary antibody.
Membranes were incubated with the following secondary antibodies in TBST
with 5% milk for one 1hr at room temperature: goat anti-rabbit IgG IRdye800CW
(Rockland, Limerick, PA, 1:5,000), goat anti-rabbit IgG Alexa Fluor 680 (ThermoFisher,
Waltham, MA1:10,000), and goat anti-mouse IgG IRDye800CW (Rockland, Limerick,
PA, 1:5,000). Membranes were washed in TBST, and then imaged and quantified using
the Li-Cor Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE). For
analysis of α-spectrin degradation, α-spectrin breakdown products were normalized to
tubulin. For analysis of mitochondrial protein, 4-HNE and acrolein were normalized to
VDAC. A protein loading control was loaded onto each gel to control for inter-gel
variability. For α-spectrin, bands at 145kD and 150kD were analyzed. Due to broad
binding of 4-HNE and acrolein to lysine, histidine, arginine, cysteine protein residues, as
well as differential banding patterns between 4-HNE and acrolein [73], mitochondrial 4HNE was analyzed between 80kD-150kD and mitochondrial acrolein was analyzed
between 60kD-100kD.
Statistical Analysis
Statistical analysis was conducted using Prism version 7.0 (Graph Pad, San
Diego, CA). Results are reported as mean ± standard deviation. Analysis was done by
one-way analysis of variance (ANOVA), followed by Student-Newman-Keuls (SNK) post-
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hoc analysis when appropriate. A p-value <0.05 was considered significant. Grubb’s test
was used to remove statistical outliers.
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Results
CCI-TBI Induced Mitochondrial Bioenergetics Dysfunction
State III: ADP Activation of ATP Synthase and Coupling of Electron Transport with
Oxidative Phosphorylation
A one-way ANOVA revealed a statistically significant effect across all groups (F
[4,35] = 19.45, p<0.0001). Post-hoc testing (SNK) revealed that compared with sham,
state III respiration was significantly impaired for vehicle (p<0.0001), PZ (p<0.0001), CsA
(p<0.0001), and PZ + CsA (p<0.0001), thus indicating that severe CCI significantly
decreased state III respiration compared with sham, and that 72h subcutaneous
continuous infusion of neither PZ, CsA, nor PZ + CsA was able to significantly attenuate
CCI-induced decreases in state III respiration (Fig. 3.2A).
State IV: Oligomycin Inhibition of ATP Synthase
A one-way ANOVA revealed a statistically significant effect across all groups (F
[4,35] = 11.44, p<0.0001). Post-hoc testing (SNK) revealed that compared with sham,
state IV respiration was significantly impaired for vehicle (p<0.0001), PZ (p<0.0001),
CsA (p<0.001), and PZ + CsA (p<0.0001), thus indicating that severe CCI significantly
decreased state IV respiration compared with sham, and that 72h subcutaneous
continuous infusion of neither PZ, CsA, nor PZ + CsA was able to significantly attenuate
CCI-induced decreases in state IV respiration (Fig. 3.2B).
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Figure 3.2 State III – State V(II): PZ, CsA, and PZ + CsA. Effect of the 15 min postinjury loading dose + 72h subcutaneous continuous infusion dosing paradigm on
mitochondrial oxygen consumption 72h following severe cortical impact injury for (A)
state III (pyruvate/malate/ADP), (B) state IV (oligomycin), (C) state V(I) (FCCP), and (D)
state V(II) (rotenone/succinate). Sham (no impact injury, no drug administration). Vehicle
(15 min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min postinjury bolus dose: subcutaneous saline; subcutaneous osmotic pump:
cremophor/ethanol/saline; subcutaneous osmotic pump: saline). PZ = phenelzine (15
min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-injury
bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump:
cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline).
CsA = cyclosporine A (15 min post-injury bolus dose: intraperitoneal 20mg/kg CsA in
cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous saline;
subcutaneous osmotic pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline;
subcutaneous osmotic pump: saline). PZ + CsA + cyclosporine A (15 min post-injury
bolus dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury
bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump:
10mg/kg/day/3d CsA in cremophor/ethanol/saline; subcutaneous osmotic pump:
10mg/kg/day/3d PZ in saline). One-way analysis of variance followed by StudentNewman-Keuls post-hoc test. ***p<0.001, ****p<0.0001 compared with sham. Error bars
represent mean ± standard deviation. n = 8 rats per group.
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Respiratory Control Ratio (RCR): State III Respiration / State IV Respiration
A one-way ANOVA revealed a statistically significant effect across all groups (F
[4,35] = 5.961, p=0.0009). Post-hoc testing (SNK) revealed that compared with sham,
RCR was significantly impaired for vehicle (p<0.05), CsA (p<0.01), and PZ + CsA
(p<0.01), whereas PZ was not significantly different from either vehicle (p>0.05) or sham
(p>0.05), thus indicating that severe CCI significantly decreased RCR compared with
sham, and that 72h subcutaneous continuous infusion of neither CsA, nor PZ + CsA was
able to significantly attenuate CCI-induced decreases in RCR. However, PZ was able to
maintain RCR, compared with sham (Fig 3.3).
State V(I): FCCP Protonophore Addition and Initiation of Maximal Complex-I Respiration
A one-way ANOVA revealed a statistically significant effect across all groups (F
[4,35] = 33.55, p<0.0001). Post-hoc testing (SNK) revealed that compared with sham,
state V(I) respiration was significantly impaired for vehicle (p<0.0001), PZ (p<0.0001),
CsA (p<0.0001), and PZ + CsA (p<0.0001), thus indicating that severe CCI significantly
decreased state V(I) respiration compared with sham, and that 72h subcutaneous
continuous infusion of neither PZ, CsA, nor PZ + CsA was able to significantly attenuate
CCI-induced decreases in state V(I) respiration (Fig. 3.2C).
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Figure 3.3 RCR: PZ, CsA, and PZ + CsA Effect of the 15 min post-injury loading dose +
72h subcutaneous continuous infusion dosing paradigm on mitochondrial respiratory
control ratio (state III respiration / state IV respiration) 72h following severe cortical
impact injury. Sham (no impact injury, no drug administration). Vehicle (15 min postinjury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus
dose: subcutaneous saline, subcutaneous osmotic pump: cremophor/ethanol/saline;
subcutaneous osmotic pump: saline). PZ = phenelzine (15 min post-injury bolus dose:
intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous
10mg/kg PZ in saline; subcutaneous osmotic pump: cremophor/ethanol/saline;
subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline). CsA = cyclosporine A (15
min post-injury bolus dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15
min post-injury bolus dose: subcutaneous saline; subcutaneous osmotic pump:
10mg/kg/day/3d CsA in cremophor/ethanol/saline; subcutaneous osmotic pump: saline).
PZ + CsA (15 min post-injury bolus dose: intraperitoneal 20mg/kg CsA in
cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous 10mg/kg PZ in
saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline;
subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline). One-way analysis of
variance followed by Student-Newman-Keuls post-hoc test. *p<0.05, **p<0.01 compared
with sham. Error bars represent mean ± standard deviation. n = 8 rats per group.
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State V(II): Rotenone Inhibition of Complex-I and Succinate Activation of Maximal
Complex-II Respiration
A one-way ANOVA revealed a statistically significant effect across all groups (F
[4,35] = 19.55, p<0.0001). Post-hoc testing (SNK) revealed that compared with sham,
state V(II) respiration was significantly impaired for vehicle (p<0.0001), PZ (p<0.0001),
CsA (p<0.0001), and PZ + CsA (p<0.0001), thus indicating that severe CCI significantly
decreased state V(II) respiration compared with sham, and that 72h subcutaneous
continuous infusion of neither PZ, CsA, nor PZ + CsA was able to significantly attenuate
CCI-induced decreases in state V(II) respiration (Fig. 3.2D).
CCI-TBI Modification of Mitochondrial Proteins by 4-HNE and Acrolein
4-HNE
A one-way ANOVA revealed a statistically significant effect across all groups (F
[4,30] = 6.765, p=0.0005). Post-hoc testing (SNK) revealed that compared with sham,
binding of 4-HNE to mitochondrial proteins was significantly increased for vehicle
(p<0.001) and PZ + CsA (p<0.01), and that binding of 4-HNE to mitochondrial proteins
was significantly decreased in the PZ group (p<0.05) and the CsA group (p<0.05)
compared with vehicle, with neither the PZ group or the CsA group being significantly
different from sham (p>0.05), thus indicating that severe CCI significantly increases
formation of 4-HNE bound mitochondrial proteins compared with sham, and that 72h
subcutaneous continuous infusion of either PZ or CsA, but nor PZ + CsA, significantly
decreases CCI-induced formation of 4-HNE bound mitochondrial proteins (Fig. 3.4A).
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Figure 3.4 4-HNE and Acrolein: Effect of PZ, CsA, and PZ + CsA. Effect of the 15 min
post-injury loading dose + 72h subcutaneous continuous infusion dosing paradigm on
binding of (A) 4-HNE (4-hydroxynonenal) or (C) acrolein to mitochondrial protein 72h
following severe cortical impact injury as assessed by Western blot. Representative
Western blot images demonstrating analysis of (B) 4-HNE between 150 kD and 80 kD
and internal loading control VDAC (voltage-dependent anion channel) and analysis of
(D) Acrolein between 100 kD and 60 kD and internal loading control VDAC. Sham (no
impact injury, no drug administration). Vehicle (15 min post-injury bolus dose:
intraperitoneal cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous
saline; subcutaneous osmotic pump: cremophor/ethanol/saline; subcutaneous osmotic
pump: saline). PZ = phenelzine (15 min post-injury bolus dose: intraperitoneal
cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous 10mg/kg PZ in
saline; subcutaneous osmotic pump: cremophor/ethanol/saline; subcutaneous osmotic
pump: 10mg/kg/day/3d PZ in saline). CsA = cyclosporine A (15 min post-injury bolus
dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury bolus
dose: subcutaneous saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA in
cremophor/ethanol/saline; subcutaneous osmotic pump: saline). PZ + CsA (15 min postinjury bolus dose: intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min
post-injury bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic
pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline; subcutaneous osmotic pump:
10mg/kg/day/3d PZ in saline). One-way analysis of variance followed by StudentNewman-Keuls post-hoc test. *p<0.05, **p<0.01, ***p<0.001 compared with sham;
#
p<0.05 compared with vehicle; ^p<0.05 compared with CsA. Error bars represent mean
± standard deviation. n = 6-8 rats per group.
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Acrolein
A one-way ANOVA revealed a statistically significant effect across all groups (F
[4,32] = 4.607, p=0.0047). Post-hoc testing (SNK) revealed that compared with sham,
binding of acrolein to mitochondrial proteins was significantly increased for vehicle
(p<0.05) and PZ + CsA (p<0.05). The PZ + CsA group was also significantly increased
as compared with the CsA group (p<0.05). Although the PZ group and the CsA group
were not significantly different from vehicle (p>0.05), there was a 42% and 51%
decrease in mean acrolein binding of mitochondrial proteins compared with vehicle for
the PZ and CsA group, respectively. Further, the PZ group and the CsA group were not
significantly different from sham (p>0.05), thus indicating that severe CCI significantly
increases formation of acrolein bound mitochondrial proteins compared with sham, and
that 72h subcutaneous continuous infusion of either PZ or CsA, but nor PZ + CsA,
decreases CCI-induced formation of acrolein bound mitochondrial proteins (Fig. 3.4C).
CCI-TBI Induced α-Spectrin Degradation: Continuous Infusion Dosing Paradigm
145 kD – Calpain-Dependent α-Spectrin Breakdown Product
A one-way ANOVA revealed a statistically significant effect across all groups (F
[4,34] = 3.032, p=0.0306). Post-hoc testing (SNK) revealed that compared with sham,
145 kD α-spectrin breakdown products were significantly increased for vehicle (p<0.05)
and CsA (p<0.05). Although the PZ group and the PZ + CsA group were not significantly
different from vehicle (p>0.05), there was a 53% and a 53% decrease in mean
absorbance compared with vehicle for the PZ and PZ + CsA groups, respectively.
Further, the PZ group and the PZ + CsA group were not significantly different from sham
(p>0.05) or from each other (p>0.05), thus indicating that severe CCI significantly
increases formation of the 145 kD calpain dependent α-spectrin breakdown product, and
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that 72h subcutaneous continuous infusion of either PZ or PZ + CsA maintain
cytoskeletal α-spectrin integrity to a similar degree, as compared with sham (Fig. 3.5A).
150 kD – Calpain/Caspase 3-Dependent α-Spectrin Breakdown Product
A one-way ANOVA revealed a statistically significant effect across all groups (F
[4,34] = 4.49, p=0.0051). Post-hoc testing (SNK) revealed that compared with sham, 150
kD α-spectrin breakdown products were significantly increased for vehicle (p<0.01) and
CsA (p<0.01). Although the PZ group and the PZ + CsA group were not significantly
different from vehicle (p>0.05), there was a 47% and 47% decrease in mean
absorbance compared with vehicle for the PZ and PZ + CsA groups, respectively.
Further, the PZ group and the PZ + CsA group were not significantly different from sham
(p>0.05) or from each other (p>0.05), thus indicating that severe CCI significantly
increases formation of the 150 kD calpain/caspase 3-dependent α-spectrin breakdown
product, and that 72h subcutaneous continuous infusion of either PZ or PZ + CsA
maintain cytoskeletal α-spectrin integrity to a similar degree, as compared with sham
(Fig. 3.5B).
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Figure 3.5 Spectrin: Effect of PZ, CsA, and PZ + CsA. Effect of the 15 min post-injury
loading dose + 72h subcutaneous continuous infusion dosing paradigm on degradation
of cytoskeletal protein α-spectrin into (A) 145 kD (calpain dependent) and (B) 150 kD
(calpain and caspase 3-dependent) α-spectrin breakdown products 72h following severe
cortical impact injury as assessed by Western blot. (C) Representative Western blot
image demonstrating analysis of 145 kD and 150 kD α-spectrin bands and the internal
loading control tubulin. Sham (no impact injury, no drug administration). Veh = Vehicle
(15 min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min postinjury bolus dose: subcutaneous saline; subcutaneous osmotic pump:
cremophor/ethanol/saline; subcutaneous osmotic pump: saline). PZ = phenelzine (15
min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15 min post-injury
bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump:
cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline).
CsA = cyclosporine A (15 min post-injury bolus dose: intraperitoneal 20mg/kg CsA in
cremophor/ethanol/saline; 15min post-injury bolus dose: subcutaneous saline;
subcutaneous osmotic pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline;
subcutaneous osmotic pump: saline). PZ + CsA (15 min post-injury bolus dose:
intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury bolus dose:
subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA
in cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in
saline). One-way analysis of variance followed by Student-Newman-Keuls post-hoc test.
*p<0.05, **p<0.01 compared with sham. Error bars represent mean ± standard deviation.
n = 7-9 rats per group.
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CCI-TBI Induced α-Spectrin Degradation: Phenelzine 12hr Intermittent Dosing
Paradigm
145 kD – Calpain-Dependent α-Spectrin Breakdown Products
A one-way ANOVA revealed a statistically significant effect across all groups (F
[2,21] = 6.128, p=0.008). Post-hoc testing (SNK) revealed that compared with sham, 145
kD α-spectrin breakdown products were significantly increased for vehicle (p<0.05) and
PZ (p<0.01), thus indicating that severe CCI significantly increases formation of the 145
kD calpain-dependent α-spectrin breakdown product, and that a subcutaneous bolus
dose of PZ (10 mg/kg) 15 min post-injury followed by subcutaneous maintenance doses
(5 mg/kg) every 12h up to and including 60h is unable to attenuate degradation (Fig.
3.6A).
150 kD – Calpain/Caspase 3-Dependent α-Spectrin Breakdown Product
A one-way ANOVA revealed a statistically significant effect across all groups (F
[2,21] = 5.426, p=0.0126). Post-hoc testing (SNK) revealed that compared with sham,
150 kD α-spectrin breakdown products were significantly increased for vehicle (p<0.05)
and PZ (p<0.05), thus indicating that severe CCI significantly increases formation of the
150 kD calpain/caspase 3-dependent α-spectrin breakdown product, and that a
subcutaneous bolus dose of PZ (10 mg/kg) 15 min post-injury followed by subcutaneous
maintenance doses (5 mg/kg) every 12h up to and including 60h is unable to attenuate
degradation (Fig. 3.6B).
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Figure 3.6 Spectrin: Intermittent PZ dosing. Effect of the 15 min post-injury loading
dose + 12h intermittent phenelzine (PZ) dosing paradigm on degradation of cytoskeletal
protein α-spectrin into (A) 145 kD (calpain dependent) and (B) 150 kD (calpain and
caspase-3 dependent) α-spectrin breakdown products 72h following severe cortical
impact injury as assessed by Western blot. (C) Representative Western blot image
demonstrating analysis of 145 kD and 150 kD α-spectrin bands and the internal loading
control tubulin. Sham (no impact injury, no drug administration). Vehicle (15 min postinjury bolus dose subcutaneous saline, followed by subcutaneous bolus saline every 12h
up to and including 60h). PZ = phenelzine (15 min post-injury bolus dose of 10mg/kg PZ
in saline, followed by subcutaneous bolus 5mg/kg PZ in saline every 12h up to and
including 60h). One-way analysis of variance followed by Student-Newman-Keuls posthoc test. *p<0.05, **p<0.01 compared to sham. Error bars represent mean ± standard
deviation. n = 7-9 rats per group.
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Discussion
TBI Induction of Mitochondrial Dysfunction and Lipid Peroxidation-Derived
Aldehyde Generation
It is has been firmly established that mitochondrial dysfunction, lipid peroxidation,
and production of LP-derived aldehydes occurs following TBI, and that each contributes
to TBI pathology [1, 17, 55, 57, 73, 163, 285]. For example, mitochondrial dysfunction
can contribute to induction of the ROS/RNS-lipid peroxidation-aldehyde cascade, energy
failure, and downstream consequences such as cytoskeletal and neuronal degeneration
and neurologic impairment [1, 17, 51, 55, 56, 70, 110, 163], while lipid peroxidation can
impair membrane fluidity and destabilize membrane integrity [256], and the LP-derived
aldehydes, including 4-HNE and acrolein, can have directly toxic effects on cellular
function [29, 72, 77, 85-89, 93, 101, 102, 257, 258], with a notably devastating effect on
the mitochondria.
Cyclosporine A and Inhibition of the Mitochondrial Permeability Transition Pore
Several approaches have been utilized to improve mitochondrial function
following TBI, including mild uncoupling [125, 248], ketogenic diet [249], induction of
endogenous antioxidant pathways [97, 113], and scavenging of lipid peroxyl radicals,
peroxynitrite, and LP-derived aldehydes [58, 69, 71, 72, 109, 257, 310, 315]. However,
inhibition of the mitochondrial permeability transition pore utilizing the FDA-approved
immunosuppressant CsA as a neuroprotective strategy following TBI has remained a
focus among the neurotrauma community for the past 20 years.

Although the

immunosuppressive effects of CsA are attributable to its ability to inhibit calcineurin and,
therefore, T-cell activation [316], its neuroprotective effects are purported to be due to
inhibition of the mPTP through direct binding of the mPTP component protein, cyclophilin
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D [218-220, 317]. In fact, in experimental TBI, CsA or its non-immunosuppressive
analog, the mPTP inhibitor NIM811, have been shown to prevent mitochondrial
dysfunction,

decrease

oxidative

damage,

attenuate

axonal

pathology

and

neurodegeneration, and improve behavioral impairments [110, 123, 124, 135, 136, 223226, 292, 309].
The continuous CsA dosing paradigm utilized here, 20 mg/kg CsA delivered
intraperitoneal 15 min post-injury combined with subcutaneous continuous infusion of
10mg/kg/day/3 days CsA, is based on previously optimized dosing paradigms
demonstrating that continuous infusion of CsA is more neuroprotective that bolus dosing
[122, 227]. Additionally, a 72h continuous infusion CsA dosing protocol has proven safe
for clinical use in severe TBI and was suggestive of improved outcomes [234]. However,
previous to our study, the effects of continuous infusion of CsA following experimental
TBI had not been assessed using outcome measures distinct from cortical tissue
sparing. Our results indicate (Table 3.3) that while CsA was able to significantly
decrease TBI-induced increases in aldehydic-modified mitochondrial proteins (Fig. 3.4),
it was unable to prevent mitochondrial respiratory dysfunction (Fig 3.2 and 3.3) or
cytoskeletal α-spectrin degradation (Fig. 3.5).
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Table 3.3 Summary of Result: Subcutaneous Continuous Infusion Dosing
Paradigm
Vehicle

PZ

CsA

PZ + CsA

↓*

↔^

↓*

↓*

↓*

↓*

↓*

↓*

Mitochondrial 4-HNE

↑*

↓

↓

↑*

Mitochondrial Acrolein

↑*

↔^

↔^

↑*

Spectrin Degradation

↑*

↔^

↑*

↔^

Mitochondrial RCR
Mitochondrial Individual
Respiratory States

#

#

Effect of the 15 min post-injury loading dose + 72h subcutaneous continuous infusion
dosing paradigm on the above listed outcome measures 72h following severe cortical
impact injury. Vehicle (15 min post-injury bolus dose: intraperitoneal
cremophor/ethanol/saline’ 15 min post-injury bolus dose: subcutaneous saline;
subcutaneous osmotic pump: cremophor/ethanol/saline; subcutaneous osmotic pump:
saline). PZ (15 min post-injury bolus dose: intraperitoneal cremophor/ethanol/saline; 15
min post-injury bolus dose: subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic
pump: cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in
saline). CsA (15 min post-injury bolus dose: intraperitoneal 20mg/kg CsA in
cremophor/ethanol/saline; 15 min post-injury bolus dose: subcutaneous saline;
subcutaneous osmotic pump: 10mg/kg/day/3d CsA in cremophor/ethanol/saline;
subcutaneous osmotic pump: saline). PZ + CsA (15 min post-injury bolus dose:
intraperitoneal 20mg/kg CsA in cremophor/ethanol/saline; 15 min post-injury bolus dose:
subcutaneous 10mg/kg PZ in saline; subcutaneous osmotic pump: 10mg/kg/day/3d CsA
in cremophor/ethanol/saline; subcutaneous osmotic pump: 10mg/kg/day/3d PZ in
saline). PZ, phenelzine; CsA, cyclosporine A; RCR, respiratory control ratio (state
III/state IV); 4-HNE, 4-hydroxynonenal; ↓* = significantly decreased from sham, ↑* =
significantly increased from sham, ↓# = significantly decreased from vehicle, ↔^ = not
significantly different from sham.
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The fact that continuous infusion of CsA is able to decrease TBI-induced
increases in mitochondrial bound 4-HNE and acrolein, is consistent with the fact that
inhibition of the permeability transition pore in brain mitochondria is able to prevent
calcium-induced increases in ROS [60], which would in turn decrease the ROS/RNSlipid peroxidation-aldehyde cascade. However, this does not seem to be enough to
maintain mitochondrial respiratory function or prevent downstream calpain-mediated
cytoskeletal degradation, at least at the 72h post-injury time point examined (Fig. 3.7). It
may be that CsA inhibition of the mPTP and sequestration of calcium has decreased
mitochondrial membrane potential and led to a decrease in respiration. Additionally,
there are known limitations to the ability of CsA to prevent permeability transition,
particularly when mitochondria are in an extremely depolarized state [318], which is
likely the case 72h following severe injury, the peak of mitochondrial dysfunction [73].
Similarly, there are types of mitochondrial permeability transition demonstrated to be
insensitive to CsA [317, 319]. In fact, thiol-crosslinking agents have been implicated in
induction of CsA-insensitive permeability through interaction with adenine nucleotide
translocase (ANT), an additional component of the mPTP [320], a significant finding in
light of the fact that LP-derived aldehydes are known to bind cysteine residues [1, 7981]. In fact, acrolein has been specifically shown capable of ANT inhibition [101].
On the other hand, it is possible that continuous infusion of CsA did have a
protective effect on mitochondrial respiration that was masked in our total mitochondrial
preparations (synaptic and non-synaptic) due to the fact that CsA has a greater
neuroprotective effect on synaptic mitochondria than non-synaptic mitochondria
following CCI (Fig. 2.1-2.6) [309], but at 72h post-injury, synaptic mitochondria make up
a minority of the mitochondrial population [121, 128, 321, 322]. However, we consider
this explanation unlikely when taken in conjunction with the fact that continuous infusion
of CsA was also unable to prevent cytoskeletal α-spectrin degradation (Fig. 3.5).
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Figure 3.7 Schematic illustration of CsA monotherapy results. CsA decreases
formation of mitochondrial bound 4-HNE and acrolein without attenuating respiratory
dysfunction or cytoskeletal spectrin degradation. CsA inhibits mitochondrial permeability
transition (mPTP) leading to attenuation of the mitochondrial dysfunction-ROS/RNS-lipid
peroxidation-4-HNE/acrolein cascade (red arrows). Which leads to significant decreases
in formation of 4-HNE/acrolein bound mitochondrial conjugates (green arrow). However,
inhibition of mPTP and attenuation of 4-HNE and acrolein are not enough to improve
overall respiratory dysfunction and downstream effects of mitochondrial calcium release,
such as cytoskeletal spectrin degradation (red X’s).
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An additional caveat to consider is the fact that the CsA dosing paradigm utilized
in this study was originally optimized using cortical tissue sparing [122, 227]. It is known
that CsA preservation of cortical tissue following experimental TBI has a U-shaped doseresponse curve [227]. It is possible that that the dose-response for CsA in relation to
cortical tissue sparing is not identical to the dose-response for CsA in relation to
mitochondrial respiratory protection. This speculation is plausible in light of the fact that
CsA has multiple mechanisms of action. For example, although it has been wellestablished that CsA is able to improve mitochondrial function at early time points and
ex-vivo through inhibition of mPTP [226, 313, 323], the neuroprotective effects of
continuous CsA infusion on cortical tissue sparing at later time points may also be due to
its immunosuppressive properties. For example, although FK506 (i.e. tacrolimus), a
calcineurin-inhibiting immunosuppressant unable to inhibit mPTP, has been shown
unable to attenuate cortical lesion volume following experimental TBI [124], several
studies have demonstrated FK506 to be neuroprotective across several other injury
paradigms [228-233], and calcineurin signaling is known to have an important role
following brain injury [229, 324].
The fact that CsA is known to have a U-shaped dose response curve [227],
combined with its multiple mechanisms of action [316, 317], may explain some of the
disparities seen between CsA TBI studies, because although there have been a
preponderance of studies supporting CsA’s neuroprotective capabilities, this is not the
first study to demonstrate that CsA is not neuroprotective across all outcome measures
[241].
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Phenelzine Scavenging of Lipid Peroxidation-Derived Aldehydes 4-HNE and
Acrolein
Several approaches have been utilized to attenuate the lipid peroxidation
cascade following neurotraumatic injury ranging from the use of antioxidants to the use
of iron chelators [1, 55, 109, 325]. However, many of these approaches are limited by a
variety of factors including, limited therapeutic window, blood-brain barrier penetrability
and elimination rate [1, 55]. Fortunately, scavenging of LP-derived aldehydes, such as 4HNE and acrolein (the stable final breakdown products of lipid peroxidation) represents a
practical therapeutic approach [1, 79].
Phenelzine, a monoamine oxidase inhibitor clinically used for intractable
depression contains a hydrazine moiety (-NH-NH2) making it capable of covalently
binding both free LP-derived neurotoxic aldehydes, such as 4-HNE and acrolein, as well
as binding aldehyde-protein conjugates, including mitochondrial protein conjugates,
preventing further cross-linking [79, 198, 258, 260-262].
Both in-vitro and in-vivo studies have shown hydrazine-containing compounds
including PZ, to be neuroprotective in models of brain and spinal cord injury, decreasing
generation of LP-derived aldehydes, improving mitochondrial bioenergetics, attenuating
tissue damage, and improving behavioral outcomes [71, 72, 74-76, 257]. Importantly, exvivo studies have confirmed that the ability of PZ to protect mitochondria against
exogenously administered 4-HNE or acrolein is due to the presence of the hydrazine
moiety [72].
The continuous PZ dosing paradigm utilized here, 10 mg/kg PZ delivered
subcutaneously 15 min post-injury combined with subcutaneous continuous infusion of
10 mg/kg/day/3 days PZ, was based on previous work showing that 12h intermittent

136

administration of PZ (10 mg/kg PZ delivered subcutaneously 15 min post-injury followed
by 5 mg/kg PZ maintenance dosing every 12 hours) was neuroprotective following
severe CCI [72], with the hypothesis being that continuous infusion of PZ should further
enhance neuroprotection over the 12h maintenance dosing paradigm.
Our results indicate (Table 3.3), that continuous infusion of PZ was able to
maintain RCR (Fig. 3.3), decrease TBI-induced increases in aldehydic-modified
mitochondrial proteins (Fig. 3.4), and maintain cytoskeletal α-spectrin integrity (Fig. 3.5),
although it was unable to prevent decreases in individual states of mitochondrial
respiration (Fig. 3.2). Encouragingly, this data parallels the results obtained in the 12h
intermittent PZ dosing paradigm studies, in which PZ also demonstrated maintenance of
RCR and decreases in 4-HNE and acrolein modification of mitochondrial proteins [72],
without being able to attenuate decreases in individual mitochondrial respiratory states
(unpublished data). However, one important improvement was seen with the continuous
infusion PZ dosing paradigm (Table 3.4) because whereas continuous infusion of PZ
was able to maintain cytoskeletal α-spectrin integrity (Fig. 3.5), 12h intermittent dosing of
PZ was not (Fig 3.6). Although both of these dosing paradigms were designed based on
an approximate 12h plasma half-life of PZ in humans, the fact that the continuous
infusion dosing paradigm represented an improvement over intermittent dosing is
unsurprising given recent findings that suggest the half-life of PZ in rats may be much
shorter than 12h [74].
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Table 3.4 α-Spectrin Degradation: Phenelzine Continuous Infusion Versus
Phenelzine Intermittent Dosing
PZCI

Spectrin Degradation

↔^

PZID

↑*

Comparison of the effect of the PZ continuous infusion dosing paradigm versus the PZ
intermittent dosing paradigm on α-spectrin degradation 72h following severe cortical
impact injury. PZCI = phenelzine continuous infusion (15 min post-injury bolus dose:
intraperitoneal cremophor/ethanol/saline’ 15 min post-injury bolus dose: subcutaneous
10mg/kg PZ in saline; subcutaneous osmotic pump: cremophor/ethanol/saline;
subcutaneous osmotic pump: 10mg/kg/day/3d PZ in saline). PZID = phenelzine
intermittent dosing (15 min post-injury subcutaneous bolus dose of 10mg/kg PZ in saline
followed by subcutaneous bolus dose of 5mg/kg PZ in saline every 12h up to and
*
including 60h). ↑ = significantly increased from sham, ↔^ = not significantly different
from sham. PZCI, phenelzine continuous infusion; PZID = phenelzine intermittent dosing.
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On that note, it is also important to state that the animals receiving continuous PZ
infusion were also receiving continuous cremophor infusion (CsA vehicle). Therefore, the
fact that the continuous infusion dosing paradigm for PZ was able to perform equally [72]
or better than (Table 3.3 and 3.4) the 12h intermittent PZ dosing paradigm indicates that
continuous infusion of the CsA vehicle, cremophor, which is purportedly toxic [245, 301]
is unlikely to be exerting detrimental effects under the current experimental conditions.
Multiple possibilities may explain the ability of continuous infusion of PZ to
decrease TBI-induced increases in mitochondrial bound 4-HNE and acrolein and
maintain RCR and cytoskeletal α-spectrin integrity without being able to improve
individual mitochondrial respiratory states. First, the ability of PZ to scavenge aldehydes
[79, 262] would have a direct effect on decreasing aldehyde binding of mitochondrial
proteins, as well as lead to attenuation of the mitochondrial dysfunction-ROS/RNS-lipid
peroxidation-aldehyde cascade (Fig. 3.1), further decreasing binding of 4-HNE and
acrolein to mitochondrial proteins. This decrease in mitochondrial bound 4-HNE and
acrolein would then prevent mitochondrial permeability transition [326], decreasing the
release of calcium back into the cytosol and attenuating calpain-dependent α-spectrin
degradation. Further, the decrease in 4-HNE and acrolein mitochondrial binding also
may result in a slight improvement in mitochondrial bioenergetics, resulting in
maintenance of RCR, a general measure of mitochondrial health, but one which does
not have a significant enough effect on mitochondrial bioenergetics to impact individual
states of respiration (Fig. 3.8).
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Figure 3.8 Schematic illustration of PZ monotherapy results. PZ attenuates
mitochondrial bound 4-HNE and acrolein, maintains respiratory control ratio (RCR) and
cytoskeletal spectrin integrity, without improving individual states of respiratory
dysfunction. PZ scavenges 4-HNE and acrolein directly, decreasing mitochondrial bound
4-HNE and acrolein (green arrow), leading to decreases in the 4-HNE/acroleinmitochondrial dysfunction-ROS/RNS-lipid peroxidation-4-HNE/acrolein cascade (blue
arrows), further decreasing mitochondrial bound 4-HNE and acrolein, and improving
respiratory control ratio (green arrows), effects which are able to improve downstream
effects of mitochondrial calcium release, such as cytoskeletal spectrin maintenance
(green arrow), but not enough to improve individual states of mitochondrial respiration
(red X). Bottom left figure demonstrates a single mitochondrion bound to phenelzine and
phenelzine-aldehyde conjugates. It is currently unknown what effect these bindings have
on mitochondrial dynamics and mitophagy.
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Second, it is possibly that we have again masked a significant mitochondrial
protective effect. As stated previously, PZ can bind mitochondrial aldehyde-protein
conjugates [79, 262]. Additionally, as an irreversible monoamine oxidase inhibitor [278],
PZ also associates with the outer mitochondrial membrane enzyme monoamine oxidase
[327]. Therefore, it is possible that each individual mitochondrion is bound to a significant
amount of PZ, and it is unknown what effect this has on post-injury mitochondrial
dynamics and mitophagy (Fig. 3.8). In fact, in general, the long-term consequences of
drug-aldehyde adduct formation are unknown [258].
It is possible that the binding of PZ to mitochondria which are beyond saving is
preventing these mitochondria from being degraded by normal post-injury processes
while also significantly improving the bioenergetics of less damaged mitochondria. The
unusual presence of these considerably damaged mitochondria in our isolated
mitochondria preps could mask improvements to individual states of mitochondrial
respiration. Such an explanation would be consistent with an overall mitochondrial
protective effect suggested by the α-spectrin data, as well as the improvement in tissue
sparing seen in our previous 12h intermittent PZ dosing studies [72], despite no
improvements to individual mitochondrial states of respiration (unpublished data).
Last, although in-vitro experiments which have compared PZ to the nonhydrazine, non-aldehyde scavenging monoamine oxidase inhibitor pargyline have
confirmed that phenelzine’s aldehyde scavenging properties are due to the presence of
the hydrazine moiety [72, 198], it is unknown what effect monoamine oxidase inhibition
has on the bioenergetics of injured mitochondria or in the broader context of TBI
pathophysiology.

The function of catecholamines and monoamine oxidase following

brain injury remains controversial, with some studies suggesting monoamine oxidase
inhibition and catecholamine agonists to be protective [154, 193, 278], with others
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suggesting them to be pathologic [328]. In fact, for PZ to remain a clinically translatable
pharmacotherapy, its role as a monoamine oxidase inhibitor in the context of brain injury
must be elucidated. As such, we have planned future experiments aimed at determining
the effect of monoamine oxidase inhibition following TBI.
Phenelzine + Cyclosporine A: A multi-mechanistic Combinatory Pharmacotherapy
Approach
As pointed out earlier, all monotherapy clinical trials for TBI have failed, and
although there have been numerous reasons cited for these failures, due to the
heterogeneity of injury and the complexity of the secondary injury cascade, there has
been a call for pre-clinical studies to focus on the development of combinational
therapies for the acute (first 72h) treatment of TBI [213]. Several strategies have been
proposed to aid in the selection of combinatorial agents, including but not limited to
therapies that affect multiple targets and therapies that target convergent pathways
[213]. This study was aimed at achieving both these goals by combining two drugs that
have separate targets, the mPTP inhibitor CsA and the LP-derived aldehyde scavenger
PZ both of which should also be capable of attenuating the convergent mitochondria
dysfunction-ROS/RNS-lipid peroxidation-aldehyde cascade (Fig. 3.1). In fact, CsA was
one of the drugs identified by the combinational therapy TBI working group as being a
promising combinational candidate [213].
Our results indicate (Table 3.3) that continuous infusion of PZ (10 mg/kg PZ
subcutaneous 15 min post-injury + 10 mg/kg/day subcutaneous infusion of PZ for 3
days) combined with continuous infusion of CsA (20 mg/kg CsA intraperitoneal 15 min
post-injury + 10 mg/kg/day subcutaneous infusion of CsA for 3 days) is unable to
improve mitochondrial bioenergetics (either RCR or individual respiratory states; (Fig.
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3.2 and 3.3) or attenuate 4-HNE or acrolein bound to mitochondrial proteins (Fig. 3.4).
Interestingly, it seems that the combining of PZ and CsA, negates the protective effects
that individual administration of PZ or CsA had on formation of 4-HNE and acrolein
bound mitochondrial proteins (Fig. 3.4). Although the combination of PZ and CsA was
able to maintain cytoskeletal α-spectrin integrity (Fig. 3.5), it did so to a degree similar to
PZ alone suggesting that this is most likely an effect mainly attributable to PZ.
While these combinatorial results are disappointing, they are not entirely
surprising given the fact that individually the continuous infusion CsA dosing paradigm
utilized, which had been previously optimized based on cortical tissue sparing [122,
227], did not have a protective effect on all of the neurochemical outcome measures
studied.
Moreover, this study combined two dosing paradigms that had been optimized
for each drug individually [72, 122]. In fact, this is not the first study to find that utilization
of doses optimized for monotherapy did not result in neuroprotection once combined
[280]. Indeed, the complex pharmacokinetics and pharmacodynamics that results from
the combining of multiple drugs has been identified as one of the most challenging
hurdles in the development of combinational therapies for the treatment of TBI [213].
Although utilization of an alternate dosing paradigm following dose-response studies of
the combined drugs together could lead to improved results, upon further consideration,
the complex pharmacokinetics of each individual drug may make the clinical translation
of the combination unfeasible.
For example, CsA is known to be metabolized by cyp3A4 [246], and although PZ
is not technically classified as a cyp3A4 inhibitor, there is data to suggest that PZ is
capable of inhibiting cyp3A4 [266, 267]. Further, CsA has a U-shaped dose response
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curve [294] and has limited blood-brain-barrier penetrability [236], which increases
following injury due to blood-brain-barrier disruption [329] and decreases in
mitochondrial production of ATP [23, 51] leading to failure of ATP-dependent pglycoprotein drug efflux pumps, of which CsA is a both a substrate and an inhibitor [236].
Taken together, these facts suggest that in a clinical setting maintaining appropriate CsA
CSF levels following TBI will be quite challenging even as a monotherapy, while
combining CsA with another drug, particularly a drug such as PZ which itself has a
complicated pharmacology as it is both a monoamine oxidase inhibitor and a
monoamine oxidase substrate which also has several active metabolites [330], would
further complicate the matter.
Along similar lines, although the choice of the combination PZ and CsA was
aimed at targeting distinct mechanisms which converge on overlapping pathways (Fig.
3.1), consistent with stated combinational TBI therapy design goals [213], both of these
drugs are capable of physically binding the mitochondria, CsA through binding of the
matrix protein cyclophilin D [218-220, 317], and PZ both through binding of 4-HNE and
acrolein bound mitochondrial conjugates [79, 258] and through irreversible binding of the
outer mitochondrial membrane protein monoamine oxidase [278, 327], which In
hindsight may have resulted in too many non-physiologic interactions for the
mitochondria to handle (Fig. 3.9).
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Figure 3.9 Schematic demonstrating a mitochondrion extensively bound to CsA
and PZ.
CsA binds to the mitochondrial matrix protein cyclophilin D. PZ binds to the outer
mitochondrial membrane protein monoamine oxidase. PZ-4-HNE and PZ-acrolein
conjugates bind mitochondrial proteins throughout the mitochondrial membranes.
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It is possible that assessment of additional outcome measures such as cortical
tissue sparing or behavior could have yielded improved results. Indeed, achieving
behavioral improvements is the utmost goal in TBI research. However, it must be noted
that although a recent summary of NIH-funded pre-clinical combinatorial TBI drug
studies reported improvements in non-behavioral outcomes, these positive effects were
not maintained in long-term behavioral studies [280]. Therefore, it is unlikely that
utilization of our current PZ + CsA combinational dosing paradigm would lead to
improvements in more difficult-to-achieve behavioral outcomes.
A better approach may have been to utilize drugs which are mechanistically
complementary but are spatially distinct, such as combining either PZ or CsA with a drug
such as tirilazad, whose primary effects are localized to the vasculature [1, 256]. In fact,
the combination of tirilazad and CsA has been one of the combinations proposed to
have beneficial effects [213].
Conclusion
In summary, we found that subcutaneous continuous infusion of PZ (10 mg/kg
PZ subcutaneous 15 min post-injury + 10 mg/kg/day subcutaneous infusion of PZ for 3
days) maintained mitochondrial RCR and neuronal cytoskeletal integrity, and decreased
binding of 4-HNE and acrolein to mitochondrial proteins 72h following severe controlled
cortical impact injury. In fact, continuous infusion of PZ was able to maintain cytoskeletal
integrity, whereas 12hr intermittent dosing of PZ was not (10 mg/kg PZ subcutaneous 15
min post-injury + 5 mg/kg PZ subcutaneous every 12h up to and including 60h).
Additionally, continuous infusion of CsA (20 mg/kg CsA intraperitoneal 15 min post-injury
+ 10 mg/kg/day subcutaneous infusion of CsA for 3 days) decreased binding of 4-HNE
and acrolein to mitochondrial proteins. Although the combination of PZ + CsA was able
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to maintain cytoskeletal integrity, it did so to a similar degree as PZ alone, suggestive of
a purely PZ effect, and was unable to attenuate other outcome measures. In fact, once
combined the protective effect PZ and CsA individually had on formation of
mitochondrial bound 4-HNE and acrolein was lost.
We concede that this study was limited to a single dosing paradigm and time
point and a limited number of outcome measures, making it difficult to conclude that the
combinational therapy PZ + CsA is unable to enhance neuroprotection under any
circumstances. However, upon contemplation of the complicated pharmacokinetics and
pharmacodynamics of each drug individually, coupled with the fact that both drugs can
physically interact with the mitochondria, in hindsight we believe the combination of CsA
and PZ may lack feasible clinical translation and that any further animal studies utilizing
the combination may prove unethical. Therefore, for the time being we feel that our
future directions are better spent further investigating the less well-characterized drug,
PZ, including long-term behavioral studies as well as the effect the non-aldehyde
scavenging PZ mechanism of action, monoamine oxidase inhibition, has on
mitochondrial function and neuroprotection following TBI. Importantly, we also believe
this study highlights some of the challenges in developing combinational therapies for
traumatic brain injury including,

optimization of

combined dosing paradigms,

consideration of altered pharmacokinetics and pharmacodynamics, choice of outcome
measure and time point, as well as variations in neuroprotective efficacy across distinct
outcome measures.
On that note, one reason the combination PZ + CsA was chosen for this study
was because both CsA and PZ are FDA-approved drugs, which would make their clinical
translation for TBI easier, faster, and cheaper than that of experimental agents.
However, combining drugs which are known to have multiple mechanisms of action, CsA
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is both a calcineurin inhibitor/immunosuppressant and an inhibitor of mPTP [219, 220,
316, 317], and PZ is both an aldehyde-scavenger and a monoamine oxidase inhibitor
[71, 72, 74, 76, 198, 278, 311], may lead to a number of confounding factors. Therefore,
although more difficult in regards to clinical translational, it may in fact represent a better
approach to limit combinational approaches to compounds with less complicated
mechanisms of action, such as the non-immunosuppressive mPTP inhibitor, NIM811, or
a pure aldehyde-scavenger, at least in the early proof–of-principle stages of
investigation.
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CHAPTER FOUR:
Comparative Effects of Phenelzine, Hydralazine, and Pargyline on Learning and
Memory and Cortical Tissue Sparing Following Experimental Traumatic Brain
Injury

Preface: Portions of Chapter Four to be submitted for publication as: Kulbe JR,
Dunkerson JA, Huettl PF, Wang JA, Smith R, Gerhardt GA, and Hall ED. Comparative
Effects of Phenelzine, Hydralazine, and Pargyline on Learning and Memory and Cortical
Tissue Sparing Following Experimental Traumatic Brain Injury.
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Introduction
Traumatic brain injury (TBI) represents a significant health crisis. Within the
United States, 2.8 million TBIs are diagnosed annually [2]. Although the most severe
injuries, those resulting in death or requiring hospitalization account for a minority of the
TBI diagnoses, they account for 90% of TBI-associated costs [10, 11]. The most severe
injuries also result in the highest rates of morbidity. In fact, over fifty percent of TBI
patients requiring hospitalization will continue to suffer from TBI-related cognitive,
physical or emotional disabilities more than a year following injury [13]. However, to
date, no FDA-approved neuroprotective pharmacotherapies exist for acute TBI [1].
Therefore, it is imperative that more robust pharmacological neuroprotective agents be
developed.
Lipid peroxidation (LP) is a well-documented pathology that occurs following TBI
[1, 17, 55] (Fig. 4.1). LP is initiated by reactive oxygen and nitrogen species (ROS/RNS),
which extract electrons from the polyunsaturated fatty acids located within neuronal and
organelle membranes, generating lipid and lipid peroxyl radicals [1, 55]. Although
dysfunctional mitochondria and the electron transport chain serve as a primary source
for generation of pathologic ROS/RNS [1, 17, 55], these reactive species are also
produced by other sources. Such sources include the metabolism of monoamines by
monoamine oxidase (MAO), autoxidation of biogenic amines, inflammatory cell oxidative
bursts, and the metabolism of arachidonic acid [1]. LP is a self-propagating process
which terminates upon formation of LP-derived neurotoxic aldehydes such as 4hydroxynonenal (4-HNE) and 2-propenal (i.e. acrolein) [1, 55]. These LP-derived
neurotoxic aldehydes covalently bind to proteins, inducing protein dysfunction, cell death
and neuronal degeneration [1, 17, 55, 77, 85, 88].
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Figure 4.1 Simplified schematic of traumatic brain injury (TBI) pathophysiology
and pargyline (PG), phenelzine (PZ) and hydralazine (HZ) mechanisms of action.
TBI induces generation of reactive oxygen and nitrogen species, leading to lipid
peroxidation of polyunsaturated fatty acids. Lipid peroxidation terminates upon formation
of neurotoxic aldehydes, such as 4-hydroxynonenal (4-HNE) and 2-propenal (acrolein).
4-HNE and acrolein covalently bind proteins, including mitochondrial proteins, causing
dysfunction, neurodegeneration, and neurologic impairment. PZ and HZ are capable of
scavenging 4-HNE and acrolein. Additionally, PZ, along with PG, can inhibit monoamine
oxidase (MAO), an outer mitochondrial membrane protein responsible for metabolizing
monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine.
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Importantly, LP-derived neurotoxic aldehydes and their protein-aldehyde
derivatives are longer lived than their free radical predecessors [77, 331]. Therefore,
scavenging of LP-derived neurotoxic aldehydes offers a practical therapeutic approach
[1, 79, 331, 332].
Fortunately, a drug-class exists that is capable of scavenging LP-derived
aldehydes. Compounds which contain a hydrazine moiety (-NH-NH2), including the FDAapproved drugs phenelzine (PZ) and hydralazine (HZ) [198], can scavenge LP-derived
neurotoxic aldehydes through formation of hydrazone derivatives [258, 261]. Clinically
PZ, a non-selective irreversible monoamine oxidase inhibitor (MAOI), is used in the
treatment of intractable depression and as an anxiolytic [169]. However, PZ has also
been shown to be neuroprotective in experimental TBI, especially in regard to
biochemical outcome measures such as attenuating TBI-induced mitochondrial
respiratory dysfunction [71, 72, 333, 334]. Similar to TBI, PZ and HZ, clinically used as
an anti-hypertensive, have been shown to be neuroprotective in models of spinal cord
injury (SCI) [74, 75]. Although the neuroprotection PZ and HZ provide is well-established
to rely on the presence of their aldehyde-scavenging hydrazine moieties (-NH-NH2) [72,
198, 258], it is currently unclear what effect the MAOI properties of PZ may have on TBI
pathophysiology.
MAO is an outer mitochondrial membrane enzyme responsible for the
metabolism of monoamine neurotransmitters such as norepinephrine (NE), serotonin (5HT), and dopamine (DA) [197]. Therefore, inhibition of MAO can lead to increases in
these neurotransmitters [197]. The effect MAO inhibition and increases in monoamine
neurotransmitters would have on TBI pathophysiology remains controversial. For
instance, oxidative deamination of monoamine neurotransmitters by MAO generates
ROS [193], suggesting that MAO inhibition could reduce ROS and provide an additional
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antioxidant neuroprotective mechanism. However, inhibition of MAO also leads to
increases in biogenic amines, such as DA, which is capable of directly inhibiting
mitochondrial respiration [194], and undergoing non-enzymatic autoxidation formation of
toxic H2O2 and quinones [194], suggesting that MAO inhibition could also lead to
increases in neurotoxicity and oxidative stress. Additionally, while some studies have
shown that acute administration of monoamine agonists can be neuroprotective
following TBI; [154] others have shown a correlation between high levels of
monoamines, such as NE, and poor outcome [181].
Several pre-clinical studies have indicated that PZ shows promise for use as a
neuroprotective agent in brain injury [71, 72, 76, 333, 334]. However, in order for PZ to
be further developed for use in clinical TBI, the effect its MAOI properties have on TBI
pathophysiology must first be explored. Therefore, the goal of this study was to further
investigate PZ’s MAOI effects following TBI by comparing PZ, an aldehyde-scavenger
and MAOI, to the non-MAOI aldehyde scavenge HZ, and the non-aldehyde-scavenger
MAOI pargyline (PG) (Fig. 4.2). This is not only the first study to evaluate the effects of
PG and HZ in experimental TBI, but also the first study to assess the behavioral effects
of PZ in experimental TBI. We evaluate the ability of PZ, HZ, and PG to improve learning
and memory and enhance cortical tissue sparing following a severe controlled cortical
impact injury (CCI) in 3-month old male Sprague-Dawley rats. Additionally, HPLC is
used to measure NE, 5-HT, DA, and their metabolites in uninjured cortical tissue in order
to determine the effect of the PZ, HZ, and PG dosing paradigms on MAO inhibition.
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Figure 4.2 Chemical structures of pargyline, phenelzine and hydralazine. Both
phenelzine and hydralazine are capable of scavenging aldehydes via a hydrazine (-NHNH2) moiety. Pargyline does not contain a hydrazine moiety (-NH-NH2) and is unable to
scavenge aldehydes. Pargyline and phenelzine are monoamine oxidase inhibitors
(MAOI), whereas hydralazine is not.
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Methods
Animals
Three-month-old male Sprague-Dawley rats (Harlan, Indianapolis, IN) were
housed in the Division of Laboratory Animal Resources of the University of Kentucky
Medical Center. All animal and husbandry were conducted in accordance with the
University of Kentucky Institutional Animal Care and Use Committee. Animals were
housed in a 12hr light and dark cycle and allowed food and water ad libitum. Animals
were housed in pairs of two in housing containing Enviro-dry enrichment. For behavioral
experiments, animals were weighed and handled on a daily basis through the day of
euthanasia beginning five days prior to surgery.
Experimental

Design:

High

Performance

Liquid

Chromatography

(HPLC)

Monoamine and Metabolite Analysis (Fig. 4.3)
In order to assess MAO inhibition of our dosing paradigm we used HPLC to
evaluate monoamine and metabolite tissue levels and turnover ratios in uninjured cortex.
Uninjured animals (n = 6 animals per group) were administered an intraperitoneal (i.p.)
dose of saline, PZ (Sigma, St. Louis, MO), HZ (Sigma, St. Louis, MO), or PG (Sigma, St.
Louis, MO) at time 0h, 24h, and 48h for a total of three injections. Sample size was
based upon the University of Kentucky Center for Microelectrode Technology (CenMeT)
standard of practice. PZ was administered at 15mg/kg in saline [74], HZ was
administered at 5mg/kg in saline [74], and PG was administered at 15mg/kg to parallel
in-vitro experiments in which equal concentrations of PZ and PG were utilized [72].
Animals were euthanized by CO2 and decapitation 72h following the first drug
administration (24h following third drug administration).
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Figure 4.3 Monoamine and metabolite HPLC experimental design. Uninjured rats
received intraperitoneal injections (Inj.) of vehicle (saline), pargyline (15mg/kg),
phenelzine (15mg/kg), or hydralazine (5mg/kg) at 0h, 24h, and 48h for a total of 3
injections, representative of the dosing paradigm utilized in CCI-MWM studies. Animals
were euthanized and tissue was collected for HPLC analysis 72h following the first
injection.
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A sterile biopsy punch (Integra Miltex, Plainsboro, NJ) was used to collect cortical
punches 3mm in diameter and 2mm in thickness from the parietal cortex in the same
anatomic location to which injured animals would have received a CCI injury. Tissue was
immediately placed on dry ice, weighed and stored at -80°C until time of analysis. Tissue
was sent to CenMeT for HPLC evaluation of norepinephrine (NE), dopamine (DA), 5hydroxytryptamine (5-HT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid
(HVA), and 5-hydroxyindoleacetic acid (5-HIAA).
High Performance Liquid Chromatography with Electrical Detection (HPLC-EC) for
Monoamine and Metabolite Tissue Levels
Cortical tissue samples (5mg – 25mg) for HPLC-EC were thawed and
immediately processed by CenMeT as previously described [187]. A total of 50μl of
filtrate (in mobile phase) was injected onto an HPLC column. Retention times for NE, 5HT, 5-HIAA, DA, DOPAC, and HVA standards and dihydroxybenzylamine (DHBA),
which was used as an internal standard, were used to identity peaks and to determine
tissue levels of each neurotransmitter or metabolite found in each brain sample
represented as ng/g wet weight of tissue sample [187].
Controlled Cortical Impact Traumatic Brain Injury (CCI)
Animals were anesthetized using 4% isoflurane, shaved, and placed into a
stereotaxic frame (David Kopf, Tujunga, CA), where isoflurane was maintained at 3% for
the duration of the procedure. Following ethanol and betadine sterilization, a midline
incision was made to expose the skull, and a 6mm craniotomy was created lateral to the
sagittal suture and midway between lambda and bregma using a Michele Trephine
(Miltex, Bethpage, NY). The exposed brain with intact dura received a severe CCI using
a computer controlled pneumatic impact device (TBI 03010; Precision Systems and
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Instrumentation, Fairfax Station, VA) fitted with a 5mm beveled tip and set to impact at a
depth of 2.0mm with a 500ms dwell time and an impact velocity of ~3.5m/s, as described
previously [71]. After injury, Surgicel (Johnson & Johnson, Arlington, TX) was placed
onto the dura and an 8mm plastic disk was affixed to the skull using tissue adhesive
(Gesswein, Bridgeport, CT) to close the craniotomy site and the incision was closed
using wound clips. Sham animals (n=13) underwent the same procedure, but did not
receive an impact injury and did not receive drug administration. Our previously
published PZ experiments which reported the results of biochemical measurements
utilized sample sizes = 8 [71, 72, 333]. Therefore, to account for a potential increase in
variability the sample size was increased by a factor of 1.5 for the behavioral
experiments detailed here. A single experimenter completed all surgeries.
CCI Dosing Paradigm (Fig. 4.4)
Animals exposed to CCI were randomly assigned to vehicle (n=13), PZ (n=13),
HZ (n=13), or PG (n=13). As 48h-72h represents the peak of LP-derived aldehyde
formation [73], it follows that drug should be administered throughout this acute time
period [72, 333]. Therefore, drug or vehicle was administered 15min, 24h, and 48h postinjury (three injections per animal). PZ was administered at 15mg/kg in saline. HZ was
administered at 5mg/kg in saline. As this is the first study to directly compare PZ and HZ
in experimental TBI, the dosing paradigms chosen were based on previously optimized
doses in which PZ and HZ were compared in SCI [74], and are slightly higher than our
previously published PZ dosing paradigms (10mg/kg/day subcutaneous)[72, 333].
Similar to PZ, PG was administered 15mg/kg in saline, to parallel ex-vivo mitochondrial
studies in which equivalent concentrations of PZ and PG were used [72]. The vehicle
group received an equal amount of saline as was administered to drug groups. Drug and
vehicle were prepared and coded by a separate experimenter.
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Figure 4.4 Controlled cortical impact and Morris water maze experimental design.
Beginning on D0 rats were subjected to a severe controlled cortical impact injury (CCI).
15min following injury animals received intraperitoneal injections (Inj.) of vehicle (saline),
pargyline (15mg/kg), phenelzine (15mg/kg), or hydralazine (5mg/kg). Sham animals
underwent surgical procedures but did not receive an impact or injections. Doses were
repeated 24h (D1) and 48h (D2) following injury. On D3-D6 animals underwent Morris
water maze (MWM) acquisition, which was followed by a probe trial for reference
memory on post-CCI D7. Animals were euthanized, perfused, and whole brains were
collected on post-CCI D8.
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Morris Water Maze (Fig. 4.4)
Animals began Morris water maze (MWM) testing 72h following injury and 24h
following the final drug administration. Animals began MWM testing at this early time
point in order to parallel our previous in-vivo PZ studies which evaluated mitochondrial
bioenergetics, aldehyde-protein modification, and cytoskeletal degradation 72h following
injury [72, 333], the peak of mitochondrial dysfunction, lipid peroxidation, and αII-spectrin
degradation [73]. The day prior to the start of MWM testing a circular pool (127 cm
diameter x 56 cm height) was filled and water was allowed to acclimate to room
temperature overnight. A submerged escape platform (13.5 cm diameter) was placed in
the center of one quadrant approximately 2cm below the water’s surface. Visual cues
were placed on curtains surrounding the pool. The pool was filled with black non-toxic
paint to ensure opacity. All trials were recorded and analyzed with Noldus Ethovision XT
version 12.0 (Cincinnati, OH). MWM acquisition trials were conducted daily from postCCI D3 through D6 to assess working memory. On post-CCI D3 through D6, animals
were given four trials (N, S, E, and W quadrant start) per day. At the beginning of each
trial animals were placed into the pool facing the wall. The direction the first trial began
from was varied each day. For each trial, animals were allowed 60 seconds to find the
platform. Animals that did not find the platform were guided to the platform and manually
placed there. Once on the platform, animals were allowed to remain for 20 seconds. A
trial was considered successful when an animal reached the platform within 60 seconds
and remained there for at least five seconds, which triggered the software to end the
trial. Animals were allowed to rest 5min between trials. Software data was confirmed
against manual time recordings.

To assess reference memory, a probe trial was

conducted on post-CCI D7 in which the platform was removed and the animals were
given 30 seconds to search the pool for the platform. To prevent hypothermia, all
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animals were dried between trials and placed into dry cages sitting on heating pads near
a ceramic heat source. At the beginning of the trials, all wound sites were inspected for
signs of infection. No signs of infection were seen, but to insure asepsis, betadine was
applied to the wound site at the conclusion of the day’s trials. Experimenters responsible
for behavioral experiments were kept consistent throughout each day and block of
testing.
Tissue Processing for Histology (Fig. 4.4)
On post-CCI D8 (one day following completion of MWM testing) animals were
euthanized with an overdose of sodium pentobarbital (150mg/kg). Animals were
transcardially perfused with phosphate buffer solution (PBS) followed by 4%
paraformaldehyde (PFA) in PBS. Following perfusion, brains were extracted and placed
into 4% PFA at 4°C for 48h-72h. Brains were then transferred to a 30% sucrose solution
in PBS at 4°C and allowed to sink before being flash frozen in isopentane and stored at 80°C until further processing. Coronal slices 40μm thick were cut on a freezing
microtome using a blade angle of 7.5° to the tissue surface. Sections were taken
between the septal area and the posterior hippocampus. Every tenth section was
collected per series. Sections were store at -20°C in cryoprotectant (30% ethylene
glycol, 30% glycerol, Tris-buffered saline (TBS)).
Sections were mounted onto Superfrost Excell microscope slides (ThermoFisher
Scientific, Waltham, MA) in TBS and dried. Mounted tissue was soaked in a CHCL3
(100mL) + EtOH (400ml 95% EtOH) solution for 30min. Slides were then soaked in
decreasing concentrations of EtOH (95%, 70%) for 3min each.. Slides were then soaked
for 6-8min in a cresyl violet solution (5.64ml 1M acetic acid, 0.816g sodium acetate,
500ml ddH2O, 0.2g cresyl violet powder). Slides were then dipped 8x each in the
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following solutions: ddH2O, 50% EtOH, and 70% EtOH, 95% EtOH + acetic acid,
followed by 2min in 95% EtOH, 100% EtOH, and Xylene. Slides were then cover slipped
using permount.
Slides were imaged using Axio Scan.Z1 (Zeiss, Thornwood, NY) at 20x
magnification and analyzed using HALO version 2.0 (Indica Labs, Corrales, NM).
Cortical area was measured from the dorsal aspect of lamina I to the dorsal aspect of
the corpus callosum, from the midline to the rhinal sulcus landmark laterally, from
interaural level 8.20mm – 3.40mm (12 slices, 400μM apart). For the total percent cortical
tissue sparing the area for each coronal section was multiplied by the distance between
coronal sections (400μM) and then summed and the ipsilateral total was divided by the
contralateral total to give total percent cortical tissue spared [∑(area x distance) ipsilateral] /
[∑(area x distance)contralateral] x 100% [71, 72]. Sample size (n = 8-9) was based upon
previously published histological data indicating that multiple PZ doses can improve
cortical tissue sparing at 72h, an early point in tissue degeneration [72], and that single
dose PZ can improve cortical tissue sparing at 14d [71]. For histologic analysis, animals
were excluded if tissue showed evidence of damage sustained during tissue processing
Statistical Analysis
Statistical analysis was conducted using Prism version 7.0 (Graph Pad, San
Diego. CA). All data are reported as mean ± standard deviation or median ± interquartile
range as indicated. A p value <0.05 was considered significant. HPLC data were
analyzed using a one-way ANOVA, followed by post-hoc Tukey’s. In cases in which
homogeneity of variance was violated (Brown-Forsythe, p < 0.05), data was analyzed
using Kruskal-Wallis, followed by post-hoc Dunn’s. Due to low levels of dopaminergic
metabolites in the cortex, some samples showed non-detectable levels of homovanillic

162

acid (HVA) and were thus excluded as indicated in the results section. Additionally, for
HPLC data Grubb’s test (α = 0.05) was used to remove statistical outliers as indicated in
the results section. During the MWM acquisition trials (post-CCI D3 – D6) the four trials
per day were averaged for each animal and statistical analysis of latency, distance, and
swim speed was conducted using two-way repeated measures ANOVA, followed by
post-hoc Tukey’s. Probe trial, weight, and total cortical tissue sparing were analyzed
using a one-way ANOVA, followed by post-hoc Tukey’s. To determine if there was a
difference in % cortical tissue sparing (ipsilateral/contralateral) between groups at the
level of individual coronal sections (i.e. intraaural level) a two-way repeated measures
ANOVA was utilized to analyze the CCI groups (vehicle, PG, PZ, and HZ).
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Results
PG, PZ, or HZ: HPLC Monoamine and Metabolite Tissue Levels and Turnover
Ratios in Uninjured Cortical Tissue (Fig. 4.5 – 4.7)
PG and PZ are classified as monoamine oxidase inhibitors, whereas HZ is not.
Saline, PG (15mg/kg), PZ (15mg/kg), or HZ (5mg/kg) were administered intraperitoneally
at 0h, 24h, and 48h for a total of three doses and tissue was collected at 72h to parallel
CCI-MWM experiments. However, uninjured animals were used in this set of
experiments to determine the basal level of MAO inhibition induced by the dosing
paradigms. The monoamine neurotransmitters NE, 5-HT, and DA, which are
metabolized by MAO into metabolites, were measured along with the 5-HT metabolite 5HIAA, and the DA metabolites DOPAC and HVA. Monoamine turnover ratios
(metabolite/monoamine) are used as a proxy measure of MAO inhibition. Although the
metabolism of NE also involves MAO-A, as well as a variety of other enzymes, and
results in the formation of metabolites such as VMA and MHPG, NE metabolites were
not measured as part of this study due to their low cortical tissue levels. 5-HT is
metabolized to 5-hydroxyindoleacetic acid (5-HIAA) by MOA-A and ALDH [186], and is
measured as part of this dissertation.
For NE, a single saline sample was identified as an outlier (Grubb’s) and
excluded (G = 1.915, Y = 6). For NE, a one-way ANOVA revealed a statistically
significant effect across all groups (F[3,19] = 10.84, p = 0.0002). Post-hoc testing
(Tukey’s) revealed that compared to saline, NE (ng/g) was significantly increased in PZ
(p<0.001), and that compared to HZ, NE (ng/g) was significantly increased in PZ
(p<0.001)(Fig. 4.5). Thus, PZ results in an increase in NE.
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Figure 4.5 Tissue Level (ng/g) of norepinephrine (NE) in 72h uninjured cortex. NE
measured via HPLC 72h following an initial intraperitoneal injection (0h) of saline,
pargyline (PG), phenelzine (PZ), or hydralazine (HZ), with additional doses given at 24h
and 48h. Values = mean ± standard deviation; one-way analysis of variance followed by
Tukey post hoc; ***p < 0.001, compared to saline, ###p < 0.001 compared to HZ; n = 5-6
per group.
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Figure 4.6 Tissue Level (ng/g) of serotonin (5-HT) and metabolites in 72h uninjured
cortex. (A) 5-HT, (B) the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA), (C) and
the 5-HT turnover ratio (5-HIAA/5-HT) in uninjured cortex as measured via HPLC 72h
following an initial intraperitoneal injection (0h) of saline, pargyline (PG), phenelzine
(PZ), or hydralazine (HZ), with additional doses given at 24h and 48h. Values = (A)
median ± interquartile range, Kruskal- Wallis followed by Dunn post-hoc (B,C) mean ±
standard deviation, one-way analysis of variance followed by Tukey post hoc; *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 compared to saline; ###p < 0.001, ####p < 0.0001
compared to HZ; n = 5-6 per group.
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Figure 4.7 Tissue Level (ng/g) of dopamine (DA) and metabolites in 72h uninjured
cortex. (A) DA, (B) the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), (C) the
DA metabolite homovanilic acid (HVA), and the DA turnover ratios (D) (DOPAC + HVA) /
DA, (E) DOPAC / DA, (F) and HVA / DA in uninjured cortex as measured via HPLC 72h
following an initial intraperitoneal injection (0h) of saline, pargyline (PG), phenelzine
(PZ), or hydralazine (HZ), with additional doses given at 24h and 48h. Values = (B)
median ± interquartile range, Kruskal-Wallis followed by Dunn post-hoc (A,C-F) mean ±
standard deviation, one-way analysis of variance followed by Tukey post hoc; *p<0.05,
****p < 0.0001 compared to saline; ####p < 0.0001 compared to HZ; ^p < 0.05; n = 4-5
per group.
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For 5-HT, a one-way ANOVA revealed a statistically significant effect across all
groups (F[3,20] = 44.81, p < 0.0001). However, Brown-Forsythe revealed an inequality
of variance (p = 0.0075). Therefore, Kruskal-Wallis was used in lieu of a one-way
ANOVA. KW revealed a significant effect across all groups (H[3, n = 24] = 19.5, p =
0.0002). Post-hoc testing (Dunn’s) revealed that compared to saline, 5-HT (ng/g) was
significantly increased in PZ (p<0.01), and that compared to HZ, 5-HT (ng/g) was
significantly increased in PZ (p<0.001)(Fig. 4.6A). Thus, PZ results in an increase in 5HT.
For the 5-HIAA, a one-way ANOVA revealed a statistically significant effect
across all groups (F[3,20] = 23.64, p < 0.0001). Post-hoc testing (Tukey’s) revealed that
compared to saline, 5-HIAA (ng/g) was significantly decreased in PZ (p<0.0001) and PG
(p<0.001), and that compared to HZ, 5-HIAA (ng/g) was significantly decreased in PZ
(p<0.0001) and PG (p<0.001)(Fig. 4.6B). Thus, both PZ and PG result in a decrease in
5-HIAA, a 5-HT metabolite.
For the ratio 5-HIAA / 5-HT, a single HZ sample was identified as an outlier
(Grubb’s) and excluded (G = 2.2024, Y = 6). For the ratio 5-HIAA / 5-HT, a one-way
ANOVA revealed a statistically significant effect across all groups (F[3,19] = 54.29, p <
0.0001). Post-hoc testing (Tukey’s) revealed that compared to saline, the ratio 5-HIAA /
5-HT was significantly decreased in PZ (p<0.0001), PG (p<0.0001), and HZ (p<0.05)
and that compared to HZ, the ratio 5-HIAA / 5-HT was significantly decreased in PZ
(p<0.0001) and PG (p<0.001)(Fig. 4.6C). Thus, PZ, PG, and HZ result in a significant
decrease in 5-HT turnover to 5-HIAA (i.e. increase in MAO inhibition). However, PZ and
PG do so to a significantly greater degree than HZ.
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Prior to statistical analysis, due to undetectable HVA levels, one animal was
removed from each group (saline, PG, PZ, HZ) for all analysis of DA and DA
metabolites. Additionally, during HVA statistical analysis, a single PZ sample was
identified as an outlier (Grubb’s) and excluded (G = 2.2024, Y = 6). In order to maintain
consistency and be able to calculate DA metabolite/DA turnover ratios, this PZ animal
was further excluded from the entire DA data set.
For DA, a one-way ANOVA did not reveal a statistically significant effect across
all groups (F[3,15] = 0.06434, p = 0.9779 (Fig. 4.7A). Thus, PZ, PG, nor HZ affected DA
levels.
For DOPAC, a one-way ANOVA revealed a statistically significant effect across
all groups (F[3,15] = 32.07, p < 0.0001). However, Brown-Forsythe revealed an
inequality of variance (p = 0.0156). Therefore, Kruskal-Wallis was used in lieu of a oneway ANOVA. KW revealed a significant effect across all groups (H[3, n = 19] = 14.1, p =
0.0028). Post-hoc testing (Dunn’s) revealed that compared to saline, DOPAC (ng/g) was
significantly decreased in PZ (p<0.0001) and PG (p<0.0001)(Fig. 4.7B). Thus, both PZ
and PG result in a decrease in DOPAC, a DA metabolite.
For HVA, a one-way ANOVA revealed a statistically significant effect across all
groups (F[3,15] = 3.875, p = 0.0310. Post-hoc testing (Tukey’s) revealed a significant
difference between PZ and PG (p<0.05)(Fig. 4.7C). Thus, PZ results in a decrease in
HVA, a DA metabolite, but only when compared to PG.
For the ratio (HVA + DOPAC) / DA, a one-way ANOVA revealed a statistically
significant effect across all groups (F[3,15] = 56.69, p < 0.0001). Post-hoc testing
(Tukey’s) revealed that compared to saline, the ratio (HVA + DOPAC) / DA is
significantly decreased in PZ (p<0.0001) and PG (p<0.0001), and that compared to HZ,
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the ratio (HVA + DOPAC) / DA is significantly decreased in PZ (p<0.0001) and PG
(p<0.0001)(Fig. 4.7D). Thus, both PZ and PG result in a decrease in DA turnover to
HVA+DOPAC (i.e. increase in MAO inhibition).
For the ratio DOPAC / DA, a one-way ANOVA revealed a statistically significant
effect across all groups (F[3,15] = 63.42, p < 0.0001). Post-hoc testing (Tukey’s)
revealed that compared to saline, the ratio DOPAC / DA was significantly decreased in
PZ (p < 0.0001) and PG (p < 0.0001), and that compared to HZ, the ratio DOPAC / DA
was significantly decreased in PZ (p<0.0001) and PG (p<0.0001)(Fig. 4.7E). Thus, both
PZ and PG result in a decrease in DA turnover to DOPAC (i.e. increase in MAO
inhibition).
For the ratio HVA / DA, a one-way ANOVA did not reveal a statistically significant
effect across all groups (F[3,15] = 1.916, p = 0.1704)(Fig. 4.7F). Thus, PZ, PG, nor HZ
affected the turnover of DA to HVA.
Overall these results indicate that for the specific dosing paradigms utilized,
administration of PG or PZ, the two MAOIs, results in significant MAO inhibition as
evidenced by the decrease in both 5-HT (Fig. 4.6C) and DA (Fig. 4.7D-F) turnover.
Interestingly, HZ, which is not classified as an MAOI, also showed some possible MAOI
inhibition as HZ administration resulted in a significant decrease to 5-HT turnover (Fig.
4.6C). However, HZ did not have the same effect in regards to DA turnover (Fig. 4.7DF). Overall these results also indicate that for the specific dosing paradigms utilized,
administration of PZ led to a significant increase in the monoamine neurotransmitters NE
and 5-HT (Fig. 4.5 and 4.6A).
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Morris Water Maze Latency to Platform (MWM D1-D4, Post CCI D3-D6) (Fig. 4.8A)
For latency to platform, a two-way repeated measures ANOVA revealed a
statistically significant effect across time (F[3,180] = 31.26, p < 0.0001), and treatment
(F[4,60] = 12.22, p < 0.0001). However, the interaction between time x treatment was
not significant (F[12,180] = 1.681, p = 0.0743). Post-hoc testing (Tukey’s) revealed that
all groups other than PZ learned to find the platform significantly faster on subsequent
trial days. For the sham group, animals found the platform significantly faster on D2 (p <
0.01), D3 (p < 0.0001), and D4 (p < 0.0001) compared to D1. For the vehicle group,
animals found the platform significantly faster on D2 (p < 0.05), D3 (p < 0.01), and D4 (p
< 0.01) compared to D1. For the PG group, animals found the platform significantly
faster on D3 (p < 0.01) and D4 (p < 0.001) compared to D1. For the HZ group, animals
found the platform significantly faster on D2 (p < 0.01) and D3 (p < 0.0001) compared to
D1. However, HZ latency to platform was not significantly different on D4 compared to
D1 (p > 0.05). Further, on D4 of MWM, vehicle (p < .05), PG (p < 0.05), PZ (p < 0.0001),
and HZ (p < 0.0001) all took significantly longer to find the platform compared to sham
(not annotated on figure). Thus, during the first four days of MWM all groups showed a
decrease in the time it took to find the submerged platform. However, PZ was the only
group in which none of these decreases reached statistical significance, suggesting that
the PZ group had the most difficulty in learning to find the platform day to day during the
first four days of MWM. Similarly, across the first four days of MWM, post-hoc testing
(Tukey’s) revealed that the overall treatment effect showed a near significant difference
between vehicle and PZ (p = 0.0706), but not between vehicle and PG (p = 0.9191) or
vehicle and HZ (p = 0.6971) (not graphically shown).
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Figure 4.8 Morris water maze latency and distance to platform. Rats began the
Morris water maze (MWM D1) three days following controlled cortical impact injury
(CCI). Animals and were given 4x60s trials to find the submerged platform per day for a
total of four days (MWM D1 – D4). (A) All groups other than PZ were able to find the
platform significantly faster (seconds) on subsequent MWM days (D2, D3, D4) when
compared to within group MWM D1. (B) All groups other than PZ traveled a significantly
shorter distance (centimeters) to the platform on subsequent MWM days (D2, D3, D4)
when compared to within group MWM D1. Values = mean ± standard deviation;
repeated measures two-way analysis of variance followed by Tukey post hoc; *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 compared to within group MWM D1; Sham, Veh
= vehicle + CCI, PG = pargyline + CCI, PZ = phenelzine + CCI, HZ = hydralazine + CCI;
n = 13 per group.
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Morris Water Maze Distance to Platform (MWM D1-D4, Post CCI D3-D6) (Fig. 4.8B)
For distance to platform, a two-way repeated measures ANOVA revealed a
statistically significant effect across time (F[3,180) = 25.75, p < 0.0001), and treatment
(F[4,60] = 9.364, p < 0.0001). However, the interaction between time x treatment was
not significant (F[12,180] = 1.611, p = 0.0918). Post-hoc testing (Tukey’s) revealed that
all groups other than PZ traveled significantly shorter distances to find the platform on
subsequent trial days. For the sham group, animals traveled significantly less distance to
the platform on D2 (p < 0.01), D3 (p < 0.0001) and D4 (p < 0.0001) compared to D1. For
the vehicle group, animals traveled significantly less distance to the platform on D3 (p <
0.05) and D4 (p < 0.05) compared to D1. For the PG group, animals traveled
significantly less distance to the platform on D3 (p < 0.01) and D4 (p < 0.001) compared
to D1. For the HZ group, animals traveled significantly less distance to the platform on
D2 (p < 0.05) and D3 (p < 0.001) but not D4 (p > 0.05) compared to D1. Further, on D4
of MWM, vehicle (p < .01), PG (p < 0.05), PZ (p < 0.0001), and HZ (p < 0.0001) all
traveled significantly greater distance to the platform compared to sham (not annotated
on figure). Thus, during the first four days of MWM all groups showed a decrease in the
distance traveled to the submerged platform. However, PZ was the only group in which
none of these decreases reached statistical significance, suggesting that the PZ group
had the most difficulty in learning to find the platform day to day during the first four days
of MWM. In regards to overall treatment effect, post-hoc testing (Tukey’s) revealed that
across the first four days of MWM, there is not a significant difference between vehicle
and PZ (p = 0.3412), vehicle and PG (p = 0.8911) or vehicle and HZ (p = 0.7387) (not
graphically shown).
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Morris Water Maze Swim Speed (MWM D1-D4, Post CCI D3-D6) (Fig. 4.9)
For swim speed (i.e. velocity), a two-way repeated measures ANOVA revealed a
statistically significant effect across time (F[3,180) = 12.52, p < 0.0001), and treatment
(F[4,60] = 3.889, p = 0.007). However, the interaction between time x treatment was not
significant (F[12,180] = 1.634, p = 0.0858). Post-hoc testing (Tukey’s) revealed that for
the treatment main effect, PG (p < 0.05), PZ (p < 0.05) and HZ (p < 0.05), but not vehicle
(p > 0.05) had a significantly increased swim speed compared to sham. Thus, during the
first four days of MWM, the PZ, PG, and HZ groups had faster mean swim speeds than
sham.
Morris Water Maze Reference Memory (Fig. 4.10)
Following removal of the platform (MWM D5, post-CCI D7), a one-way ANOVA
revealed a statistically significant effect across all groups (F[4,60] = 8.22, p < 0.0001).
Post-hoc testing (Tukey’s) revealed that the number of platform crossings was
significantly decreased for vehicle (p < 0.01), PG (p < 0.01), PZ (p < 0.0001), and HZ (p
< 0.001) compared to sham. Thus, PG, PZ, nor HZ significantly improved CCI-induced
decreases in platform crossings, indicating the drugs were unable to improve CCIinduced deficits to reference memory.
Percentage Weight Loss Following CCI-MWM (Fig. 4.11)
For percentage weight loss between D0 (surgery day) and post-injury D7 (last
MWM day), a one-way ANOVA revealed a statistically significant effect across all groups
(F[4,60] = 6.646, p = 0.0002). Post-hoc testing (Tukey’s) revealed that the PZ group lost
a significant amount of weight compared to sham (p < 0.001), vehicle (p < 0.05), PG (p <
0.05), and HZ (p < 0.001). Thus, PZ animals lost a significant amount of weight
compared to all other groups.
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Figure 4.9 Overall Morris water maze swim speed. The mean swim speed (velocity,
cm/sec) across the first four MWM days was significantly different between groups
following controlled cortical impact injury (CCI). The swim speed of the PG, PZ, and HZ
groups was significantly increased compared to sham. Values = mean ± standard
deviation; repeated measures two-way analysis of variance followed by Tukey post hoc;
*p < 0.05 compared to sham; Sham, Veh = vehicle + CCI, PG = pargyline + CCI, PZ =
phenelzine + CCI, HZ = hydralazine + CCI; n = 13 per group.
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Figure 4.10 Morris water maze reference memory. On MWM D5 (post-CCI D7) the
platform was removed and the number of platform crossing was counted within the 30s
timeframe. Following controlled cortical impact injury (CCI), Veh, PG, PZ, and HZ
performed significantly worse than sham. Values = mean ± standard deviation; one-way
analysis of variance followed by Tukey post hoc; **p < 0.01, ***p < 0.001, ****p < 0.0001
compared to sham; Sham, Veh = vehicle + CCI, PG = pargyline + CCI, PZ = phenelzine
+ CCI, HZ = hydralazine + CCI; n = 13 per group.
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Figure 4.11 Percent weight loss between D0 (CCI) and D7 (MWM probe trial). All
groups lost significantly less weight compared to PZ. Values = mean ± standard
deviation; one-way analysis of variance followed by Tukey post hoc; *p < 0.05, ***p <
0.001 compared to PZ; Sham, Veh = vehicle + CCI, PG = pargyline + CCI, PZ =
phenelzine + CCI, HZ = hydralazine + CCI; n = 13 per group.
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Total Percentage Cortical Tissue Sparing (Fig. 4.12 and 4.13)
For total cortical tissue sparing (ipsilateral / contralateral), a one-way ANOVA
revealed a statistically significant effect across all groups (F(4,37) = 21.07, p<0.0001).
Post-hoc testing (Tukey’s) revealed a significant decrease in cortical tissue sparing
compared to sham for vehicle (p < 0.0001), PG (p < 0.0001), PZ (p < 0.0001), and HZ (p
< 0.0001). The mean (± s.d.) cortical tissue sparing (ipsilateral / contralateral) for each
group is as follows: sham = 97.1% ± 4.9%, vehicle = 70.0% ± 6.1%, PG = 74.0 % ±
6.3%, PZ = 72.4% ± 6.4%, HZ = 76.9% ± 8.9%. Based upon mean values each drug
increased cortical tissue sparing compared to vehicle as follows (% treatment / %
vehicle): PG = 5.7%, PZ = 3.3%, and HZ = 9.8% (Table 4.1). Thus, PG, PZ, nor HZ was
able to significantly improve CCI-induced decreases in cortical tissue sparing. However,
HZ performed the best with a near 10% improvement compared to vehicle.
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Figure 4.12 Total percent cortical tissue sparing (ipsilateral/contralateral) D8 postCCI. For each individual animal the total percent cortical tissue sparing was calculated
as the sum of ipsilateral cortical tissue spared across 12 coronal sections / sum of
contralateral cortical tissue across 12 coronal sections. All groups show a significant
decrease in cortical tissue sparing compared to sham eight days following controlled
cortical impact injury (CCI). Values = mean ± standard deviation; one-way analysis of
variance followed by Tukey post hoc; ****p < 0.0001 compared to sham; Sham, Veh =
vehicle + CCI, PG = pargyline + CCI, PZ = phenelzine + CCI, HZ = hydralazine + CCI; n
= 8-9 per group.
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Figure 4.13 Representative cortical tissue sparing on post-CCI day 8. Selected
coronal sections (40uM) imaged at 20x and stained with cresyl violet for the groups
vehicle, pargyline, phenelzine, and hydralazine. Percent cortical tissue sparing was
calculated as ipsilateral / contralateral. The cortical area measure ranges from the dorsal
aspect of lamina I to the dorsal aspect of the corpus callosum and the midline to rhinal
sulcus, and is demonstrated by the black outline in the contralateral hemisphere of
vehicle.
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Table 4.1 Mean Percent Cortical Tissue Sparing for Vehicle, Pargyline, Phenelzine,
and Hydralazine on Post-CCI D8

Vehicle

Treatment

Treatment

% Improvement

% Tissue Spared

Drug

% Tissue Spared

from vehicle

70.0

Pargyline

74.0

5.7

70.0

Phenelzine

72.4

3.3

70.0

Hydralazine

76.9

9.8

The percent improvement from vehicle calculated based upon the following equation:
100% x [1- (% tissue spared treatment / % tissue spared vehicle)].
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Individual Coronal Section Percent Cortical Tissue Sparing (Fig. 4.14)
For the CCI groups (vehicle, pargyline, phenelzine, hydralazine) the percent
cortical tissue sparing (ipsilateral/contralateral) of each individual coronal sections (12
per animal) was compared. A two-way repeated measures ANOVA revealed a
statistically significant effect across coronal section number (interaural level) (F[11,330]
= 68.2, p < 0.0001), but not treatment (F[3,30]) = 1.386, p = 0.2661) or interaction
(section x treatment) (F[33,330] = 1.204, p = 0.2099). Therefore, within each group there
are significant differences in percent cortical tissue sparing between coronal section
numbers (i.e. interaural levels), but within each corresponding coronal section number
(i.e. interaural level) there are not significant differences between vehicle and drug
groups (p > 0.05), indicating lack of a neuroprotective drug effect which is consistent with
the total cortical tissue sparing results (Fig. 4.12).
Qualitative Behavioral Observations of PZ group
Based upon our previous experience with PZ [71, 72, 333, 334] as well extensive
literature findings [74, 76, 206-208, 335] we did not expect PZ administration at the
dosing paradigm chosen to result in adverse effects. Therefore, the current study was
not designed to include quantitative analysis of behaviors such as hyperactivity, anxiety,
stereotypy, etc.

Although not measured directly, qualitative observations of the PZ

group suggested an increase in locomotor activity (e.g. jumping off platform), stress (e.g.
porphyrin secretion from eyes and nose), and stereotypy (e.g. rearing, head bobbing,
etc. following PZ administration). In hindsight, inclusion of a more extensive battery of
behavioral tests could have led to more thorough interpretation of the results.
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Figure 4.14 Individual coronal section percent cortical tissue sparing post-CCI day
8. Mean % cortical tissue sparing (ipsilateral/contralateral) for each coronal section (12
per animal) by group. Coronal sections are 40μM thick, 400μM apart, and were collected
between approximately interaural level 8.20mm and 3.40mm Values = ± standard
deviation; (A) Overlay of all groups, (B) vehicle + CCI, (C) phenelzine + CCI, (D) sham,
(E) pargyline + CCI, (F) hydralazine + CCI. n = 8-9 per group. Repeated measure twoway analysis of variance revealed a non-significant (p > 0.05) treatment effect for CCI
groups.
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Discussion
Overall, these results indicate that for the dosing paradigms utilized PZ (aldehyde
scavenger, MAOI), PG (non-aldehyde scavenger, MAOI), and HZ (aldehyde scavenger,
non-MAOI) (Fig. 4.2) led to little improvement of the outcomes measured. None of the
drugs were able to improve CCI-induced deficits to reference memory (Fig. 4.10), or to
significantly improve cortical tissue sparing following injury (Fig. 4.12). However, HZ, the
non-MAOI aldehyde scavenger, improved cortical tissue the most, increasing the
amount of tissue spared compared to vehicle by nearly 10% (Table 4.1). Of concern,
PZ, lost a significant amount of weight compared to all other groups (Fig. 4.11), and was
the only group that did not show significant improvement in platform latency/distance
performance over the first four days of MWM (Fig. 4.8). It is possible that the PZ results
seen here are at least partially explained by an MAO inhibition effect as evidenced by
the significant elevation to NE and 5-HT seen in uninjured cortical tissue following
administration of the same PZ dosing paradigm utilized for CCI experiments (Fig. 4.5
and 4.6A). However, at the dosage utilized other PZ non-aldehyde scavenging
mechanisms of action or excessive aldehyde-scavenging could also be contributory
factors.
Lipid Peroxidation and TBI Secondary Injury
Although the current study does not include direct measurements of
mitochondrial function or LP-derived neurotoxic aldehyde formation (e.g. 4-HNE,
acrolein), both are central mediators of the TBI secondary injury cascade [1, 25, 51, 55,
332] and our previous work primarily focused on understanding the effects of PZ on
mitochondria [71, 72, 333, 334]. Therefore, the synergistic role mitochondria and LPderived neurotoxic aldehydes play in exacerbating TBI pathophysiology and initiating
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downstream consequences such as neurodegeneration and neurologic impairment is
detailed here for context. However, it should be noted that ROS and neurotoxic
aldehydes can be derived from a variety of non-mitochondrial sources such as the
metabolism of arachidonic acid by prostaglandin synthase or 5-lipoxygenase, or the
activities of several oxidases including xanthine, polyamine, and spermine [1, 336].
Following TBI increases in intracellular calcium are taken up by mitochondria in
an attempt to maintain homeostasis [25, 51]. However, one consequence of elevations
in intra-mitochondrial calcium is increased generation of ROS/RNS species [51], such as
superoxide (O2●-), nitric oxide (NO●), and peroxynitrite (PN) [17]. Highly reactive PNderived radicals are critical in initiating lipid peroxidation (LP). During LP, a hydrogen
atom and its electron are extracted from membranous polyunsaturated fatty acids
(PUFA) to form lipid (L●) and lipid peroxyl radicals (LOO●) [1, 55]. LP self-propagates
throughout adjacent PUFA, but is also catalyzed by factors such as the presence of iron
or low pH which occur following TBI [1, 55]. LP terminates upon a scission reaction
which produces carbonyl end products such as the neurotoxic aldehydes 4hydroxynonenal (4-HNE) and 2-propenal (acrolein) [1, 55].
These neurotoxic aldehydes have multiple reactive sites, making it possible for
them to covalently bind lysine, histidine, arginine and cysteine protein residues through
both Schiff base and Michael addition reactions [1, 79, 81]. As a major site of PN
formation, mitochondria are particularly susceptible to attack by LP-derived neurotoxic
aldehydes. Following TBI, binding of LP-derived neurotoxic aldehydes to mitochondrial
proteins further exacerbates TBI-induced impairment of mitochondrial bioenergetics and
the ROS/RNS-LP-aldehyde cascade, which combined with high levels of intramitochondrial calcium leads to opening of the mitochondrial permeability transition pore
(mPTP) [17, 51], causing cessation of ATP generation, release of cytochrome c and
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other apoptotic proteins [51], and extrusion of mitochondrial-sequestered calcium back
into the cytosol where it activates calcium-dependent proteases, such as calpain [51],
leading

to

degradation

of

cytoskeletal

proteins

(e.g.

αII-spectrin)

[106],

neurodegeneration, neuronal cell death, and neurologic impairment [1, 55, 116, 332].
Overall, several studies have confirmed that mitochondrial dysfunction and LP
peroxidation/formation of LP-derived aldehydes occur upstream of neurodegeneration
and neurologic impairment [55, 56, 73] and that targeting mitochondrial dysfunction or
lipid peroxidation can attenuate neurodegeneration and improve cognitive deficits [1, 25,
51, 55, 110, 122, 125, 303].
Aldehyde Scavengers and Neuroprotection
LP-derived aldehydes such as the α,β-unsaturated fatty acids, 4-HNE and
acrolein, are strong electrophiles [260], and therefore can be scavenged by strong
nucleophiles [260], including drugs that contain a hydrazine moiety (-NH-NH2). In fact,
hydrazine (-NH-NH2) compounds have been demonstrated to be some of the most
potent aldehyde scavengers available and are capable of scavenging both free
aldehydes and binding aldehyde-protein conjugates, the latter of which prevents the
formation of damaging cross-linking reactions [79, 258, 261].
Of the FDA-approved hydrazine (-NH-NH2) drugs, PZ and HZ have been the
most studied in the context of brain and spinal cord injury. In-vitro, PZ has been found to
improve mitochondrial function and decrease formation of mitochondria-aldehyde protein
conjugates following exogenous administration of the neurotoxic aldehydes 4-HNE and
acrolein [72]. Similarly, PZ attenuates retinal ganglion cell death following administration
of the neurotoxic aldehyde 3-aminopropanal (3-MP) [76], and protects both neurons and
glia from exogenous formaldehyde administration [311]. In experimental TBI, PZ has
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been shown to improve mitochondrial function, decrease aldehyde load, attenuate
cytoskeletal degradation, and improve cortical tissue sparing [71, 72, 333, 334].
Additionally, PZ improves survival of CA1 hippocampal neurons in ischemic-reperfusion
injury [76]. Further, PZ has also been demonstrated to be neuroprotective in models of
SCI, decreasing aldehyde load and pain hypersensitivity, attenuating motor dysfunction,
and improving tissue and neuronal survival [74, 337].
Likewise, although the neuroprotective effects of HZ have not previously been
evaluated in experimental TBI, in-vitro and in-vivo models of SCI and of exogenous
acrolein administration demonstrate that HZ decreases aldehyde-load, attenuates
mitochondrial dysfunction and free radical generation, restores antioxidant activity,
improves tissue sparing and axonal function, and attenuates pain hypersensitivity and
motor dysfunction [75, 88, 257, 270, 338].
Monoamines and Monoamine Oxidase (MAO)
The neurotransmitters measured in the current study (Fig. 4.5 – 4.7), DA, NE,
and 5-HT, are classified as monoamine neurotransmitters. DA and NE are
catecholamines, sequentially synthesized from the amino acid tyrosine, whereas the
non-catecholamine 5-HT is derived from tryptophan [151, 169].

The complexity,

nuances, and interplay of the DA, NE, and 5-HT monoaminergic systems are beyond the
scope of this study however; their general roles will be briefly reviewed here for context.
Dopamine
Within the nervous system DA is involved with a wide range of processes
including movement, motivation, reward, addiction, memory, stress and mood [154].
Although the majority of DA is found within the striatum, DA is found throughout the brain
[154]. For example, within the mesocorticolimbic system, DA neurons from the ventral
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tegmental area project directly to the hippocampus and prefrontal cortex [153, 170].
Further, although the nigrostriatal pathway, predominately involved in movement
regulation, consists of dopaminergic neurons projecting directly from the substantia nigra
to the striatum, it is part of complex circuitry that includes input and output to the motor
cortex, along tracts that pass through the thalamus [153]. As a catecholamine, in
addition to binding DA receptors, DA can bind adrenergic receptors [154]. Clinically, DA
can be used as a vasopressor to elevate cerebral perfusion pressure and mean arterial
blood pressure following severe TBI [154].
Norepinephrine
Within the brain NE neurons are concentrated in the locus coeruleus with
widespread connections to areas including the cortex, limbic system, and thalamus, and
it is involved in modulation of arousal, attention, mood, cognition and memory [150, 151].
As a catecholamine, NE, also known as the “flight or fight” neurotransmitter can bind
adrenergic receptors and induce sympathetic responses such as vasoconstriction [154,
171]. As such, similar to DA, NE can be used as vasopressor in clinical TBI [154].
Serotonin
Within the CNS, 5-HT neurons arise from the raphe nuclei and project
extensively throughout most of the brain including the cortex, limbic system, and
thalamus [151], modulating arousal, mood, cognition and memory [155]. Interestingly,
the majority of 5-HT is found outside the CNS, within the gastrointestinal tract [155].
Additionally, 5-HT plays a role in platelet activation, vasodilation, and vasoconstriction
[172].
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Monoamine Oxidase (MAO)
The enzyme monoamine oxidase (MAO) exists as two subtypes, MAO-A and
MAO-B, both of which are located in the outer mitochondrial membrane. MAO contains a
flavin group allowing it to participate in oxidative deamination reactions [186]. MAO is
responsible for the metabolism of the monoamine neurotransmitters NE, 5-HT, and DA,
measured within the current study, but additionally participates in the metabolism of
epinephrine (EPI), several amino acids, and phenethylamine (PEA), a trace amine under
physiologic conditions, but which is also an active metabolite of PZ [186, 189]. MAO-A
and MAO-B have differing substrate affinities. For example, MAO-A is selective for NE
and 5-HT, and the neurotransmitter EPI, whereas MAO-B is selective for PEA [186]. DA,
on the other hand, is metabolized by both MAO-A and MAO-B [186]. However, the
metabolism of DA by MAO differs between rodents and humans, with DA being
predominately metabolized by MAO-A in rats and MAO-B in humans [186]. In the brain,
monoamines are removed from the synaptic cleft by reuptake into pre-synaptic nerve
terminals and glial cells [151]. In fact, the majority of MAO in the brain is located within
the glial [190], with the MAO-B isoform predominating in glia as well as in serotonergic
neurons and platelets [190].
Several additional enzymes are involved in monoamine metabolism such as the
mitochondrial matrix protein aldehyde dehydrogenase (ALDH) and the cytosolic enzyme
catechol-O-methyl transferase (COMT) [186]. Of note to this study is the involvement of
COMT in the metabolism of DA to HVA which can take two paths. In one DA is first
metabolized by MAO to the intermediate DOPAC, and then DOPAC is metabolized by
COMT to HVA (DA → MAO → DOPAC → COMT → HVA). In the other DA is first
metabolized by COMT to the intermediate 3-methoxytyramine (3-MT), and then 3-MT is
metabolized by MAO to HVA (DA → COMT → 3-MT → MAO → HVA). These dual
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pathways likely explain why the MAO inhibitory effects of PZ and PG are more apparent
in regards to DOPAC tissue levels than HVA tissue levels (Fig. 4.7).
Choice of Experimental Design: Dosing Paradigms
As lipid peroxidation and associated pathologies such as mitochondrial
dysfunction and formation of LP-derived aldehydes peak 48h-72h following CCI [73], it
follows that drug administration over the first 48h-72h may offer the best chance of
neuroprotective success. Therefore, based on this assumption and previous studies
demonstrating neuroprotective success with daily administration of PZ or HZ [72, 74, 75,
333], drugs were administered 15min, 24h, and 48h following injury.
Prior to this study neither PG nor HZ had been utilized in an experimental TBI
study. Therefore, the HZ dosage chosen (5mg/kg/day, intraperitoneal) was based upon
a dosage optimized for SCI by Shi and colleagues [74, 75]. Similarly, although our
previous

PZ

studies

showed

protection

with

10mg/kg/day

subcutaneous

PZ

administration [72, 333], here we chose to administer PZ intraperitoneal at 15mg/kg/day
[75], a dosage which was shown to be neuroprotective in SCI in a study which directly
compared PZ to HZ [74]. In fact, subcutaneous PZ administration at 15mg/kg/day has
also shown to be neuroprotective in a gerbil model of ischemic-reperfusion injury [76].
PG (15mg/kg/day, intraperitoneal) was administered at an equal concentration to
PZ to parallel ex-vivo experiments in which the ability of PZ to protect isolated
mitochondria from exogenous administration of 4-HNE and acrolein was compared to
that of PG [72]. Similarly, equal concentrations of PG and PZ have been utilized in-vivo
to study the effects of aldehyde scavenging on preventing vascular carbonyl stress and
atherosclerosis [198]. PG is similarly structured to PZ. However, unlike PZ, PG does not
contain the aldehyde-scavenging hydrazine moiety (-NH-NH2) (Fig. 4.2). Our previous
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ex-vivo results indicated that while PZ protected isolated cortical mitochondria against
exogenously administered aldehydes, an equivalent concentration of PG did not,
confirming that the presence of the hydrazine moiety (-NH-NH2) and not steric hindrance
is responsible for PZ’s aldehyde scavenging properties [72]. Although the study did not
likely allow for rigorous assessment of MAOI affects, as MAO substrates are largely
absent from isolated mitochondria preparations [72], similar results were seen in an invivo study which demonstrated PZ, but not PG prevented formation of carbonyls and
atherosclerotic plaques [198].
Although PZ and PG are both considered non-selective irreversible MAOIs, it
must be noted that PZ is more selective toward MAO-A, whereas PG is more selective
toward MAO- B [197], and both drugs have differing pharmacokinetics [189, 197, 208].
Therefore, although the choice was made to administer the two MAOIs, PG and PZ, in
equivalent concentrations for the current study as an extension to previous work [72],
results must be interpreted with caution as equal in-vivo concentrations of the two
cannot be necessarily treated as equivalent in regards to their MAOI properties. In fact,
this likely explains the HPLC data in which PZ administration leads to significant
increases in NE and 5-HT, whereas PG administration at the same concentration does
not (Fig. 4.5 and 4.6A).
Choice of Experimental Design: Morris Water Maze
Our previous PZ studies have focused on evaluating biochemical outcome
measures 72h post-CCI, the peak of lipid peroxidation and mitochondrial dysfunction
[72, 73, 333, 334]. Therefore, in order to correlate the current study with previous in-vivo
PZ biochemical TBI studies, the current study began MWM testing at the early time point
of 72h (3 days) post-CCI (Fig. 4.4). In theory, drugs capable of attenuating mitochondrial
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dysfunction and preventing formation of LP-derived aldehydes such as PZ over the first
72h following injury [71, 72, 109, 333, 334] should also be able to attenuate downstream
consequences such as neurodegeneration and neurologic impairment [1, 25, 51, 55,
110, 122, 125, 303]. Although based upon the literature, 72h (3 days) does appear to be
an early point in which to begin cognitive behavioral testing, interventional improvements
to TBI-induced cognitive deficits have been previously seen at this acute time period
[141, 273]. Additionally, although the results of this study indicate that none of the drugs
were able to improve CCI-induced deficits to reference memory (Fig. 4.10), all CCI
groups, PZ excluded, were able to find the platform significantly faster as MWM
acquisition trial days progressed (Fig. 4.8), indicating that following severe CCI the rats
do have intact working memory at the acute 72h (3 days) post-CCI time point. However,
it should be noted that sham animals took an average of 20s to find the platform on
MWM day 4, which is longer than times reported in MWM studies that where conducted
at later time points [125, 387] and may be the result of a residual anesthesia effect [388].
Similarly, although direct assessments of motor function were not conducted as part of
this study (in order to avoid overloading the rats with too many behavioral tasks during
the acute post-CCI period), the ability of rats to decrease their latency to platform (Fig.
4.8) and the lack of swim speed deficits in vehicle (Fig. 4.9) over the first four MWM
days should indicate that if any CCI-induced motor or sensory deficits are present they
are not interfering with MWM performance to a substantial degree.
In additional consideration to MWM performance, is the fact that monoamine
neurotransmitters, such as NE, 5-HT, and DA, have important roles in cognitive and
motor function [150, 151, 153-155]. Therefore, it is possible that MAO inhibition and the
resulting increase in monoamine neurotransmitter levels, as was seen with PZ
administration in the uninjured cortical tissue HPLC experiment (Fig. 4.5 and 4.6A),
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could have had an effect on MWM performance absent injury or neuroprotective effects.
For example, low-dose amphetamines are known to improve learning and memory,
whereas high-dose amphetamines can be detrimental [339].

This is an interesting

question which could have potentially been answered by adding additional cohorts of
uninjured + drug or sham + drug groups to the study. However, several anti-depressants
which modulate monoaminergic systems, including MAOIs, have been shown to have no
ill effects on MWM performance in control animals [156-158]. Therefore, in the interest of
reducing animal numbers and focusing specifically on protective effects (i.e. CCI + drug
vs. CCI + vehicle), these extra cohorts were not included in the current study. However,
it should be noted that upon further review of the literature the effect of acute PZ
administration (15min – 2h prior to behavioral testing) on learning and memory seems to
be mixed with some studies indicating impairment [159, 339] and some indicating
improvement [340], with impairment seeming to be more likely to occur at higher PZ
doses [159, 339] (for further discussion see “The Effects of Phenelzine on Behavior”
section)
Although delaying the start of MWM testing beyond the acute time point chosen
(3 days post-CCI, 24h following final drug administration) (Fig. 4.4) may have decreased
the potential for MAOI-induced elevated monoamine levels to directly impact MWM
performance, it is unlikely to have completely remitted theoretical effects because of the
long lasting nature of irreversible MAOIs (e.g. PZ and PG). Whereas the plasma half-life
of PZ is estimated to be anywhere from 30 minutes in rats to 11.5 hours in humans [74,
341], due to the fact that PZ and PG are irreversible MAOIs, their MAOI effects are much
longer than their plasma-half lives would suggest and rely on MAO turnover rates. In
rats, the half-life of MAO in healthy brain is 10-13 days [195]. In fact, both MAO isoforms
remain significantly inhibited for at least a week following single PZ administration [342].
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However, the effective recovery time for rat brain MAO may be lower, due to the fact that
65-80% of MAO inhibition is likely necessary to modulate monoamine neurotransmitter
levels [186, 342]. Therefore, based upon previous studies of neurotransmitter levels in
uninjured brain following PZ

administration, the “wash out” period following single

administration may range anywhere from 48h to greater than one week [205, 342].
Therefore, we concede that delaying the start of MWM beyond this timeframe may have
resulted in a less confounding experimental design. However, considering that MAO is a
mitochondrial enzyme [186], mitochondrial trafficking is impaired following TBI [19], and
that mitochondrial dysfunction has been documented for weeks following TBI [22], MAO
turnover may be much longer in injured brain, particularly in critical pre-synaptic nerve
terminals, as regeneration of MAO within presynaptic nerve terminals requires trafficking
of MAO and mitochondrion to the synapse [191]. Therefore, it is unknown the length of
time MWM would have had to been delayed for direct MAOI/monoamine effects to
completely “wash out” in order to conduct a cognitive assessment more isolative of
neuroprotective effects. Further, as our research has focused on investigating PZ as a
neuroprotectant for acute use in TBI [71, 72, 333, 334], and early and intensive
neurorehabilitation following severe TBI is encouraged [343], the effects of PZ on
behavior acutely following TBI are still important to discern.
Finally, in regard to the MWM protocol utilized here, on MWM day 5 during
reference memory testing, following removal of the platform, platform crossings were
only counted for 30s. Upon analysis of the latency to platform times during the MWM
acquisition phase, only the sham group was on average able to find the platform in fewer
than 30s on MWM day 4 (Fig. 4.8). Therefore, it unsurprising that during reference
memory testing that there were no differences found between the vehicle and drug
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groups (Fig. 4.10). In hindsight, allowing animals 60s to complete the reference memory
task on day 5 of MWM would have represented a better experimental approach.
Phenelzine: A Comparison to Previous Neuroprotective CCI Studies
The results of the current study indicate that 15mg/kg PZ administered
intraperitoneal 15min, 24h, and 48h following severe CCI was unable to significantly
improve injury-induced deficits to reference memory on post-CCI D7 (Fig. 4.10) or to
improve cortical tissue sparing on post-CCI D8 (Fig. 4.12). These results differ from
previous findings in which PZ was found to be protective in CCI [71, 72, 333, 334].
However, many of these prior PZ studies reported PZ improvement to more biochemicaltype outcome measures such as mitochondrial function and protein-aldehyde conjugate
formation at early time points ranging from 3h-72h [71, 72, 333, 334]. Although there is
robust evidence in the literature that acute pharmacologic attenuation of mitochondrial
dysfunction and lipid peroxidation can in turn lead to downstream behavioral and
histologic improvements at later time points [1, 25, 51, 55, 110, 122, 125, 303], it is
possible that while PZ can acutely (3h-72h) improve mitochondrial respiration and
calcium-buffering

capacity,

and

decrease

formation

of

mitochondrial-aldehyde

conjugates [71, 72, 333, 334], that such early biochemical protections do not translate to
improvements in learning and memory or cortical tissue sparing. There is some evidence
within the previous PZ studies to support this idea. For example, the ability of PZ to
prevent cytoskeletal spectrin degradation or attenuate cellular wide protein-aldehyde
formation, outcome measures that can also correlate with behavioral and histologic
outcomes [56, 109, 110], but which are affected to a greater degree by mitochondrialindependent secondary injury mechanisms [1, 16, 59, 161], is more variable and less
robust than it’s mitochondrial specific effects [333, 334].
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Additionally, it could also be the case that the protection provided by PZ acutely
[71, 72, 333, 334] is not sustained out to more subacute time points. For example, in the
current study, administration of PZ (15mg/kg, i.p., 15min, 24h, 48h post-CCI) was unable
to improve cortical tissue sparing 8 days post-CCI (Fig. 4.12), whereas we had
previously shown that subcutaneous (s.c.) administration of PZ (10mg/kg) 15min postCCI followed by maintenance dosing (5mg/kg) every 12hr up to and including 60h, could
significantly improve cortical tissue sparing 72h post-CCI [72]. Admittedly, 72h was an
early time point for previous studies to conduct histologic analysis, as cortical contusions
have been documented to continue to increase in volume for at least 28 days following
experimental TBI [164]. However, because the primary targets of PZ (i.e. LP-derived
neurotoxic aldehydes and aldehyde-damaged mitochondria) peak 48h-72h following
injury before recovering 5-7 days post injury [73], it would be expected that a robust PZ
protection of cortical tissue at 72h post-CCI [72] would maintain some effect at 8 days
post-CCI.
Therefore, the inability of PZ to improve cortical tissue sparing here (Fig. 4.12)
whereas it has been previously reported to do so at 72h [72], may be more likely due to
methodological differences. For one, the current study included an early behavioral task,
whereas the study by Cebak et al. did not [72]. Although other research groups have
implemented water maze testing in rodents acutely following experimental TBI with no ill
effects [141, 273], it is possible that the early use of MWM in this study could have led to
an increase in neurodegeneration which expanded cortical lesion volumes. Although this
study did not include any non-behavioral cohorts in which this question could have been
analyzed directly, this is unlikely the case as the cortical lesion volumes observed here
do not vary widely from those reported in similar studies in which MWM was not
performed [122, 124, 227, 294].

Further, although clinical guidelines regarding the
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optimal timing and structure of rehabilitation following severe TBI are still being
developed [344], current evidence suggests that early and intensive neurorehabilitation
following TBI promotes the best functional recovery [343].
The second major methodological difference between the current study and the
72h PZ histology study conducted by Cebak et al. [72] is the dosing paradigm. The
current study represents an increase in total amount of PZ received over the first 48h, as
well an increase in the amount of PZ received per bolus dose. Although our reasoning
behind administering PZ over the first 48h-72h [72, 333] has been based on the idea that
drug should be administered throughout the peak lipid peroxidation and mitochondrial
dysfunctional periods [73], recent data from our lab indicates that lower dose PZ may
actually offer better protection [334] than prolonged dosing [72, 333]. For example, PZ
(10mg/kg, s.c.) administered 15min post-CCI with a second dose (5mg/kg, s.c.) given
12h post-injury is able to improve individual states of mitochondrial respiration [334],
whereas 10mg/kg/day/3d subcutaneous continuous infusion of PZ or equivalent bolus
dosing cannot [72, 333]. Similarly, an early PZ study showed that a single dose of PZ
(10mg/kg) administered 15min following CCI can improve cortical tissue sparing 14 days
post-injury [71].
Further, the current study was the first time in which PZ was administered
intraperitoneal following experimental TBI, a route that results in more rapid drug
absorption

than

subcutaneous

administration

[345].

Although

intraperitoneal

administration of PZ up to 60mg/kg has been reported safe under different conditions
[74], it is unknown if this remains true in TBI. In fact, the majority of the MAO substrate,
5-HT, is found outside the CNS, within the gastrointestinal tract [155], as are naturally
occurring trace amounts of tyramine, an amino acid known capable of inducing
hypertensive crisis at extra-physiologic levels through both conversion to and
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displacement of NE [346]. Therefore, it is possible that intraperitoneal administration of
PZ following TBI had a greater effect on monoamines outside the CNS than
subcutaneous administration, and the elevation of such monoamines had adverse
effects.
Phenelzine as a Monoamine Oxidase Inhibitor
As PZ is an irreversible non-selective MAOI, as well as an MAO substrate, it is
possible that the decrease in protective effects seen here and with the higher PZ dosing
paradigms [71, 72, 333, 334] is related to its MAOI effects. In fact, the PZ dosing
paradigm utilized here, when evaluated in uninjured cortical tissue, shows significant
MAO inhibition as measured by the decrease in 5-HT turnover to 5-HIAA (Fig. 4.6C) and
DA turnover to DOPAC and/or HVA (Fig. 4.7D-F). In fact, not only does PZ result in
MAO inhibition, but the MAO inhibition leads to a significant increase in NE (Fig. 4.5)
and 5-HT (Fig. 4.l6A). This is unsurprising given the fact that although classified as a
non-selective MAO inhibitor, PZ is more selective toward MAO-A than MAO-B with a
reported MAO-A: MAO-B selectivity ratio of 2:1 [197], and that both NE and 5-HT are
selectively metabolized by MAO-A [186]. Interestingly, PZ did not affect overall DA tissue
levels (Fig. 4.7A), possibly due to the lower affinity of PZ for MAO-B [197], the lower
affinity of MAO-B for DA in rat [347], overall low tissue levels of DA in the cortex [348], or
a compensatory-type effect as in addition to metabolism, monoamine turnover levels are
affected by monoamine synthesis, release and re-uptake [349]. One consideration in
regards to HPLC analysis is that it was conducted on cortical tissue samples which had
not undergone saline perfusion. Therefore, neurotransmitters measurements, particularly
that of 5-HT, a neurotransmitter which can be transported in platelets [172], are not
necessarily specific to neuronal or glial compartments, however; in general the HPLC
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data should be representative of an overall measure of drug-induced changes to
monoamine turnover and monoamine and metabolite tissue levels.
The Effects of Phenelzine on Weight
As the PZ dosing paradigm utilized for the current experiment was unable to
attenuate CCI-induced memory impairment of enhance cortical tissue sparing (Fig. 4.8,
4.10, 4.12) and led to significant weight loss (Fig. 4.11), the decision was made to
forego HPLC analysis of PZ effects on MAO inhibition and monoamine tissue levels
following CCI. However, extrapolating from the effect the PZ dosing paradigm had on
cortical tissue levels of NE (Fig. 4.5) and 5-HT (Fig. 4.6A) in uninjured tissue, it is
possible similar elevations could explain the significant weight loss seen in PZ animals
following CCI (Fig. 4.11). For example, catecholamines and 5-HT can induce weight loss
through a variety of mechanisms ranging from increasing locomotor activity to
decreasing appetite [350]. In fact, multiple PZ doses also led to weight loss in uninjured
animals, albeit to a lesser degree (see “Chapter Five”). Similarly, non-PZ MAOIs have
been shown to decrease weight gain and induce anorexia in a dose-dependent manner
[158, 351]. Further, one of PZ’s metabolites, phenethylamine (PEA) [189], itself an MAO
substrate with amphetamine-like stimulatory effects [207], could have also contributed to
the observed weight loss.
Additionally, it is possible that the weight loss experienced by the PZ group, as
well as any associated anorexia or muscle wasting, could have been a factor in the poor
performance of the PZ group during the first four days of MWM (4.8). However, if so,
such factors did not seem to impair swim speed as compared to other CCI groups (4.9).
Further, weight loss is unlikely to be a contributing factor in previous PZ studies which
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found that acute administration of PZ can impair cognitive performance, particularly as
dosage increases [159, 339].
The Effects of Phenelzine on Behavior
Although PZ animals performed the worst during assessment of reference
memory, it was not significantly different from other CCI groups. (Fig. 4.10) However,
over the first for days of MWM (MWM D1-D4, post-CCI D3-76), the PZ group was the
only group which showed no significant improvement in finding the platform between
MWM D1 and subsequent MWM days (Fig. 4.8). Additionally, in regards to latency to
platform, for the overall treatment effect across the first four days of MWM there was a
trend toward PZ being significantly impaired as compared with vehicle (p = 0.07). This
suggests that PZ animals may have been struggling more with working memory than
other groups, including vehicle. This is in contrast to several previous studies which have
shown that use of anti-depressants either chronically or during MWM do not negatively
affect working memory in naive rodents [156, 157], including such MAOI’s as PG,
deprenyl (MAO-B), and clorgyline (MAO-A) [158].
On the other hand, previous reports regarding the effects of acute PZ
administration on cognition are variable. Low dose PZ (20mg/kg) administered 2h prior
to training has been shown to improve Y-maze performance in rats [340]. However,
20mg/kg PZ administered 15min prior to training has also been shown to nonsignificantly impair T-maze performance in mice [339]. Similarly, administering PZ (1530mg/kg) 2h prior to beginning MWM acquisition has been shown to impair reference
memory [159], whereas delaying PZ administration until the start of reference memory
(i.e. probe trial) tests does not, suggesting PZ may interfere with storage processing
rather than retrieval [159]. Interestingly, the higher PZ dose used for those trials
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(30mg/kg) also impaired the rate of MWM acquisition, while not abolishing learning
completely, whereas the lower PZ dose (15mg/kg) did not [159]. Those findings are in
line with the ones of the current study in which PZ was the only CCI group which did not
show significant improvement throughout the MWM acquisition phase, although nonsignificant decreases in latency and distance were achieved (Fig. 4.8). Therefore, as
previous studies have shown dose-dependent increases in cognitive impairment with PZ
[339] it is possible that the MWM performance of the PZ+CCI group observed in the
current study was due to the amount of PZ administered. However, an additional CCIinduced exacerbation of PZ effects due to injury-induced increases in monoamines or
MAO inhibition cannot be ruled out (see “Monoamines and TBI” section for further
discussion).
If PZ itself did contribute to cognitive impairment, there are several mechanisms
of action in which it could have done so. For example, it is possible that PZ induced
elevations to catecholamine levels (Fig. 4.5) and such elevated catecholamine levels
induced cognitive impairment, as occurs with high dose amphetamines [339, 352].
Additionally, the PZ metabolite and MAO-substrate, PEA, [189] also has amphetaminelike properties [207]. Similarly, high levels of 5-HT (Fig. 4.6A), such as those that occur
in serotonin syndrome, are capable of inducing cognitive dysfunction [346]. Further, the
PZ metabolite, phenylethyldenehydrazine (PEH), can inhibit GABA-transaminase
(GABA-T), leading to increased levels of GABA, a neurotransmitter that has also been
implicated in cognitive impairment [159, 335, 342].
On the other hand, poor MWM performance is not always a reflection of cognitive
impairment per se, but can instead be representative of sensorimotor dysfunction [147,
353]. On cursory inspection PZ animals do not appear to have motor deficits as their
swim speed is not impaired (Fig. 4.9). In fact their swim speed is significantly increased
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compared to sham (Fig. 4.9), an effect which has been previously demonstrated to
occur following amphetamine or MAOI administration [158], and is usually contributed to
an increase in monoamine levels. In fact, high catecholamine levels can induce motor
dysfunction, including hyperactivity and “amphetamine-stereotyping” behaviors [352355]. Similarly, high levels of 5-HT, as occur in serotonin syndrome, can induce motor
dysfunctions characterized by restlessness, agitation, myoclonus, hyperreflexia, tremor,
and ataxia [346, 354, 355]. Interestingly, previous studies have indicated that high
(50mg/kg) – very high (80mg/kg) PZ doses can induce tremor and ataxia, respectively
[207, 339]. Although sensorimotor function, locomotor activity, and “amphetaminestereotypy” behaviors were not quantitatively assessed as part of this study, qualitative
observations of the PZ group as a whole suggest increased “amphetamine-stereotypy”
behavior (directly following PZ administration) as well as an increase in hyperactivity. In
fact, PZ animals tended to have more difficulty remaining on (i.e. increases tendency to
jump off) the MWM platform, which can confound the ability to interpret MWM results as
memory deficits [147]. Therefore, it is possible PZ-induced sensorimotor effects, rather
than PZ-induced cognitive impairment, contributed to the inability of the PZ group, in
contrast to all other groups, to significantly improve their performance over the first four
days of MWM.
In hindsight, inclusion of tests to quantitatively assess sensorimotor function,
locomotor activity, or an alternative memory test would have further clarified the effects
of PZ on behavior following CCI. In fact, PZ has been shown to have task-dependent
effects on memory. For example, whereas high dose PZ impairs spatial memory in the
MWM task, the same PZ dose enhances memory during the continuous multiple trial
inhibitory avoidance (CMIA) task [159].
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Phenelzine: A Comparison to Previous Neuroprotective SCI and IschemicReperfusion Injury Studies
Still, when taken in comparison to previous SCI and ischemic-reperfusion
studies, which saw neuroprotection with 15mg/kg daily intraperitoneal PZ dosing
paradigms and which extended out 7-14 days [74, 76], it is surprising that the PZ dosing
paradigm (15mg/kg, i.p., 15min, 24h, 48h post-CCI) utilized in the current study was not
only unable to enhance cortical tissue sparing (Fig. 4.12), but also had a negative effect
on weight and behavior (Fig. 4.8, 4.11, qualitative observation). Contrarily, in SCI,
intraperitoneal administration of PZ (15mg/kg/day/14d) beginning immediately following
injury attenuates motor dysfunction and improves tissue sparing [74]. Similarly,
subcutaneous administration of PZ (15mg/kg/day/7d) improves CA1 neuron survival in a
gerbil modal of global ischemic-reperfusion injury [76].
It is possible this finding is due to differences in temporal assessments, species,
or injury models. For example, although TBI and SCI share similar secondary injury
characteristics [51, 55, 356], they are not equivalent models. Beyond structural
differences, LP-derived aldehydes remain elevated longer in SCI than TBI [73, 338],
brain and spinal cord mitochondria have different sensitives to lipid peroxidation [29, 33]
and

inflammatory

responses

differ

between

TBI

and

SCI

[356].

Further,

pharmacotherapies do not always translate from one injury paradigm to the other. For
instance, while acute methylprednisolone is a treatment option for SCI [55], its use is
contraindicated in TBI [209].
Additionally, acrolein has been demonstrated to be extremely toxic to myelin due
to its high protein and lipid content [357]. Given the anatomical differences between
brain and spinal cord, attenuation of acrolein-induced myelin damage utilizing aldehyde-
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scavengers, such as PZ, may lead to a more quantitatively observable behavioral effect
in spinal cord than in brain. Moreover, in SCI, aldehyde-scavengers, including PZ, have
a well demonstrated role in reducing pain hypersensitivity, which may help in attenuating
other outcomes which have been assessed in SCI such as motor dysfunction, but which
were not directly measured in the current study [74, 337, 338, 358, 359].
Further, PZ was recently identified as an agonist of the neuronal cell adhesion
molecule L1 (L1CAM) [360], a compound which has been shown to promote axonal
growth and re-myelination in the injured spinal cord [361]. In fact, in models of SCI PZ
can decrease astrogliosis, enhance axonal growth and sprouting, and improve motor
function in an L1CAM-dependent manner [361, 362]. Yet, the role L1CAM may have in
recovery and regeneration following TBI is less well understood.
However, it is also possible that the PZ dosing paradigm utilized in the current
study did have subtle neuroprotective effects which were not apparent upon cortical
tissue sparing analysis (Fig. 4.12), but which may have been revealed by use of
histological methods more sensitive to neurodegeneration, such as silver stain, or
through analysis or specific regions, such as the hippocampus, as was done in the gerbil
ischemic-reperfusion injury study [76]. However, given the overall PZ results for the
current study, this is unlikely to be true and even less likely to be clinically relevant.
Yet, given the success of a similar dosing paradigm in other models of CNS
injury, combined with the knowledge that intraperitoneal administration of PZ up to
60mg/kg has been reported to be safe in rodents following SCI [74], the PZ results
obtained in the current study beg the following question: Is there something about TBI
that causes a PZ dosing paradigm which is neuroprotective (or at the very least safe) in
other models (e.g. SCI, ischemic-reperfusion, naïve), to become ineffective or even
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detrimental following severe CCI? Is it possible that TBI itself leads to either an inhibition
of monoamine oxidase or an increase in monoamine levels, effects which are then
exacerbated by repetitive use of an irreversible MAO, such as PZ? Unfortunately, in
general there is a paucity of information regarding acute monoamine dysfunction
following TBI.
Monoamines and TBI
Neurobehavioral sequelae following TBI are common and include dysregulation
of cognition (e.g. attention, memory), mood (e.g. depression, anxiety), and emotion (e.g.
aggression) [127]. Given the role the monoamines DA, NE, and 5-HT have in modulating
these domains, sustained neurobehavioral impairments following TBI points to chronic
dysregulation of monoamine neurotransmitter systems. In fact, pharmacologic agents,
such as anti-depressants and stimulants, which modulate monoamine neurotransmitter
systems, are often used to treat chronic TBI-induced neurobehavioral sequelae [127].
However, less is understood about acute effects to monoamine systems
following TBI, with the majority of work being focused on DA systems [154, 170].
Although, we did not detect cortical elevations of DA, NE, or 5-HT in the pericontusional
site over the first 24h following CCI (see “Chapter Five”), there is evidence that levels of
DA, NE, and 5-HT become acutely elevated throughout various brain regions and
systemically following TBI [154, 173, 174, 178, 182, 363-365].
Although acute administration of DA agonists (e.g. bromocriptine, amantadine,
etc.) and 5-HT agonists (e.g. 8-OH-DPAT, buspirone, etc.) have shown great promise as
neuroprotective agents in TBI, the administration of DA agonists is often delayed until
24h post-TBI [154, 170, 271], and therapeutic agonists are often receptor subtype
specific. For example, bromocriptine is specific to the DA receptor subtype D2 [154],
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amantadine doubles as an NMDA glutamate receptor antagonist [154], and 8-OH-DPAT
and buspirone are specific to 5-HT1A, which is an inhibitory receptor [271]. Therefore,
use of such agents, which target specific receptor subtypes, is not equivalent to
increasing overall monoamine levels, as would be the case with the use of an MAOI,
such as PZ.
Interestingly, following TBI, high catecholamine levels are associated with
increased peripheral inflammation [366], cerebral edema [367], and poor outcome [181],
However, because catecholamine levels increase with activation of the sympathetic
nervous system, as would occur following trauma, it is difficult to determine whether high
catecholamine levels following TBI are an actual cause or rather an effect of injury
severity [181]. Yet, early administration of NE in experimental TBI has been shown to
increase pericontusional extracellular glutamate levels [368], and high dose NE leads to
increases in systolic arterial blood pressure and intraparenchymal hemorrhage [369].
Further, acute administration of DA antagonists following experimental TBI has antiexcitotoxicity and neuroprotective effects [154].
Therefore, it is possible that in the current experiment, PZ-induced elevations to
monoamines or PZ-enhancement of TBI-induced monoamine elevations [154, 173, 174,
178, 182, 363-365], led to exacerbation of dysfunction or even negated PZ aldehydescavenging protective effects, further impairing MWM performance (Fig. 4.8) and
increasing weight loss (Fig. 4.11) compared to the CCI + vehicle group.
Extra-physiologic monoamines levels could have caused detrimental effects
through a variety of mechanisms including direct catecholamine toxicity [170],
vasoconstriction or thrombotic-induced ischemia [154, 171, 172, 182], or autoxidation
generation of ROS/RNS [170, 194]. However, the latter scenario is unlikely, as even high
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dose PZ has been shown to decrease markers of oxidative stress [72, 333]. Given the
complexity, pervasiveness, and interconnectedness of the monoaminergic system, and
the dearth of what is known regarding acute monoaminergic dysfunction in TBI, the
complete answer of how PZ’s MAOI mechanism of action effects TBI pathophysiology
and outcome is

likely complex. Further, as the current experiment did not directly

measure MAO inhibition or monoamine tissue levels in PZ + CCI animals, the effects
can only be hypothesized. As such, additional PZ mechanisms of action must also be
considered.
Phenelzine: Other Possible Confounding Mechanisms of Action
In general PZ has complicated pharmacokinetics. PZ is itself a MAO substrate
with several active metabolites such as PEA and PEH [189]. As mentioned previously,
PEA, also metabolized by MAO is an amphetamine-like metabolite that can produce
stimulatory effects [207], and it is therefore possible that PEA, rather than more
prevalent monoamine neurotransmitters such as DA, NE, and 5-HT, is responsible for
PZ-induced weight loss (Fig. 4.11), working memory impairment (Fig. 4.8), and
qualitative behavioral observations [352]. Additionally, the PZ metabolite, PEH, inhibits
several important transaminases, including GABA transaminase (GABA-T), alanine
transaminase (ALA-T), and ornithine transaminase (ORN-T) [169]. Although, GABA,
ALA, and ORN levels were not measured as part of the current study, previous studies
have shown a dose dependent increase in all three following PZ administration [342]
[169, 335], and it is possible that inhibition of these transaminases following TBI could
have negatives consequences. For example, GABA-T is responsible for the conversion
of the inhibitory neurotransmitter GABA, to succinic semi-aldehyde, which can be further
oxidized to succinate [169], a substrate of the Krebs cycle and complex II of the ETC.
Therefore, inhibition of GABA-T could lead to increases in GABA, which can
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paradoxically cause excitotoxicity following neuronal injury through reversal of chloride
channels [264], as well as decreases in ETC substrates during a time in which there is
ongoing mitochondrial dysfunction and ATP depletion [22, 25, 51, 73]. Similarly,
inhibiting ALA-T, the enzyme which catalyzes the reaction of alanine + α-ketoglutarate to
form glutamate + pyruvate, could also lead to decreased formation of Kreb cycle
substrates. Further, ORN-T catalyzes the formation of glutamate, from the urea cycle
product, ORN. However, inhibition of ORN-T could alternately lead to decarboxylation of
ORN by ornithine decarboxylase (OCD), the result of which is formation of neurotoxic
polyamines [169].
On the other hand, because PEA and PEH are metabolites of PZ metabolism by
MAO, the effects of PZ metabolites, such as PEH, can be inhibited through pre-inhibition
of MAO [169]. Therefore, the effect multiple PZ doses would have on GABA, ALA, and
ORN levels, particularly in the context of TBI is unknown. However, PZ itself is also
capable of inhibiting transaminases, as well as enzymes involved in the biosynthesis of
neurotransmitters such as DA, 5-HT, and glutamate, as it can scavenge physiologically
important carbonyls, such as the B6-derived cofactor, pyridoxal phosphate [78].
Furthermore, it is currently unknown how drug-aldehyde-protein ternary complexes are
metabolized or what the longer-term consequences of ternary complex formation are
[78]. In fact, evidence suggests that such complexes can be immunogenic [258].
Therefore, it is possible that in-vivo several PZ mechanisms of action could be interfering
with its neuroprotective aldehyde-scavenging effects, particularly at higher doses.
Pargyline
The results of the current study indicate that 15mg/kg PG administered
intraperitoneal 15min, 24h, and 48h following severe CCI was unable to significantly
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improve injury-induced deficits to reference memory on post-CCI D7 (Fig. 4.10) or to
improve cortical tissue sparing on post-CCI D8 (Fig. 4.12). However, PG animals were
able to significantly improve the time/distance it took to find the platform over the first
four MWM days (Fig. 4.8), and did not lose a significant amount of weight following
injury (Fig. 4.11).
In the literature PG is interchangeably referred to as a non-selective irreversible
MAOI [191], and an MAO-B specific irreversible inhibitor [197], as the IC50 values of PG
for MAO-A and MAO-B are 0.011522 μmol/L and 0.00820 μmol/L, respectively [202]. In
fact, the ED50 for oral administration of PG gives a 6.6:1 selectivity ratio for MAO-B to
MAO-A (1.4mg/kg for MAO-B, 9.3mg/kg for MAO-A) [197], whereas the ED50 for oral
administration of PZ gives a 2:1 selectivity ratio of MAO-A to MAO-B (6mg/kg for MAO-A
and 12mg/kg) [197]. The fact that PG is less selective for MAO-A, in conjunction with
other pharmacokinetic differences between PG and PZ [189], likely explains why that for
the dosing paradigms utilized in the current study, although both PG and PZ significantly
inhibited MAO as measured by 5-HT and DA turnover (Fig. 4.6C and 4.7D-F), PG,
unlike PZ, did not significantly raise tissue levels of the MAO-A substrates, NE (Fig. 4.5)
or 5-HT (Fig. 4.6A).
These findings are in line with previous studies which directly compared the
effects of PG and PZ on drug (e.g. nicotine, cocaine, ethanol) substitution and
discrimination [205-208], processes thought to require both MAO-A and MAO-B
inhibition [205-207]. Those studies found that PZ, administered at lower doses than PG,
was able to enhance the discriminatory effects of nicotine [205] and nicotine-induced
locomotor activity [206], whereas PG was not [205]. Further, although PZ and PG were
both able to decrease cocaine and ethanol self-administration, PZ did so at lower doses
and with prolonged effects [207, 208]. This data suggests that PG, at least when used at

209

a similar dosing concentration to PZ, has less of an effect than PZ on behavioral
processes mediated by MAO inhibition. This knowledge, combined with the current
study’s HPLC data (Fig. 4.5 – 4.7), likely explains why the qualitative behavioral
observations and negative effects such as weight loss (Fig. 4.11) and poor MWM
acquisition performance (Fig. 4.6) that occurred in the PZ animals, was not seen in the
PG group following CCI, despite both compounds being irreversible MAOIs. However, as
with PZ, PG did significantly increase swim speed following CCI (Fig 4.9), suggesting
that PG still possibly had some effect on elevating catecholamine levels following CCI
[158]. Therefore, the absence of other confounding PZ mechanisms of action, such as
formation of active metabolites or ternary drug-aldehyde-protein complexes (see
“Phenelzine: Other Possible Confounding Mechanisms of Action” for further discussion)
as factors in the behavioral differences between PG and PZ following CCI also cannot
be ruled out.
As stated previously, PG was chosen as a comparison to PZ because it is
similarly structured but lacks the aldehyde-scavenging hydrazine moiety (-NH-NH2) (Fig.
4.2), and that the dosing paradigms for the two were kept equivalent to parallel previous
ex-vivo experiments [72]. However, we concede that choosing a non-hydrazine MAOI
with more similar MAO-A to MAO-B affinity ratios, such as tranylcypromine [189, 197,
208], or altering PG concentrations to better reflect PZ MOAI affinities or other
pharmacokinetics may have offered more clear insight into the effects of MAOI following
TBI.
Due to PG’s lack of an aldehyde-scavenging hydrazine (-NH-NH2) moiety it was
not surprising that PG was unable to improve behavioral deficits or cortical tissue
sparing following CCI (Fig 4.8, 4.10, 4.12). However, it should be noted that some
studies have demonstrated MAOIs to have neuroprotective effects. For example, MAO
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substrates such as DA and tyramine (an MAO substrate incapable of undergoing
autoxidation) have been shown to induce mitochondrial dysfunction, an effect which can
be attenuated by administration of a variety of irreversible MAOIs, including PG [193].
Similarly, in-vitro, MAOIs can prevent mitochondrial-dependent apoptosis following
serum withdrawal [275]. Although these results may seem to contradict our previous
findings that PG is unable to protect mitochondria from exogenous administration of the
toxic aldehydes 4-HNE and acrolein ex-vivo [72], the differences are likely explained by
the isolative nature of the mitochondrial preparation technique in which monoamine
substrates or other molecules such as those involved in apoptotic signaling are likely
absent. As such, although not included as part of this study, evaluating the effects of invivo administration of PG following CCI on mitochondrial function, as we have previously
done with PZ [71, 72, 333, 334] could have yielded interesting results.
Further, several irreversible MAOIs have demonstrated in-vivo neuroprotection in
models of stroke [272], TBI [273], and aging [279]. However, many of these studies
suggest that the neuroprotective effects of MAOIs are independent of MAO inhibition
[274, 275], and are instead possibly due to the presence of an N-propargyl moiety, a
structure shared by several demonstratively neuroprotective MAOIs, including deprenyl
(selegiline), clorgyline, rasagiline, and importantly, PG [192, 201, 276-278]. Hypotheses
regarding the mechanisms of action in which N-propargyl compounds may exert their
neuroprotective effects are vast and include modulation of apoptotic proteins and protein
kinase C (PKC), upregulation of antioxidants and growth factors, or direct targeting of
the mPTP [192, 274-276, 278, 279].
Therefore, even though PG did not demonstrate protective effects following CCI
in the current experiment, and other studies have demonstrated that PG can actually
exacerbate DA neurotoxicity [194], it is possible that under different experimental
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parameters, such as an alternative dosing paradigm, that PG could demonstrate acute
neuroprotective effects following CCI, possibly due to the presence of an N-propargyl
moiety. On the other hand, it should be noted that in addition to possible MAOI effects
(see “Monoamines and TBI” section for further discussion), PG has several properties
which could instead either negate protective effects or exacerbate dysfunction. Although
the latter is unlikely the case as out of all three drugs, PG performed most similarly to
vehicle (Fig. 4.8 – 4.12).
First, PG is metabolized by the liver enzyme CYP2E1 to the toxic aldehyde,
propioaldehyde, which has similar effects to acrolein and can induce hepatocyte toxicity,
lipid peroxidation, and glutathione (GSH) depletion [370]. Interestingly, CYP2E1, itself a
producer of ROS during substrate metabolism, is found in rat brain at 25% the levels of
that in the liver and is highly expressed within rat brain mitochondria [371]. Although PG
appears to be non-toxic to rat brain mitochondria when exogenously applied ex-vivo [72],
it is unknown what role CYP2E1 and its potential products have in the metabolism of
PG, particularly multiple doses of PG, following CCI.
Second, although developed and classified as an MAOI, PG was more frequently
used clinically as an anti-hypertensive [203]. Although this sounds counterintuitive given
the known risk of hypertensive crisis that can be induced by combining MAOIs with
ingestion of tyramine-rich foods [191], its anti-hypertensive properties are thought to be
due to MAOI-induced increases in NE and its action on inhibitory α2-adrenergic
receptors of the brainstem and periphery [204]. Although only slight and non-significant
changes in NE tissue level were seen following multiple PG administration in uninjured
animals (Fig. 4.5), and previous studies have not detected blood pressure changes in
Sprague-Dawley rats over a 24h period following intravenous PG (10mg/kg)
administration [204], as blood pressure was not measured during the current study, it is
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unknown what effect PG has on blood pressure following CCI, an experimental model of
TBI which can induce hypotension acutely following impact [372]. In fact, it is known that
hypotension can exacerbate dysfunction following experimental TBI [373, 374].
Interestingly, given the proposed mechanism of action regarding PG’s anti-hypertensive
effects, it is possible that as a drug class all MAOIs, and therefore PZ, could have antihypertensive effects. In fact low blood pressure is an uncommon side effect of PZ [198,
341]. Further, the third drug used in this study, HZ, also has potential anti-hypertensive
effects [268] (see “Hydralazine” section for further discussion). On the other hand, blood
pressure monitoring following drug administration could have revealed the opposite
effect, as MAOI-induced catecholamine elevations can elicit increases in blood pressure
[346]. Admittedly, including blood pressure measurements as part of the current study
may have revealed important physiologic changes subsequent to CCI + drug
administration.
Hydralazine
The results of the current study indicate that 5mg/kg HZ administered
intraperitoneal 15min, 24h, and 48h following severe CCI was unable to significantly
improve injury-induced deficits to reference memory on post-CCI D7 (Fig. 4.10).
However, HZ animals were able to significantly improve the time/distance it took to find
the platform over the first four MWM days (Fig. 4.8), and did not lose a significant
amount of weight following injury (Fig. 4.11). Although HZ was unable to significantly
decrease cortical degeneration on post-CCI D8 (Fig. 4.12), of the three drugs tested, HZ
did lead to the greatest amount of cortical tissue spared, improving the amount of
cortical tissue sparing seen in the vehicle group by nearly 10% (Table 4.1). As this was
the first time HZ was investigated in the context of TBI, it is possible that choosing an
alternative HZ dosing paradigm could have enhanced protective effects.
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For example, the plasma half-life of HZ is only 60 minutes [74, 78]. Therefore,
theoretically more frequent doses of HZ could have led to enhanced protection.
However, that is not the case in SCI, where intraperitoneal dosing of 5mg/kg HZ every
24h has been shown to be neuroprotective, improving motor function, increasing tissue
sparing, and decreasing pain hypersensitivity [74, 75, 338, 358]. In fact, as HZ can exert
its effects as an aldehyde-scavenger by binding protein-bound aldehydes and preventing
damaging cross-linking reactions [79, 262], its neuroprotective aldhehyde-scavenging
effects are likely prolonged beyond its short plasma half-life. However, additional
neuroprotective mechanisms of action for HZ have also been recently proposed. For
example, HZ has been shown capable of activing Nrf2 (nuclear factor erythroid 2-related
factor), a transcription factor which activates antioxidant genes following neuronal injury
[375], which would also act in prolonging its neuroprotective effects.
Unfortunately, the HZ dosing paradigm utilized in the current study did not
translate well from SCI to TBI. As discussed previously, this is not entirely surprising as
the SCI and CCI injury models are not necessarily equivalent. In fact, it is possible that
additional, non-aldehyde-scavenging HZ mechanisms of actions are more confounding
in TBI than they are in SCI.
First, like PZ and PG, HZ has MAOI properties [258, 269], likely due to the
presence of its hydrazine moiety (-NH-NH2), which is known to participate in one
mechanism of MAO inhibition [199].

Specifically, HZ has been demonstrated to

reversibly inhibit MAO-A and MAO-B, with a slight preference for MAO-A [269]. Such a
property likely explains the results shown in Fig. 4.6C in which HZ causes a slight but
significant decrease in 5-HT turnover in uninjured cortex, as well as the slight but
significant increase in swim speed (Fig. 4.9) seen in HZ animals following CCI, which
was similar to that seen with the MAOIs PG and PZ. And although inhibiting MAO along
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with scavenging acrolein may synergistically attenuate pain hypersensitivity in SCI [74,
338], as discussed previously, modulation of MAO following TBI may have unintended
negative consequences (see “Monoamines and TBI” section for further discussion).
More concerning, however, is the fact that HZ is an anti-hypertensive, clinically
used to treat emergent and essential hypertension [268]. The anti-hypertensive
properties of HZ are due to its ability to act as an arteriolar vasodilator. Although the
exact mechanism of action remains unclear, it has been hypothesized to be due to
activation of guanylate cyclase, inhibition of sarcoplasmic reticulum calcium release, or
increased

conductance

of

calcium-dependent

K+

channels

[258].

Although

intraperitoneal doses of HZ ranging from 5mg/kg - 25mg/kg have been reported not to
induce changes to systolic blood pressure in rats [270], because CCI can acutely induce
hypotension [372], and as mentioned previously blood pressures were not measured as
part of the current study, it is currently unknown whether HZ induced hypotension under
the current experimental conditions. However, if under the current experimental
conditions HZ did induce hypotension and as a consequence cerebral hypoperfusion
occurred, it could explain the differences between the results seen here and those seen
in previous SCI studies [74, 75, 338, 358], as any protective aldehyde-scavenging
effects could have been partially negated by the consequences of cerebral
hypoperfusion. In fact decreases in cerebral perfusion pressure have been shown to
exacerbate functional deficits and cortical lesion volumes [373, 374]. Admittedly,
including blood pressure measurements, as well as measures of aldehyde load, either
by tissue staining or evaluation of urine metabolites such as 3-HPMA (N-acetyl-S-3hydroxypropylcysteine) [270], could have potentially helped to interpret the current
study’s results in regards to HZ’s aldehyde-scavenging properties versus its antihypertensive effects.
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Clinical Translation of PZ, HZ, and Other Aldehyde Scavengers
The ultimate goal in evaluating neuroprotective agents in experimental TBI is to
translate their use into the human TBI population. Therefore, selecting study compounds
which are FDA-approved for other indications and which could be potentially repurposed
for use in TBI often offers a faster and more cost-effective approach than development
of novel agents. Of the hydrazine (-NH-NH2) aldehyde scavenging drugs available, three
are currently FDA-approved and in clinical use, including PZ, HZ, and the antituberculosis agent isoniazid, which itself has some MAOI properties [198, 376].
As MAOIs were designed to target the CNS, along with concerns that an antihypertensive like HZ would be dangerous for use clinically in TBI, our lab originally
selected PZ for its studies into the protective effects of aldehyde scavengers following
TBI [71, 72, 333, 334]. Despite previous studies by our lab and other groups
demonstrating PZ to be neuroprotective in experimental models of CNS injury [71, 72,
74-76, 333, 334, 361, 362], unfortunately the PZ dosing paradigm utilized in the current
study (15mg/kg, i.p., 15min, 24h, 48h post-CCI) was unable to provide protective effects
in regards to reference memory (Fig. 4.10) or cortical degeneration (Fig. 4.12), while
also inducing significant weight loss (Fig. 4.11) and impairing MWM acquisition
performance (Fig. 4.8). As discussed previously, it is becoming clearer that lower doses
of PZ may offer better protection [71, 334], possibly due to several PZ mechanisms of
action which may confound neuroprotective effects as dosage increases, including its
MAOI properties (Fig. 4.5 – 4.7). As such, it may be possible to optimize PZ for
neuroprotection in experimental TBI using low or single dosing paradigms. However, as
an MAOI, even conservative dosing paradigm may still prove impractical for clinical
translation.
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For example, in rats a single dose of PZ has been shown capable of inhibiting
MAO and increasing monoamine levels for at least a week following administration [205,
342]. However, the half-life of MAO in healthy human brain is reported to be as much as
30 days [196], three times that in the rat [195]. Further, it is currently unknown what
effect TBI has on the turnover of MAO in human brain, suggesting that even a single
dose of PZ could have either prolonged effects or unintended negative consequences in
TBI patients. For example, although in general there is little known about the
monoaminergic system acutely following TBI, high catecholamine levels have been
shown to correlate with poor outcome [181], and therefore, administration of PZ acutely
in clinical TBI, even at low doses, may represent a risk in regards to modulating the
monoaminergic system in a way that leads to direct catecholamine toxicity [170], or
catecholamine-induced vasoconstrictive or ischemic events [154, 171, 172, 182].
Additionally, clinical administration of PZ would likely be restricted to patients not
receiving vasopressors (e.g. NE or DA) as part of their clinical treatment, and
contraindicated for use in patients taking serotonin modulating drug such as SSRIs
(serotonin-reuptake inhibitors) or SNRIs (serotonin-norepinephrine-reuptake inhibitors)
[346], a medical history unlikely to be known at the time of acute clinical treatment given
the severe nature TBI. Of additional concern in regards to clinical translation of PZ is
that anti-depressants can lower seizure threshold [265], a complication for which TBI
patients are already at increased risk [209], although of all the anti-depressant drug
classes, MAOIs are at the least risk to do so [265]. Therefore, use of PZ could increase
the risk of post-traumatic seizure in TBI patients.
Similarly, although HZ was unable to provide significant protection in the current
study (Fig. 4.8, 4.10, 4.12), it has shown extensive promise as a neuroprotective agent
in experimental SCI [74, 75]. Yet, even if a HZ dosing paradigm for protection in
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experimental TBI could be optimized, its anti-hypertensive properties also likely make it
impractical for clinical translation. In fact, anti-hypertensives would be contraindicated for
use in clinical TBI, as maintaining systolic blood pressure is important for decreasing
mortality and improving outcome [209], particularly in patients in which autoregulation is
impaired [377].
However, despite the likely difficulty in clinical translation that PZ and HZ would
face in order to be used in TBI, and despite the poor performance of the chosen PZ and
HZ dosing paradigms in the current study in regards to the outcome measures
evaluated, there is a preponderance of evidence that hydrazine (-NH-NH2) compounds
such as PZ and HZ can provide protection in-vitro and in-vivo under a variety of injury
paradigms [71, 72, 74-76, 88, 257, 270, 311, 333, 334, 337, 338]. Therefore, in our
opinion it is still too early to abandon pursuit of aldehyde scavengers as therapeutic
agents in TBI.
However, there is a need for new hydrazine compounds (-NH-NH2) to be
developed, such as ones with less complicated pharmacokinetics that do not result in
potentially confounding off target effects such as MAO inhibition or hypotension.
Although it should be noted that the hydrazine moiety (-NH-NH2) is purported to interact
with MAO to cause inhibition [199], a variety of hydrazine (-NH-NH2) containing
compounds have been shown to have differing levels of inhibitor activity [199, 378],
therefore, development of an aldehyde-scavenging hydrazine (-NH-NH2) compound with
no MAOI effects should theoretically be possible. Alternatively, although not as potent as
the hydrazine (-NH-NH2) compounds, additional aldehyde-scavenging moieties exist
including cysteines, histidines, and pyridines, and could also serve as the basis for
further development [79].
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Conclusion
In conclusion, utilizing a severe CCI model of TBI in 3mo male Sprague-Dawley
rats, intraperitoneal administration (15min, 24h, 48h post-CCI) of the drugs PG
(15mg/kg, MAOI, non-aldehyde scavenger), PZ (15mg/kg, MAOI, aldehyde scavenger),
and HZ (5mg/kg, non-MAOI, aldehyde scavenger) were unable to attenuate reference
memory deficits (D7 post-CCI) (Fig. 4.10) or improve cortical tissue sparing (D8 postCCI) (Fig. 4.12) following injury. However, although non-significant, HZ led to the most
improvement to cortical tissue sparing (Table 4.1). Of concern, following CCI PZ animals
lost a significant amount of weight (Fig. 4.11), and their MWM acquisition performance
did not significantly improve across time (D3-6 post-CCI) (Fig. 4.8), possibly due to PZinduced high monoamine levels as was seen in uninjured cortical tissue utilizing the
same PZ dosing paradigm (Fig. 4.5 – 4.7). Similarly, qualitative behaviors observed in
the PZ group following CCI may have also been suggestive of elevated monoamine
levels. However, the effects of other PZ mechanism of actions, such as inhibition of
GABA-T or formation of PEA, cannot be ruled out as factors effecting outcome.
Admittedly, this study had several limitations that make precise data interpretation
difficult. Namely, MAO inhibition and monoamine levels were not evaluated following
CCI + drug administration, MWM testing began very early following CCI and final drug
administration, blood pressure was not monitored, and quantitative behavioral testing
was limited to one task. Although the precise reasons the aldehyde-scavengers PZ and
HZ were unable to provide significant protection in the current study cannot be identified
with certainty, the dosing paradigm and experimental parameters utilized are likely
contributory factors, as a number of previous studies have shown that the aldehydescavengers PZ and HZ are indeed protective under different conditions (e.g. lower
doses, SCI, mitochondrial bioenergetics, etc.). However, given the fact that PZ is a non-
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selective irreversible MAOI with complicated pharmacokinetics and active metabolites
and HZ is an anti-hypertensive, clinical translation of either drug for use in TBI patients
may prove challenging. Therefore, we urge the development of aldehyde-scavenging
drugs that do not contain confounding mechanisms of action such as irreversible MAO
inhibition or hypotension, and for such compounds to be used in future investigations of
aldehyde-scavenging as a means of neuroprotection in experimental TBI.
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CHAPTER FIVE:
Supplementary Data: Comparative Effects of Phenelzine, Hydralazine, and
Pargyline on Learning and Memory and Cortical Tissue Sparing Following
Experimental Traumatic Brain Injury

Introduction
The data presented here is an extension of the work presented in “Chapter 4:
Comparative Effects of Phenelzine, Hydralazine, and Pargyline on Learning and Memory
and Cortical Tissue Sparing Following Experimental Traumatic Brain Injury”. High
Performance Liquid Chromatography (HPLC) is utilized to analyze the tissue levels of
monoamines, metabolites, and turnover ratios in order to assess monoamine oxidase
(MAO) inhibition in uninjured cortical tissue following a single dose of phenelzine (PZ),
pargyline (PG), or hydralazine (HZ). Additionally, HPLC is utilized to analyze the tissue
levels of monoamines, metabolites, and turnover ratios in the penumbra of cortical tissue
in order to assess MAO inhibition and metabolite tissue levels 3h, 12h, and 24h following
a severe controlled cortical impact injury (CCI). Further, percent weight loss for uninjured
animals following two doses of PZ, PG, or HZ is presented.
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Methods
Please see “Chapter Four: Comparative Effects of Phenelzine, Hydralazine, and
Pargyline on Learning and Memory and Cortical Tissue Sparing Following Experimental
Traumatic Brain Injury” for detailed methods regarding animals, HPLC tissue collection,
HPLC, CCI, choice of drug concentration, statistical analysis, etc.
Experimental Design: 24h HPLC Monoamine and Metabolite Analysis (Fig. 5.1)
In order to assess MAO inhibition 24h following single drug administration HPLC
was used to evaluate monoamine and metabolite tissue levels and turnover ratios in
uninjured cortex. Uninjured animals (n = 6 animals per group) were administered an
intraperitoneal (i.p.) dose of saline, PZ (15 mg/kg), HZ (5 mg/kg) or PG (15 mg/kg) [72,
74]. Animals were euthanized 24h following drug administration and cortical tissue
punches were collected for HPLC analysis.
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Figure 5.1 Monoamine and metabolite 24h HPLC experimental design. Uninjured
rats received intraperitoneal injections of vehicle (saline), pargyline (15mg/kg),
phenelzine (15mg/kg), or hydralazine (5mg/kg) at 0h. Animals were euthanized and
cortical tissue was collected for HPLC analysis 24h following injection.
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Experimental Design: CCI Time Course HPLC Monoamine and Metabolite Analysis
(Fig. 5.2)
HPLC was utilized to assess MAO inhibition and monoamine neurotransmitter
tissue levels following severe CCI. Animals received a severe CCI (n = 6 per time point)
or sham surgery (n = 6). At 3h, 12h, and 24h post-CCI 3mm cortical tissue punches were
collected from the penumbra region lateral to the epicenter of injury and sent for HPLC
analysis. Sham tissue was collected 12h post-surgery.
Percent Weight Loss in Uninjured Rats Following PG, PZ, or HZ Administration
Animals were weighed daily prior to each drug administration for the uninjured
72h HPLC experiments (Fig. 4.3). However, a final weight was not measured at the 72h
time point prior to euthanasia. Therefore, percent weight loss is calculated between day
zero (prior to drug administration) and day two following intraperitoneal administration of
saline, PG (15mg/kg), PZ (15mg/kg), or HZ (5mg/kg) on day zero and day one.
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Figure 5.2 Monoamine and metabolite CCI time course experimental design. Rats
received severe a CCI (TBI). Cortical punches were collected from penumbral tissue
lateral to the injury epicenter at 3h, 12h, and 24h following injury. Sham tissue was
collected 12h following sham surgery. Tissue was sent for HPLC analysis.
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Results
24h Single Dose PG, PZ, or HZ: HPLC Monoamine and Metabolite Tissue Levels
and Turnover Ratios in Uninjured Cortical Tissue (Fig. 5.3 – 5.5)
For norepinephrine (NE), a single saline sample was identified as an outlier
(Grubb’s) and excluded (G = 2.009, Y = 6). For NE, a one-way ANOVA revealed a
statistically significant effect across all groups (F[3,19] = 15.74, p < 0.0001). However,
Brown-Forsythe revealed an inequality of variance (p = 0.0002). Therefore, KruskalWallis was used in lieu of a one-way ANOVA. KW revealed a significant effect across all
groups (H[3, n = 23] = 15.33, p = 0.0016). Post-hoc testing (Dunn’s) revealed that
compared with saline, NE (ng/g) was significantly increased in PZ (p<0.05) and PG
(p<0.05), and that compared with HZ, NE (ng/g) was significantly increased in PZ
(p<0.05) (Fig. 5.3). Thus, PZ and PG result in an increase in NE.
For the analysis of 5-HT and 5-HT metabolites, during 5-HIAA analysis, a single
PZ sample was identified as an outlier (Grubb’s) and excluded (G = 1.903, Y = 6). In
order to maintain consistency and be able to calculate the 5-HIAA/5-HT ratio, this PZ
animal was excluded from the entire 5-HT data set.
For serotonin (5-HT), a one-way ANOVA revealed a statistically significant effect
across all groups (F[3,19] = 28.13, p < 0.0001). Post-hoc testing (Tukey’s) revealed that
compared with saline, 5-HT (ng/g) was significantly increased in PZ (p<0.0001) and PG
(p<0.01), and that compared with HZ, 5-HT (ng/g) was significantly increased in PZ
(p<0.0001) and PG (p<0.05), and that PZ and PG were significantly different from each
other (p<0.01) (Fig. 5.4A).Thus, PZ and PG result in an increase in 5-HT. However, the
increase in 5-HT is greater with PZ.
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Figure 5.3 Tissue Level (ng/g) of norepinephrine (NE) in 24h uninjured cortex. NE
measured via HPLC 24h following single intraperitoneal injection of saline, pargyline
(PG), phenelzine (PG) or hydralazine (HZ). Values= median ± interquartile range;
Kruskal-Wallis followed by Dunn post hoc; *p < 0.05 compared with saline; #p < 0.05
compared with HZ; n = 5-6 per group.
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Figure 5.4 Tissue Level (ng/g) of serotonin (5-HT) and metabolites in 24h uninjured
cortex. (A) 5-HT, (B) the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA), (C) and
the turnover ratio (5-HIAA / 5-HT) in uninjured cortex as measured via HPLC 24h
following single intraperitoneal injection of saline, pargyline (PG), phenelzine (PG) or
hydralazine (HZ). Values = mean ± standard deviation; one-way analysis of variance
followed by Tukey post hoc; **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with
saline; #p < 0.05, ###p < 0.001, ####p < 0.0001 compared with HZ; ^^p < 0.01, n = 5-6 per
group.
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Figure 5.5 Tissue Level (ng/g) of dopamine (DA) and metabolites in 24h uninjured
cortex. (A) DA, (B) the DA metabolite 3,4 5-dihydroxyphenylacetic acid (DOPAC), (C)
the DA metabolite homovanillic acid (HVA), and the DA turnover ratios (D) (DOPAC +
HVA / DA, (E) DOPAC / DA, and (F) HVA / DA in uninjured cortex as measured via
HPLC 24h following single intraperitoneal injection of saline, pargyline (PG), phenelzine
(PG) or hydralazine (HZ). Values = mean ± standard deviation; one-way analysis of
variance followed by Tukey post hoc; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
compared to saline; #p < 0.05, ##p < 0.01, ####p < 0.0001 compared to HZ; n = 4-6 per
group.
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For 5-hydroxyindoleacetic acid (5-HIAA), a one-way ANOVA revealed a
statistically significant effect across all groups (F[3,19] = 17.74, p < 0.0001). Post-hoc
testing (Tukey’s) revealed that compared with saline, 5-HIAA (ng/g) was significantly
decreased in PZ (p<0.001) and PG (p<0.001), and that compared with HZ, 5-HIAA
(ng/g) was significantly decreased in PZ (p<0.001) and PG (p<0.001)(Fig. 5.4B). Thus,
both PZ and PG result in a decrease in the 5-HT metabolite, 5-HIAA.
For the ratio 5-HIAA / 5-HT, a one-way ANOVA revealed a statistically significant
effect across all groups (F[3,18] = 46.37, p <0.0001). Post-hoc testing (Tukey’s) revealed
that compared with saline, the ratio 5-HIAA / 5-HT was significantly decreased in PZ
(p<0.0001) and PG (p<0.0001), and that compared with HZ, the ratio 5-HIAA / 5-HT was
significantly decreased in PZ (p<0.0001) and PG (p<0.0001)(Fig. 5.4C). Thus, PZ and
PG result in a decrease in 5-HT turnover to 5-HIAA (i.e. increase in monoamine oxidase
inhibition).
Prior to statistical analysis, due to undetectable HVA levels, two animals were
removed from the PZ group for all analysis of DA and DA metabolites. Additionally,
during HVA statistical analysis, a saline sample (G = 1.995, Y = 6) and PG sample (G =
2.2027, Y =6) were identified as an outliers (Grubb’s) and excluded. In order to maintain
consistency and be able to calculate DA metabolite/DA turnover ratios, these animals
were further excluded from the entire DA data set.
For dopamine (DA), a one-way ANOVA revealed a statistically significant effect
across all groups (F[3,16] = 9.424), p = 0.0008). Post-hoc testing (Tukey’s) revealed that
compared with saline, dopamine (ng/g) was significantly increased in PZ (p<0.05) and
PG (p<0.01), and that compared with HZ, dopamine (ng/g) was significantly increased in
PZ (p<0.05) and PG (p<0.01)(Fig. 5.5A). Thus, PZ and PG result in an increase in DA.
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For 3,4-dihydroxyphenylacetic acid (DOPAC), a one-way ANOVA revealed a
statistically significant effect across all groups (F[3,16]) = 12.17, p = 0.0002). Post-hoc
testing (Tukey’s) revealed that compared with saline, DOPAC (ng/g) was significantly
decreased in PZ (p<0.001) and PG (p<0.01), and that compared with HZ, DOPAC (ng/g)
was significantly decreased in PZ (p<0.01) and PG (p<0.05)(Fig. 5.5B). Thus, PZ and
PG result in a decrease in the DA metabolite, DOPAC.
For homovanillic acid (HVA), a one-way ANOVA did not reveal a statistically
significant effect across all groups (F[3,16] = 0.1774, p = 0.9101)(Fig. 5.5C). Thus, PZ,
PG, nor HZ affected HVA levels.
For the ratio (HVA + DOPAC) / DA, a one-way ANOVA revealed a statistically
significant effect across all groups (F[3,16] = 80.58, p < 0.0001). Post-hoc testing
(Tukey’s) revealed that compared with saline, the ratio (HVA + DOPAC) / DA was
significantly decreased in PZ (p<0.0001), HZ (p<0.05) and PG (p<0.0001), and that
compared with HZ, the ratio (HVA + DOPAC) / DA was significantly decreased in PZ
(p<0.0001) and PG (p<0.0001) (Fig. 5.5D). Thus, PZ, PG, and HZ result in a decrease
in DA turnover to HVA+DOPAC (i.e. increase in monoamine oxidase inhibition).
However, PZ and PG do so to a greater degree.
For the ratio DOPAC / DA, a one-way ANOVA revealed a statistically significant
effect across all groups (F[3,16] = 83.17, p < 0.0001). Post-hoc testing (Tukey’s)
revealed that compared with saline, DOPAC / DA was significantly decreased in PZ
(p<0.0001), HZ (p<0.05), and PG (p<0.0001), and that compared with HZ, DOPAC / DA
was significantly decreased in PZ (p<0.0001) and PG (p<0.0001)(Fig. 5.5E). Thus, PZ,
PG, and HZ result in a decrease in DA turnover to DOPAC (i.e. increase in monoamine
oxidase inhibition). However, PZ and PG do so to a greater degree.
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For the ratio HVA / DA, a one-way ANOVA did not reveal a statistically significant
effect across all groups (F[3,16] = 0.8669, p = 0.4785)(Fig. 5.5F). Thus, PZ, PG, nor HZ
affected DA turnover to HVA.
CCI Time Course HPLC Monoamine and Metabolite Tissue Levels and Turnover
Ratios in Penumbral Cortical Tissue (Fig. 5.6 – 5.8)
For NE, a one-way ANOVA revealed a statistically significant effect across all
groups (F[3,20] = 31.91, p < 0.0001). However, Brown-Forsythe revealed an inequality
of variance (p = 0.0152). Therefore, Kruskal-Wallis was used in lieu of a one-way
ANOVA. KW revealed a significant effect across all groups (H[3, n = 24] = 18.63, p =
0.0003). Post-hoc testing (Dunn’s) revealed that compared with sham NE (ng/g) was
significantly decreased at 3h (p < 0.05) and 24h (p < 0.001) post-injury (Fig. 5.6). Thus,
following CCI NE is decreased at 3h and 24h.
For 5-HT, a one-way ANOVA revealed a statistically significant effect across all
groups (F[3,20] = 21.29, p < 0.0001). However, Brown-Forsythe revealed an inequality
of variance (p = 0.0324). Therefore, Kruskal-Wallis was used in lieu of a one-way
ANOVA. KW revealed a significant effect across all groups (H[3, n = 24] = 15.65, p =
0.0013) Post-hoc testing (Dunn’s) revealed that compared with sham 5-HT (ng/g) was
significantly decreased at 3h (p < 0.05) and 24h (p < 0.01) post-injury (Fig. 5.7A). Thus,
following CCI 5-HT is decreased at 3h and 24h.
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Figure 5.6 Tissue Level (ng/g) of norepinephrine (NE) in penumbral cortical tissue
measured via HPLC 3h, 12h, and 24h following severe CCI. Values= median ±
interquartile range; Kruskal-Wallis followed by Dunn post hoc; *p < 0.05 ***p < 0.00
compared with sham; n = 6 per group.
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Figure 5.7 Tissue Level (ng/g) of serotonin (5-HT) and metabolites in penumbral
cortical tissue measured via HPLC 3h, 12h, and 24h following severe CCI (A) 5-HT,
(B) the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA), (C) and the turnover ratio
(5-HIAA / 5-HT). Values= median ± interquartile range; Kruskal-Wallis followed by Dunn
post hoc; *p < 0.05, **p < 0.01 compared with sham; n = 5-6 per group.
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Figure 5.8 Tissue Level (ng/g) of dopamine (DA) and metabolites in penumbral
cortical tissue measured via HPLC 3h, 12h, and 24h following severe CCI (A) DA, (B)
the DA metabolite 3,4 5-dihydroxyphenylacetic acid (DOPAC), (C) the DA metabolite
homovanillic acid (HVA), and the DA turnover ratios (D) (DOPAC + HVA) / DA, (E)
DOPAC / DA, and (F) HVA / DA. Values = mean ± standard deviation; one-way analysis
of variance followed by Tukey post hoc; *p < 0.05, **p < 0.01, ***p < 0.001 compared
with sham; #p < 0.05 compared with 12h; n = 3-5 per group.
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For 5-HIAA, a one-way ANOVA revealed a statistically significant effect across all
groups (F[3,20] = 8.059, p = 0.001). However, Brown-Forsythe revealed an inequality of
variance (p = 0.0001). Therefore, Kruskal-Wallis was used in lieu of a one-way ANOVA.
KW revealed a significant effect across all groups (H[3, n = 24] = 13.98, p = 0.0029).
Post-hoc testing (Dunn’s) revealed that compared with sham 5-HIAA (ng/g) was
significantly decreased 3h (p < 0.01) (Fig. 5.7B) post-injury. Thus, following CCI the 5HT metabolite 5-HIAA is decreased at 3h.
For the ratio 5-HIAA / 5-HT, a single 3h sample was identified as an outlier
(Grubb’s) and excluded (G = 1.922, Y = 6). For the ratio 5-HIAA / 5-HT, a one-way
ANOVA revealed a statistically significant effect across all groups (F[3,19) = 6.91, p =
0.0025). However, Brown-Forsythe revealed an inequality of variance (p = 0.0365).
Therefore, Kruskal-Wallis was used in lieu of a one-way ANOVA. KW revealed a
significant effect across all groups (H[3, n = 23] = 11.76, p = 0.0082). Post-hoc testing
(Dunn’s) revealed that the 5-HIAA / 5-HT at 24h was significantly increased compared
with sham (p < 0.01)(Fig. 5.7C). Thus, following CCI there is an increase in the 5-HT
turnover to 5-HIAA at 24h.
Prior to statistical analysis, due to undetectable HVA levels, one animal was
removed from the 3h group and two animals were removed from the 12h group for all
analysis of DA and DA metabolites. Additionally, during DA statistical analysis, a sham
sample (G = 1.908, Y = 6) and 24h sample (G = 2.009 Y =6) were identified as outliers
(Grubb’s) and excluded. In order to maintain consistency and be able to calculate DA
metabolite/DA turnover ratios, these animals were further excluded from the entire DA
data set. During HVA statistical analysis, a sham sample (G = 1.759, Y = 5) and a 12h
sample (G 1.653, Y = 4) were identified as outliers (Grubb’s) and excluded. In order to
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maintain consistency and be able to calculate DA metabolite/DA turnover ratios, these
animals were further excluded from the entire DA data set.
For DA, a one-way ANOVA revealed a statistically significant effect across all
groups (F[3,13] = 12.01, p = 0.0005). Post-hoc testing (Tukey’s) revealed that compared
with sham DA (ng/g) was significantly decreased at 3h (p < 0.01) and 24h (p < 0.001)
post-injury. Additionally, DA (ng/g) was significantly decreased at 24h (p < 0.05)
compared with 12h post-injury (Fig. 5.8A). Thus, following CCI DA is decreased at 3h
and 24h.
For DOPAC, a one-way ANOVA revealed a statistically significant effect across
all groups (F[3,13] = 11.5, p = 0.0006). Post-hoc testing (Tukey’s) revealed that
compared to sham DOPAC (ng/g) was significantly decreased at 3h (p < 0.01), 12h (p <
0.05), and 24h (p < 0.001) post-injury (Fig. 5.8B). Thus, following CCI the DA metabolite
DOPAC is decreased at 3h, 12h, and 24h.
For HVA, a one-way ANOVA did not reveal a statistically significant effect across
all groups (F[3,13] = 1.633, p =0.2300) (Fig. 5.8C). Thus, the DA metabolite HVA
remains unchanged following CCI.
For the ratio (HVA + DOPAC) / DA, a single 24h sample was identified as an
outlier (Grubb’s) and excluded (G = 1.771, Y = 5). For the ratio (HVA + DOPAC) / DA, a
one-way ANOVA did not reveal a statistically significant effect across all groups (F[3,12])
= 0.6453, p = 0.6006) (Fig 5.8D). Thus, the turnover of DA to HVA+DOPAC remains
unchanged following CCI.
For the ratio DOPAC / DA, a single 24h sample was identified as an outlier
(Grubb’s) and excluded (G = 1.754, Y = 5). For the ratio DOPAC / DA, a one-way
ANOVA did not reveal a statistically significant effect across all groups (F[3,12]) =
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0.5785, p = 0.6402) (Fig. 5.8E). Thus, the turnover of DA to DOPAC remains unchanged
following CCI.
For the ratio HVA / DA, a single 24h sample was identified as an outlier (Grubb’s)
and excluded (G = 1.768, Y = 5). For the ratio HVA / DA, a one-way ANOVA did not
reveal a statistically significant effect across all groups. (F[3,12] = 1.1782, p = 0.2040
(Fig. 5.8F). Thus, the turnover of DA to HVA remains unchanged following CCI.
Percent Weight Loss in Uninjured Rats Following PG, PZ, or HZ Administration
(HPLC Experiments) (Fig. 5.9)
For the 72h triple dose HPLC monoamine and metabolite uninjured cortical
tissue experiment a final weight for animals was taken at time 48h following
intraperitoneal administration of saline, PG, PZ, or PG at time 0h and 24h for a total to
two injections (Fig. 4.3). Animals were not weighed at the time of euthanasia (72h) and
therefore had not received the third/final injection (48h) at the time of final weigh-in. For
percent weight loss in uninjured rats between D0 (before first injection) and D2 (after
second injection), a one-way ANOVA revealed a statistically significant effect across all
groups (F[3, 20] = 5.157, p = 0.0084).

Post-hoc testing (Tukey’s) revealed that

compared to the saline group (p < 0.01) and the PG group (p < 0.05), PZ lost a
significant amount of weight.
Thus indicating that intraperitoneal administration of PZ (15mg/kg) at 0h and 24h
leads to significant weight loss at 48h in uninjured animals.
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Figure 5.9 Percent weight loss in uninjured animals for 72h HPLC experiment.
Percent weight loss in uninjured rats between D0 (before first injection) and D2 (after
second injection). Animals were not weighed following third/final injection prior to
euthanasia. Values mean ± standard deviation; one-way analysis of variance followed
by Tukey post hoc; *p < 0.05, ** p < 0.01 compared with PZ; Saline, PG = pargyline, PZ
= phenelzine, HZ = hydralazine; n = 6 per group.
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Discussion and Conclusion
24h Single Dose PG, PZ, or HZ: HPLC Monoamine and Metabolite Tissue Levels
and Turnover Ratios in Uninjured Cortical Tissue
Overall these results indicate that 24h following a single intraperitoneal injection
of the MAOIs PG (15mg/kg) and PZ (15mg/kg) there is significant MAO inhibition in
uninjured cortical tissue as evidenced by the significant decrease in both 5-HT turnover
(Fig 5.4C) and DA turnover (Fig 5.5D-F), as well as the significant increase in the tissue
level of the MAO substrate NE (Fig 5.3). Additionally, the non-MAO HZ (5 mg/kg) also
led to a significant decrease in DA turnover (Fig. 5.5D-F), likely due to a MAO effect as
the significant decrease in DA turnover is seen in the ratios that contain the MAO
product DOPAC (Fig. 5.5D-E). Interestingly, this is different than what was seen
following the triple dosing HPLC experiments (Fig. 4.3), in which HZ led to a significant
decrease in 5-HT turnover (Fig. 4.6C). However, it is likely still explained by the fact that
HZ has previously been demonstrated to have reversible MAO inhibitory effects with a
preference toward MAO-A [269]. As stated previously, NE and 5-HT are selectively
metabolized by MAO, and although DA can be metabolized by either MAO isoform, the
majority of DA in rats is metabolized by MAO-A [186].
There are several other important differences found between the single and triple
dosing paradigms in regard to monoamine and metabolite tissue levels. First, continuing
with DA, the 24h single injection dosing paradigm (Fig 5.1) led to a significant increase
in DA tissue level (Fig 5.5A), whereas the 72h triple injection dosing paradigm (Fig.
4.7A) did not, despite having a significant effect on DA turnover (Fig. 4.7D-F). It is
unknown why this is, but as stated previously, the results obtained in Fig. 4.7A may be
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due to some type of compensatory effect [349], which was not affected by the single
dose administrations (Fig 5.5A).
Further, although direct statistical comparisons were not done, three doses of PZ
or PG (Fig 4.3) caused more monoamine oxidase inhibition than single doses (Fig. 5.1).
For example, in regards to NE a single dose of PG or PZ led to a mean (± standard
deviation) tissue level (ng/g) of 852.90 ± 57.23 and 980.10 ± 186.30, respectively,
whereas three doses of PG or PZ led to a mean (± standard deviation) tissue level (ng/g)
of 940.2 ± 90.58 and 1155 ± 242.9, respectively. In regards to 5-HT, a single dose of PG
or PZ led to a mean (± standard deviation) tissue level (ng/g) of 394.10 ± 87.92 and
580.60 ± 69.98, respectively, whereas three doses of PG or PZ led to a mean tissue
level of 499.20 ± 49.01 and 855.00 ± 180.00, respectively. In regards to 5-HT turnover, a
single dose of PG or PZ led to a mean (± standard deviation) turnover ratio of 0.57 ±
0.18 and 0.34 ± 0.08, respectively, whereas three doses of PG or PZ led to a mean (±
standard deviation) turnover ratio of 0.28 ± 0.03 and 0.13 ± 0.04, respectively. Further,
this effect is most evidenced in the (DOPAC + HVA) / DA turnover ratios in which a
single dose of PG or PZ led to a mean (± standard deviation) turnover ratio of 0.54 ±
0.29 and 0.39 ± 0.16, respectively, whereas three doses of PG or PZ led to a mean (±
standard deviation) turnover ratio of 0.053 ± 0.013 and 0.035 ± 0.002, respectively. In
fact, the change in DA turnover ratios were so great between the single and triple dosing
paradigms that the scale of the x-axis in the triple dosing paradigm (Fig. 4.7D-F) had to
be decreased by a factor of 4 from the scale of the x-axis for the single dosing paradigm
(Fig. 5.5D-F). However, it should be noted that this was also true for the saline and HZ
groups as well (Fig. 4.7 and Fig. 5.5). Therefore, it is possible that the very large
change in DA turnover seen between the single dosing paradigm (Fig. 4.7D-F) and triple
dosing paradigm (Fig. 4.7D-F) may be due to a technical or collection issue between
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HPLC experiments or due to the total number of injections given (1 vs 3), as stress has
been shown to increase endogenous inhibition of monoamine oxidase [379]. However,
the latter may not be the case because the effect of saline on NE (Fig. 4.5 and Fig. 5.3)
and 5-HT (Fig. 4.6 and Fig. 5.4) do not widely differ between the single and triple dosing
paradigms.
CCI Time Course HPLC Monoamine and Metabolite Tissue Levels and Turnover
Ratios in Penumbral Cortical Tissue
As discussed in “Chapter Four” the PZ dosing paradigm utilized in the current
study had previously been shown to be not only safe but beneficial in non-CCI models
such as SCI and ischemic-reperfusion injury [74, 76]. However, as shown in “Chapter
Four”, for the current study the PZ dosing paradigm utilized was not only unable to
improve reference memory (Fig. 4.10) or cortical tissue sparing (Fig. 4.12), but it also
led to significant weight loss (Fig. 4.11), qualitative behavioral concerns, and PZ animals
were unable to make significant improvements during the MWM acquisition phase (Fig.
4.8). One possible explanation for these findings is that after severe CCI monoamine
levels are significantly elevated or monoamine oxidase is significantly inhibited, and that
administration of PZ after injury, particularly multiple doses of PZ, is exacerbating these
effects, leading to negative consequences. Therefore, we hypothesized that over the first
24h following CCI monoamine tissue levels would be significantly elevated and
monoamine turnover ratios would be significantly decreased.
However, the results indicate the contrary. In fact, at 3h and 24h after severe CCI
the monoamines NE (Fig. 5.6), 5-HT (Fig. 5.7A), and DA (Fig. 5.8A), are significantly
decreased compared with sham. Interestingly, there was not a significant difference in
any of the neurotransmitter tissue levels between sham and the 12h post-CCI time point.

242

This is similar to other post-CCI processes such as mitochondrial dysfunction which
increase 3h after CCI before recovering and then beginning to decline again at 24h [73].
However, it should be noted that all sham tissue was collected at the midway time point
of 12h (Fig. 5.2). It is therefore possible that technical or tissue collection issues could
have also influenced these results.
In regards to monoamine turnover (i.e. MAO inhibition), the only significant
change from sham was seen at 24h in which there was an increase in 5-HT turnover to
5-HIAA (Fig. 5.7C). However, as both a significant decrease in tissue level of 5-HT (Fig.
5.7A) and a non-significant decrease in tissue level of the 5-HT metabolite, 5-HIAA (Fig.
5.7B) were also seen at this time point the increase in the 5-HIAA / 5-HT ratio is likely
due to the larger of the two decreases being seen in the denominator (5-HT). Although it
is possible the significant increase seen in the 5-HIAA / 5-HT ratio 24h post-CCI is in fact
due to an decrease in MAO inhibition, the more likely explanation is that due to injury 5HT has been depleted or serotonergic neurons have degenerated in the penumbral area
analyzed, whereas the metabolite 5-HIAA has not been removed to a such a degree.
Additionally, it should be noted that 5-HT may come from other sources, such as platelet
activation. However, platelets only contain MAO-B [380], whereas MAO-A selectively
metabolizes 5-HT [186], so platelets should not be a large source of the 5-HT metabolite
5-HIAA.
Although our data did not indicate any CCI-induced monoamine elevations, it
should be noted that this study was limited to analysis of the penumbral tissue directly
lateral to the epicenter of injury. It is possible that other brain regions would have shown
increases either in monoamine tissue levels or MAO inhibition as previous studies have
demonstrated that tissue levels of monoamines vary after experimental TBI depending
region [154, 173, 174, 178, 182, 363-365]. It is also possible that increases in tissue
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levels of monoamines or MAO inhibition occur at later time points still relevant to our CCI
+ drug studies (Fig. 4.4), such as 48h-72h post-CCI. However, we forewent conducting
experiments at these later time points based upon the results obtained over the first 24h
(Fig. 5.6-5.8).
Percent Weight Loss in Uninjured Rats Following PG, PZ, or HZ Administration
(HPLC Experiments)
Overall the results indicate that in uninjured animals two doses of PZ led to a
significant amount of weight loss compared with both saline and PG. Although HZ also
led to weight loss, it was not significant (Fig. 5.9). This is similar to what was seen in
CCI, in which three doses of PZ led to a significant amount of weight loss following
MWM compared with all other groups including sham, vehicle (saline), PG and HZ (Fig.
4.11). As stated previously in regard to PZ it is possible that the weight loss seen in the
current experiment was due to an increase in monoamine levels (Fig. 4.5 and 4.6A), as
monoamines are capable of inducing weight loss through a variety of mechanisms [350],
an effect which has been previously seen with non-PZ MAOIs [158, 351]. However, as
weight loss was not observed in the other MAOI group, PG, it is possible that PZ causes
weight loss through another mechanism, such as formation of the metabolite,
phenethylamine (PEA) [189], itself an MAO substrate with amphetamine-like stimulatory
effects [207].
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CHAPTER SIX:
Final Discussion and Concluding Remarks
Summary of Results and Conclusions
TBI represents a significant health crisis in the United States and worldwide.
However, currently there are no FDA-approved pharmacological agents capable of
attenuating the devastating neurologic consequences that occur after TBI [1]. As central
mediators of the TBI secondary injury cascade, mitochondria and LP-derived neurotoxic
aldehydes, such as 4-HNE and acrolein, make promising therapeutic targets (Fig 1.2). In
fact, CsA, an FDA-approved immunosuppressant capable of inhibiting the mPTP has
been shown to be neuroprotective in experimental TBI [110, 122-124, 135, 136, 223227]. Additionally, PZ, an FDA-approved non-selective irreversible MAOI-class
antidepressant has also been shown to be neuroprotective in experimental TBI due to
the presence of a hydrazine (-NH-NH2) moiety allowing for the scavenging of LP-derived
neurotoxic aldehydes [71, 72, 334].
Due to the complex pathophysiology that occurs following TBI it is imperative that
robust neuroprotective drugs be developed. It is possible that robust neuroprotection
could

be

achieved

through

effective

targeting

of

vulnerable

mitochondrial

subpopulations, such as synaptic mitochondria, the combining of two partially
neuroprotective drugs, or through use of single agents which have dually protective
mechanisms of action. Therefore, the overall goal of this dissertation was to further
examine the neuroprotective efficacy of the mPTP inhibitor CsA and the LP-derived
neurotoxic aldehyde scavenger PZ using a severe CCI model in 3-month old male
Sprague-Dawley rats. Specifically, we evaluate 1) the protective effects of CsA on
isolated synaptic and non-synaptic mitochondria, 2) the ability of a novel 72h
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subcutaneous continuous infusion of PZ combined with CsA to improve mitochondrial
respiration,

attenuate

mitochondria-aldehyde

conjugate

formation,

and

prevent

cytoskeletal spectrin degradation compared to monotherapy, and 3) the effects of PZ
(MAOI, aldehyde scavenger) on learning and memory and cortical tissue sparing
following CCI compared to the effects of PG (MAOI, non-aldehyde scavenger) and HZ
(non-MAOI, aldehyde scavenger).
Synaptic Mitochondria Sustain More Damage than Non-Synaptic Mitochondria
after Traumatic Brain Injury and are Protected by Cyclosporine A
In order to test the hypothesis that CsA has a differential protective effect on
isolated synaptic and non-synaptic mitochondrial bioenergetics following experimental
TBI, 3mo male Sprague-Dawley rats were administered an intraperitoneal dose of CsA
(20mg/kg) 15min after a severe controlled cortical impact injury (2.2mm), cortical
synaptic and non-synaptic mitochondria were isolated 24h post-CCI, and respiratory
rates were measured using a Clark-type oxygen electrode.
Results indicate that 24h after severe CCI synaptic mitochondria are more
damaged than non-synaptic mitochondria, particularly in regard to RCR (Fig. 2.4). In
fact, statistical analysis revealed a significant interaction between injury and population
for this measure, indicating that synaptic mitochondria are indeed more susceptible to
injury. There are several possibilities for why synaptic mitochondria are more vulnerable
to injury than non-synaptic mitochondria, including increased susceptibility to calciuminduced permeability transition due to high cyclophilin D content [38], increased
exposure to oxidative damage [37, 38], and decreased respiratory chain activity and
subunit content [296]. Further, non-synaptic mitochondria can tolerate larger
impairments to respiratory complex activity before ATP production is significantly
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decreased [35].

Impressively, these results also indicate that the more significantly

damaged synaptic mitochondria are protected by intraperitoneal administration of CsA
(20mg/kg) 15min post-CCI (Fig. 2.1 – 2.6). In fact, significant protection is achieved for
respiratory states II (Fig. 2.1), III (Fig. 2.2), V(II) (Fig. 2.6), and the RCR (Fig. 2.4).
Additionally, CsA improved non-synaptic respiration (Fig. 2.1 – 2.6). However, the
improvements were non-significant likely due to the fact non-synaptic mitochondria are
less severely damaged 24h after severe CCI (Fig. 2.4) [322].
This was the first study to investigate the effects of CsA on isolated and purified
synaptic and non-synaptic mitochondria after experimental TBI and the results are
important for several reasons. First, synaptic mitochondria represent a more purely
neuronal population [37-39], have been implicated in neuronal and synaptic
degeneration absent overt cell death [37, 48, 49], and are essential for proper
neurotransmission and synaptic plasticity [44-46]. Therefore, it is critically important that
synaptic mitochondrial function be protected after TBI. Yet, synaptic mitochondria are
more vulnerable to damage after experimental TBI [41, 322] and previous studies in SCI
have demonstrated that synaptic mitochondria often respond less favorably to
pharmaceutical intervention than their non-synaptic counterparts [50]. As such, the
ability of a previously optimized CsA dose [225, 294] to significantly protect the more
vulnerable synaptic mitochondria population after experimental TBI, despite high
cyclophilin D concentrations (i.e. CsA binding partner) [37], strengthens the growing
body of evidence that CsA is protective in TBI and that its clinical translation should be
pursued.
In fact, several clinical trials have shown that CsA is safe for use in patients with
severe TBI with a trend toward improved outcomes [234, 235]. Unfortunately, due a
biphasic dose-response curve [227] and concerns over the toxicity of cremophor, the
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vehicle in which the currently available commercial preparation of CsA (Sandimmune®)
is provided, [381, 382], larger CsA clinical trials have not been conducted. Although
concerns over cremophor toxicity may be overblown and limited to chronic or in-vitro
administrations [300-302], recently a novel cremophor-free lipid emulsion CsA
preparation (NeuroSTAT®) was shown to be neuroprotective in a porcine model of TBI
[381] as well to be bioequivalent to Sandimmune®. Therefore, future clinical trials
investigating the neuroprotective effects of the non-cremophor CsA preparation
NeuroSTAT® are planned [383].
As future clinical trials investigating the neuroprotective effects of CsA in TBI are
likely to use non-cremophor preparations of CsA, the use of cremophor-CsA in the
current study does represent a limitation and future experimental TBI studies of CsA
may want to consider alternately using non-cremophor CsA. This study was additionally
limited by several other factors such as the inability to further separate non-synaptic
mitochondria into neuronal and non-neuronal cell types. Previous studies have
demonstrated that mitochondria isolated from cultured neurons and glia have differing
properties [38, 296]. Therefore, it is likely that in regards to synaptic mitochondria, the
results of this study were influenced both by cell type (neuronal) and subcellular location
(pre-synaptic). As techniques to isolate mitochondria from various cell types improve,
future studies could offer insight into the differential properties of synaptic neuronal vs
non-synaptic neuronal vs non-neuronal mitochondrial populations following experimental
TBI, as well as their response to CsA. Additionally, this study was limited to one outcome
measure (i.e. respiration), time point (i.e. 24h post-CCI), and dosing paradigm (20mg/kg
CsA i.p. 15min post-CCI). Utilization of additional outcome measures such as calcium
buffering capacity, enzyme activity, or formation of aldehyde-mitochondrial conjugates
could have offered more specific insight into the differential effects of CCI and CsA on
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synaptic and non-synaptic mitochondrial function. Further, evaluation of synaptic and
non-synaptic mitochondrial function at a later time point, such as 48h, in which nonsynaptic mitochondria have sustained further damaged [322], may have shown CsA to
have an enhanced protective effect on the non-synaptic mitochondrial population. Last,
delaying CsA administration beyond 15min post-CCI may have revealed that synaptic
and non-synaptic mitochondria have different therapeutic windows, an effect which has
been previously seen in SCI [50], and one which may explain the finding that although
CsA remains neuroprotective when administration is delayed 8h, it is most effective
when administered within 3h of TBI [122].
Continuous Infusion of Phenelzine, Cyclosporine A, or Their Combination:
Evaluation of Mitochondrial Bioenergetics, Oxidative Damage, and Cytoskeletal
Degradation Following Severe Controlled Cortical Impact Traumatic Brain Injury in
Rats
To date all monotherapy clinical trials for TBI have failed [1]. Based upon the
complex secondary injury cascade that occurs following TBI combinational therapies
may offer more complete neuroprotection after injury than single agent therapies [213].
Therefore, the purpose of this study was to test the hypothesis that a 72h subcutaneous
continuous infusion of PZ combined with CsA would improve mitochondrial respiration,
attenuate formation of LP-derived aldehyde mitochondrial protein conjugates, and
maintain cytoskeletal integrity following experimental TBI to a greater degree than
monotherapy. Following a severe controlled cortical impact injury (2.2mm) in 3mo male
Sprague-Dawley rats, subcutaneous osmotic pumps containing PZ (10mg/kg/day/3d),
CsA (10mg/kg/day/3d), or PZ + CsA were implanted. Animals also received loading
doses of PZ (10mg/kg s.c.), CsA (20mg/kg i.p.), or PZ + CsA 15min post-CCI (Table
3.1). At 72h post-injury cortical mitochondria (total) respiratory rates were assessed
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using a Clark-type oxygen electrode and cortical mitochondria (total) bound 4-HNE and
acrolein were assessed using Western blot. Additionally, Western blot was used to
assess cortical tissue for 145kD (calpain-only) and 150kD (calpain/caspase 3) αIIspectrin breakdown as a marker for cytoskeletal integrity. Further, Western blot of
spectrin breakdown products was used to compare a 72h subcutaneous continuous
infusion PZ dosing paradigm to a dosing paradigm in which bolus PZ doses were
administered every 12h over the first 72h following CCI (Table 3.2).
Our results (Table 3.3) indicate that a 72h subcutaneous continuous infusion of
PZ (10 mg/kg subcutaneous loading dose 15 min post-injury + 10 mg/kg/day
subcutaneous infusion of PZ for 3 days) maintained mitochondrial RCR and cytoskeletal
integrity, and decreased binding of 4-HNE and acrolein to mitochondrial proteins 72h
following severe CCI. In fact, continuous infusion of PZ was able to maintain cytoskeletal
integrity, whereas 12hr intermittent dosing of PZ was not (10 mg/kg PZ subcutaneous
loading dose 15 min post-injury + 5 mg/kg PZ subcutaneous maintenance bolus every
12h up to and including 60h) was not. Additionally, continuous infusion of CsA (20
mg/kg CsA intraperitoneal loading dose 15 min post-injury + 10 mg/kg/day subcutaneous
infusion of CsA for 3 days) decreased binding of 4-HNE and acrolein to mitochondrial
proteins. Although the combination of PZ + CsA was able to maintain cytoskeletal
integrity, it did so to a similar degree as PZ alone, suggestive of a purely PZ effect, and
was unable to attenuate other outcome measures. In fact, once combined the protective
effect PZ and CsA individually had on formation of mitochondrial bound 4-HNE and
acrolein was lost.
Although enhanced protection was not seen with the combination PZ + CsA and
the protection that was seen with each individual therapy was limited, it should be noted
that this study had several limitations. First, only one dosing paradigm was investigated.
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This study was designed to combine an optimized CsA dosing paradigm [122] with a PZ
dosing paradigm previously demonstrated to be neuroprotective in experimental TBI
[72]. However, the results were similar to previous combinational therapy studies in
which utilization of drug doses optimized for monotherapy did not result in enhanced
protection once combined [280]. A better approach likely would have been to either
combine sub-therapeutic doses of PZ and CsA or to conduct a dose-response of the
combined therapy.
Second, the study was limited to one time point (i.e. 72h post-CCI) and only a
few biochemical outcome measures (i.e. total mitochondrial respiration, mitochondriaaldehyde conjugate formation, spectrin degradation). It is possible that a greater degree
of neuroprotection was achieved with the dosing paradigms utilized, but that such
neuroprotection was not seen in the specific outcome measures evaluated. For example,
as the CsA dosing paradigm utilized has previously been shown to improve cortical
tissue sparing [225, 294], it is possible that the same dosing paradigm did have a
protective effect on mitochondrial respiration, but that the effect was masked in the total
mitochondrial preparations (synaptic and non-synaptic mitochondria) because CsA has a
greater effect on synaptic mitochondria than non-synaptic mitochondria (Fig. 2.1 – 2.6)
[309], but at 72h post-injury synaptic mitochondria make up a minority of the
mitochondrial population [121, 128, 321]. On the other hand, the inability of CsA to
improve mitochondrial respiration makes sense physiologically as CsA inhibition of the
mPTP allows mitochondria to sequester calcium, causing the mitochondrial membrane
potential to decrease and respiration to slow. Although neither of these scenarios may
be the case, as continuous infusion of CsA was also unable to prevent cytoskeletal αspectrin degradation (Fig. 3.5). However, it should be noted that pharmacologicdependent neurologic improvements have been documented absent attenuation of
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spectrin degradation [132]. Further, based upon the preponderance of studies
demonstrating CsA to be protective in experimental TBI, including its effects on synaptic
mitochondria (Fig. 2.1 – 2.6) [309], we do not believe the absence of protective effects
seen here preclude its future development as a translational therapy for TBI.
Similar to CsA, it is possible that the mitochondria isolation technique utilized has
also masked PZ protective effects to individual states of mitochondria respiration. For
example, PZ binds mitochondrial aldehyde-protein conjugates [79, 262], but it is
unknown what effect this has on post-injury mitochondrial dynamics, such as fission,
fusion and mitophagy. It is possible that binding of PZ to mitochondria which are beyond
saving is preventing these mitochondria from being degraded by normal post-injury
processes and at the same time significantly improving the bioenergetics of the less
damaged mitochondria. The unusual presence of these considerably damaged
mitochondria in the mitochondria preps could mask improvements to individual states of
mitochondrial respiration. Additionally in that regard, if aldehyde-scavengers are going to
be pursued as therapeutic agents for TBI it will be important for future studies to
investigate their effects on post-injury homeostatic mechanisms such as mitochondrial
dynamics, mitophagy, and protein degradation. Also of note is the possibility that the
significant

decrease

seen

in

aldehyde-mitochondrial

conjugates

following

PZ

administration (Fig. 3.4) is due to the inability of the 4-HNE and acrolein antibodies to
recognize ternary drug-aldehyde-protein complexes. However, this is likely not the case
as the continuous PZ dosing paradigm did demonstrate partial protective effects as
evidence by the maintenance of RCR (Fig. 3.3) and cytoskeletal integrity (Fig. 3.5).
Additionally, this study may have been complicated by the choice of drug
combination. For example, CsA and PZ both physically bind mitochondria [79, 218, 258],
which may have resulted in too many non-physiologic interactions for mitochondria,
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particularly damaged mitochondria, to handle (Fig. 3.9). Additionally, CsA has a biphasic
dose-response curve [294] and is metabolized by cyp3A4 [246], an enzyme which can
be inhibited by PZ [266, 267]. In fact, although CsA has been previously identified as a
good candidate for combination drug therapies [213], because it is metabolized by
cyp3A4 [246], has a biphasic dose-response curve [294], and is a calcineurin inhibiting
immunosuppressant [316], the number and types of drugs it could be safely combined
with may be severely limited. In fact, a previous experimental TBI study which combined
CsA with the antibiotic minocycline resulted in a 100% lethality rate [215, 283].
Therefore, clinical translation of CsA for use in TBI may hold the most promise if its use
is restricted to that of a monotherapy agent. Similarly, given the complicated
pharmacokinetics of PZ, an irreversible MAOI and MAO substrate, with several active
metabolites [169, 189], PZ also may not represent the optimal choice for combinational
drug therapy.
However, several combinational therapy experimental designs do exist that avoid
the above complications. First, two drugs that are mechanistically complementary but
spatially distinct could be combined. For example, a blood brain barrier penetrable drug
could be combined with tirilazad, as tirilazad’s primary effects are localized to the
vasculature [1, 256]. Second, although the use of FDA-approved drugs such as CsA and
PZ potentially makes clinical translation for TBI easier, faster, and cheaper than the use
of experimental agents, combining drugs with less complicated mechanisms of action,
such as the non-immunosuppressive mPTP inhibitor, NIM811, or a pure aldehydescavenger, may limit confounding factors and offer a more straightforward approach.
Finally, a drug could be combined with a non-pharmacological therapy such as stem cell
administration or environmental enrichment. In fact, such pharmacologic + non-
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pharmacologic combinational designs seem to have a higher success rate than purely
pharmacologic combinational approaches [215, 280].
Comparative Effects of Phenelzine, Hydralazine, and Pargyline on Learning and
Memory and Cortical Tissue Sparing Following Experimental Traumatic Brain
Injury
Several studies have indicated that PZ can offer protection in experimental brain
injury [71, 72, 76, 333, 334]. However, in order for PZ to be further developed for use in
clinical TBI, the effect its MAOI properties have on TBI pathophysiology must be
considered. Therefore, this study was designed to test the hypothesis that PZ, a LPderived neurotoxic aldehyde scavenger and MAOI, and hydralazine (HZ), an LP-derived
neurotoxic aldehyde scavenger non-MAOI would improve cognitive function and cortical
tissue sparing following experimental TBI, whereas pargyline (PG), a MAOI nonaldehyde scavenger would not. Following severe controlled cortical impact injury
(2.0mm), 3mo male Sprague-Dawley rats received an intraperitoneal dose of PZ
(15mg/kg), HZ (5mg/kg), or PG (15mg/kg) at 15min, 24h, and 48h following injury. Morris
water maze testing was conducted on day 3 – day 7 post-CCI and cortical tissue sparing
was analyzed on post-CCI day 8. Additionally, the effects of the PZ, HZ, and PG dosing
paradigms on tissue levels of monoamines and metabolites were evaluated via HPLC in
uninjured cortical tissue as a surrogate marker of MAO inhibition.
This was not only the first study to evaluate the effects of PG and HZ in
experimental TBI, but it was also the first study to assess the behavioral effects of PZ in
experimental TBI. Contrary to the hypothesis, the results indicate that PZ (15mg/kg,
MAOI, aldehyde scavenger) and HZ (5mg/kg, non-MAOI, aldehyde scavenger), as well
as PG (15mg/kg, MAOI, non-aldehyde scavenger), were unable to attenuate reference
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memory deficits (D7 post-CCI) (Fig. 4.10) or improve cortical tissue sparing (D8 postCCI) (Fig. 4.12) when administered intraperitoneal 15min, 24h, and 48h after a severe
CCI (2.0mm) in 3mo male Sprague-Dawley rats. However, although non-significant, HZ
led to the most improvement to cortical tissue sparing (Table 4.1). Of concern, following
CCI PZ animals lost a significant amount of weight (Fig. 4.11), and their MWM
acquisition performance did not significantly improve across time (D3-6 post-CCI),
possibly indicating deficits to working memory, (Fig. 4.8), and perhaps being caused by
PZ-induced high monoamine tissue levels as was seen in uninjured cortical tissue (i.e.
NE, 5-HT) utilizing the same PZ dosing paradigm (Fig. 4.5 – 4.7). Similarly, qualitative
behaviors observed in the PZ group following CCI may have also been suggestive of
elevated monoamine levels. However, the effects of excessive aldehyde savaging or
other PZ mechanisms of actions, such as inhibition of GABA-T or formation of PEA,
cannot be ruled out as factors effecting outcome.
There are several possible reasons for why, contrary to the original hypothesis, the
hydrazine (-NH-NH2) containing aldehyde scavengers PZ and HZ were unable to provide
significant protection in the current study. In regards to PZ, it is possible that at higher
doses additional PZ mechanisms of action (MAO inhibition, GABA-T inhibition, PEA
formation, etc.) or excessive aldehyde scavenging are detrimental and negate protective
effects. It does seem that in the context of experimental TBI, lower doses of PZ may be
more protective as they have been shown to improve cortical tissue sparing [71] and
individual states of mitochondrial respiration [334], whereas higher PZ doses do not (Fig.
3.2 and Fig. 4.12) [333]. However, this dose effect may also be outcome specific as
continuous infusion of PZ is able to maintain cytoskeletal integrity better than bolus
dosing (Table 3.4) [333, 334]. Although a different PZ dosing paradigm may have
resulted in better outcomes, inclusion of additional experiments, such as HPLC analysis
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of CCI + PZ tissue, measurement of GABA levels, and additional quantitative behavioral
testing may also have led to a greater understanding of the effects PZ’s non-aldehyde
scavenging mechanisms of action are having after TBI. Additionally, although a PG
concentration equal to that of PZ was utilized as an extension of previous ex-vivo studies
[72], because equal concentrations of PG and PZ are not necessarily pharmacologically
equivalent, specifically in regards to MAO inhibition [189], choosing an alternate PG
dosing concentration or a different MAOI for comparison to PZ may have led to a better
understanding of MAO effects on TBI pathophysiology.
Similarly, in regards to HZ, as this was the first study to evaluate HZ in experimental
TBI, it is possible than an alternate dosing paradigm would have led to different results.
It may be that the HZ dosing paradigm utilized was too low to achieve significant
aldehyde scavenging and protective effects. Alternately, it is possible that as an antihypertensive [268], the concentration of HZ utilized induced hypotension and negated
any protective effects. Admittedly, this study would have been strengthened by the
inclusion of blood pressure measurements after drug administration.
On the other hand, it is possible that the PZ and HZ dosing paradigms utilized can
provide protection, but that such protection was not observed in the single early
behavioral task or in the single histological method analyzed. It is possible that delay of
behavioral analysis, use of alternative behavioral tasks, or inclusion of additional
histological methods may have yielded different results.
Although it is unfortunate that the hydrazine (-NH-NH2) containing aldehyde
scavengers, PZ and HZ, were unable to provide significant protection in the current
study, both have shown extensive promise as neuroprotective agents in previous
experimental studies of CNS injury [71, 72, 74-76, 333, 334, 361, 362]. Therefore,
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aldehyde scavengers likely still offer a valid approach to neuroprotection after TBI and
their development should continue to be pursued. However, based upon the results
obtained in the current study, the PZ dosing paradigm has clearly not been optimized.
Although the limitations of the current study make it impossible to say for sure if the
effects of PZs MAOI mechanism of action are detrimental following TBI, the weight loss
(Fig.

4.11),

MWM

acquisition

performance

(Fig.

4.8),

qualitative

behavioral

observations, and uninjured HPLC data (Fig. 4.5 – 4.7) are concerning and suggestive
of an MAOI effect. These observations, combined with the knowledge that MAOIs can
lower seizure threshold [265], PZ is both an irreversible MAO inhibitor and substrate with
complicated pharmacokinetics and several active metabolites [189], may make clinical of
translation of PZ for use in human TBI difficult even if dosing paradigms are optimized in
experimental rodent models. Similarly, HZ’s antihypertensive properties may limit its
clinical translation. Therefore, if hydrazine (-NH-NH2) containing aldehyde scavengers
are going to be further pursued as neuroprotective agents for TBI, it may be beneficial
for future studies to develop hydrazine (-NH-NH2) compounds which lack confounding off
target mechanisms of action.
Further, it is interesting that the PZ dosing paradigm utilized in the current study was
not only unable to provide protection but also resulted in significant weight loss (Fig.
4.11) and negative behavioral effects (Fig. 4.8, qualitative observation), whereas
similar dosing paradigms were safe and beneficial in other models of CNS injury such as
SCI and ischemic-reperfusion [74-76]. One hypothesis for this is that PZ exacerbated
severe CCI-induced monoamine elevations or monoamine oxidase inhibition. Although
HPLC analysis of penumbral tissue did not show elevated monoamine levels post-CCI
(Fig. 5.6 – 5.8), previous studies have found elevated monoamine levels after TBI
depending on time point and brain region [154, 173, 174, 178, 182, 363-365]. However,
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there is a dearth of information regarding the monoaminergic system acutely after TBI.
Additionally, despite the central role mitochondria have in TBI and the known damage to
mitochondrial function that occurs after TBI, little is known about the function of the
mitochondrial enzyme, MAO, following injury. In fact, in general, controversy exists as to
whether monoamines and monoamine oxidase inhibition are neuroprotective or toxic
[154, 170, 181, 193, 194]. Therefore, such topics may be interesting areas of
investigation for future TBI studies to pursue.
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APPENDIX:
Abbreviations
2-propenal: acrolein
2,4-DNP: 2,4-dinitrophenol
3-HPMA: N-acetyl-S-3-hydroxypropylcysteine
3-MP: 3-aminopropanal
3-MT: 3-methoxytyramine
3-NT: 3-nitrotyrosine
4-HNE: 4-hydroxynonenal
5-HIAA: 5-hydroxyindolacetic acid
5-HT: 5-hydroxytryptamine (i.e. serotonin)
ADP: adenosine diphosphate
AIF: apoptosis inducing factor
ALA-T: alanine transaminase
ALDH: aldehyde dehydrogenase
ANT: adenine nucleotide translocase
ANOVA: analysis of variance
APP: amyloid precursor protein
ARE: antioxidant responsive element
ATP: adenosine triphosphate
CCI: controlled cortical impact traumatic brain injury
CHI: closed head traumatic brain injury
CMIA: continuous multiple trial inhibitory avoidance task
CNS: central nervous system
CO2: carbon dioxide
CO●-3: carbonate radical
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COMT: catechol-O-methyl transferase
CsA: cyclosporine A
CSF: cerebral spinal fluid
CT: computerized tomography
CyD: cyclophilin D
DA: dopamine
DHBA: dihydroxybenzylamine
DOPAC: 3,4-dihydroxyphenylacetic acid
eNOS: endothelial nitric oxide synthase
EPI: epinephrine
ER: endoplasmic reticulum
ETC: electron transport chain
FAD+ / FADH2: flavin adenine dinucleotide
FCCP: carbonyl cyanide-p-trifluoromethoxyphenylhydrazone
FDA: Federal Drug Administration
Fe2+: ferrous iron
Fe3+: ferric iron
FPI: fluid percussion traumatic brain injury
GABA: gamma-aminobutyric acid
GABA-T: GABA transaminase
GCEE: gamma-glutamylcysteine ethyl ester
GCS: Glasgow coma scale
GPx: glutathione peroxidase
GSH: glutathione
GST: glutathione-S-transferase
H2O2: hydrogen peroxide
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HPLC: high performance liquid chromatography
HO-1: heme oxygenase-1
HVA: homovanillic acid
HZ: hydralazine
iNOS: inducible nitric oxide synthase
i.p.: intraperitoneal
K+: potassium cation
L•: lipid radical
L1CAM: neuronal cell adhesion molecule L1
LOO•: lipid peroxyl radical
LP: lipid peroxidation
MAO: monoamine oxidase
MAOI: monoamine oxidase inhibitor
MAP: microtubule associated protein
Mito: mitochondria
Mn-SOD: mitochondrial superoxide dismutase 2 (i.e. manganese superoxide dismutase)
mPT: mitochiondrial permeability transition
mPTP: mitochondria permeability transition pore
MR: magnetic resonance
mtNOS: mitochondrial nitic oxide synthase
MWM: Morris water maze
NAC: n-acetylcysteine
NACA: n-acetylcysteine amide
NAD+ / NADH: nicotinamide adenine dinucleotide
NAD(P)H: nicotinamide adenine dinucleotide phosphate
NE: norepinephrine
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NH-NH2: hydrazine moiety
NIH: National Institutes of Health
NIM811: n-methyl-4-isoleucine cyclosporine
NMDA: n-methyl-D-aspartic acid
nNOS: neuronal nitric oxide synthase
NO●: nitric oxide radical
NO●2: nitrogen dioxide oxide radical
NOS: nitric oxide synthase
NqO1: NAD(P)H quinione oxidoreductase 1
Nrf2: nuclear factor (erythroid-derived 2)
NS: non-synaptic
O2: molecular oxygen
O2•-: superoxide radical
OCD: ornithine decarboxylase
OH•: hydroxyl radical
OH-: hydroxyl anion
ONOO-: peroxynitrite anion
ONOOCO2-: nitrosperoxocarbonate
ONOOH: peroxynitrious acid
ORN-T: ornithine transaminase
Pi: inorganic phosphate
PBS: phosphate buffered saline
PEA: phenethylamine
PEG-SOD: polyethylene glycol superoxide dismutase
PEH: phenylethyldenehydrazine
PFA: paraformaldehyde
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PG: pargyline
PKC: protein kinase C
PN: peroxynitrite
psi: pounds per square inch
PUFA: polyunsaturated fatty acid
PZ: phenelzine
RCR: respiratory control ratio
ROS: reactive oxygen species
RNS: reactive nitrogen species
SBDP: spectrin breakdown products
s.c.: subcutatenous
SCI: spinal cord injury
SNK: Student-Newman-Keuls
SNRI: serotonin-norepinephrine-reuptake inhibitor
SOD: superoxide dismutase
SSRI: selective serotonin reuptake inhibitor
Syn: synaptic
TCA: tricarboxylic acid cycle (i.e. citric acid cycle, Krebs cycle)
TBI: traumatic brain injury
TBS: tris-buffered saline
TBST: tris-buffered saline with tween
VDAC: voltage-dependent anion channel
WD: weight drop traumatic brain injury
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